125

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

Financial
statements

In this section
Directors’ statement of responsibilities 126
Independent Auditor’s report 128
Financial statements 140
Notes to the financial statements 144
Financial statements of GlaxoSmithKline plc
prepared under UK GAAP 219
126

GSK Annual Report 2018

Directors’ statement of responsibilities

The Directors are responsible for preparing the Annual Report, the The financial statements for the year ended 31 December 2018 are
Remuneration report and the Group and parent company financial included in the Annual Report, which is published in printed form and
statements in accordance with applicable law and regulations. made available on our website. The Directors are responsible for the
maintenance and integrity of the Annual Report on our website in
UK company law requires the Directors to prepare financial
accordance with UK legislation governing the preparation and
statements for each financial year. The Directors are required
dissemination of financial statements. Access to the website is
to prepare the Group financial statements in accordance with
available from outside the UK, where comparable legislation may
International Financial Reporting Standards (IFRS) as adopted by
be different.
the European Union. In preparing the Group financial statements,
the Directors have also elected to comply with IFRS as issued by Each of the current Directors, whose names and functions are listed
the International Accounting Standards Board (IASB). The Directors in the Corporate Governance section of the Annual Report 2018
have elected to prepare the parent company financial statements confirms that, to the best of his or her knowledge:
in accordance with United Kingdom Accounting Standards and
–– the Group financial statements, which have been prepared
applicable law (United Kingdom Generally Accepted Accounting
in accordance with IFRS as adopted by the EU and IFRS
Practice). Under company law the Directors must not approve the
as issued by the IASB, give a true and fair view of the assets,
financial statements unless they are satisfied that they give a true
liabilities, financial position and profit of the Group; and
and fair view of the state of affairs of the Group and its profit or loss
for that period. –– the Strategic report and risk sections of the Annual Report,
which represent the management report, include a fair review of
In preparing the financial statements, the Directors are required to:
the development and performance of the business and the position
–– select suitable accounting policies and then apply them of the company and the Group taken as a whole, together with a
consistently; description of the principal risks and uncertainties that it faces.
–– make judgements and accounting estimates that are Disclosure of information to auditor
reasonable and prudent;
The Directors in office at the date of this Annual Report have each
–– state that the Group financial statements comply with IFRS as confirmed that:
adopted by the European Union and IFRS as issued by the IASB,
subject to any material departures disclosed and explained in the –– so far as he or she is aware, there is no relevant audit information
Group financial statements; of which the company’s auditor is unaware; and
–– state with regard to the parent company financial statements that –– he or she has taken all the steps that he or she ought to have taken
applicable UK Accounting Standards have been followed, subject as a Director to make himself or herself aware of any relevant audit
to any material departures disclosed and explained in the parent information and to establish that the company’s auditor is aware of
company financial statements; and that information.
–– prepare the financial statements on a going concern basis unless This confirmation is given and should be interpreted in accordance
it is inappropriate to presume that the Group and the parent with the provisions of section 418 of the Companies Act 2006.
company will continue in business. Going concern basis
The Directors are responsible for keeping adequate accounting
Pages 38 to 64 contain information on the performance of the
records that are sufficient to show and explain the company’s
Group, its financial position, cash flows, net debt position and
transactions and disclose with reasonable accuracy at any time
borrowing facilities. Further information, including Treasury risk
the financial position of the Group and to enable them to ensure that
management policies, exposures to market and credit risk and
the Group financial statements and the Remuneration report comply
hedging activities, is given in Note 42 to the financial statements,
with the Companies Act 2006 and Article 4 of the IAS Regulation.
‘Financial instruments and related disclosures’. Having assessed the
They are also responsible for safeguarding the assets of the Group
principal risks and other matters considered in connection with the
and hence for taking reasonable steps for the prevention and
viability statement, the Directors considered it appropriate to adopt
detection of fraud and other irregularities.
the going concern basis of accounting in preparing the financial
The Group financial statements for the year ended 31 December statements.
2018, comprising principal statements and supporting notes,
are set out in the ‘Financial statements’ on pages 140 to 218 of this
report. The parent company financial statements for the year ended
31 December 2018, comprising the balance sheet for the year
ended 31 December 2018 and supporting notes, are set out on
pages 219 to 222.
The responsibilities of the auditor in relation to the financial
statements are set out in the Independent Auditor’s report on
pages 128 to 139.
 127

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

Directors’ statement of responsibilities continued

Internal control
The Board, through the Audit & Risk Committee, has reviewed the
assessment of risks and the internal control framework that operates
in GSK and has considered the effectiveness of the system of internal
control in operation in the Group for the year covered by this Annual
Report and up to the date of its approval by the Board of Directors.
The UK Corporate Governance Code
The Board considers that GlaxoSmithKline plc applies the principles
and complies with the provisions of the UK Corporate Governance
Code maintained by the Financial Reporting Council, as described
in the Corporate Governance section on pages 65 to 94. The Board
further considers that the Annual Report, taken as a whole, is fair,
balanced and understandable, and provides the information
necessary for shareholders to assess the Group’s position and
performance, business model and strategy.
As required by the Financial Conduct Authority’s Listing Rules,
the auditor has considered the Directors’ statement of compliance in
relation to those points of the UK Corporate Governance Code
which are specified for their review.
Annual Report
The Annual Report for the year ended 31 December 2018,
comprising the Report of the Directors, the Remuneration report,
the Financial statements and Additional information for investors, has
been approved by the Board of Directors and signed on its behalf by

Philip Hampton
Chairman

11 March 2019
128

GSK Annual Report 2018

Independent Auditor’s report to the members

of GlaxoSmithKline plc
Report on the audit of the financial statements
Opinion We confirm that non-audit services prohibited by the FRC’s Ethical
Standard were not provided to the Group or the Parent company.
In our opinion: We believe that the audit evidence we have obtained is sufficient
–– the financial statements of GlaxoSmithKline plc (the ‘Parent and appropriate to provide a basis for our opinion.
company’) and its subsidiaries (the ‘Group’) give a true and fair
view of the state of the Group’s and of the Parent company’s
Summary of our audit approach
affairs as at 31 December 2018 and of the Group’s profit for First year audit transaction
the year then ended; This is the first year we have been appointed as auditors to the
–– the Group financial statements have been properly prepared in Group. We undertook a number of transitional procedures to
accordance with International Financial Reporting Standards prepare for the audit. Before we commenced our audit we had to
(IFRSs) as adopted by the European Union and IFRSs as issued establish our independence of the Group which involved ceasing
by the International Accounting Standards Board (IASB); a number of commercial relationships. We used the time prior to
commencing our audit to meet with key members of management
–– the Parent company financial statements have been properly to gain an understanding of the business, its issues and the
prepared in accordance with United Kingdom Generally Accepted environment in which it operates.
Accounting Practice including FRS 101 ‘Reduced Disclosure
Framework’; and We became independent of the Group and commenced our audit
planning on 4 July 2017. From this date we attended all Audit & Risk
–– the financial statements have been prepared in accordance with Committee meetings, initially in an observer capacity. We worked
the requirements of the Companies Act 2006 and, as regards the alongside the former auditor and reviewed their working papers to
Group financial statements, Article 4 of the IAS Regulation. gain an understanding of the Group’s processes, their audit risk
We have audited the financial statements which comprise the: assessment, the controls on which they relied for the purposes of
issuing their audit opinion, as well as understanding the evidence
Group: they obtained on the key complex or significant judgements which
–– consolidated balance sheet as at 31 December 2018; they made.
–– consolidated income statement for the year then ended; In September 2017, we held a two day meeting of audit partners
–– consolidated statement of comprehensive income for the year and senior staff who would be responsible for undertaking the audits
then ended; in the most significant locations in the Group. The main purpose of
this meeting was to outline our central audit approach including the
–– consolidated statement of changes in equity for the year then
use of our data analytics tools, discuss possible significant audit
ended;
risks and brief our teams on the Group’s key processes, systems
–– consolidated cash flow statement for the year then ended; and and structure. A subsequent strategic planning meeting was held
–– notes 1 to 46 to the financial statements, which includes the in September 2018 with the same participants to take into account
accounting principles and policies. any current period updates that impacted our audit approach.

Parent company: During these meetings, we also heard directly from Group
–– balance sheet as at 31 December 2018; management on the changes impacting the business to inform
our audit planning and risk assessment.
–– statement of changes in equity for the year then ended; and
Key audit matters
–– notes A to N to the financial statements, which includes the The key audit matters that we identified in the current year were:
accounting principles and policies.
–– valuation of acquisition-related liabilities;
The financial reporting framework that has been applied in the
–– valuation of US Returns and Rebates (RAR) accruals;
preparation of the Group financial statements is applicable law and
IFRSs as adopted by the European Union. The financial reporting –– valuation of intangible assets;
framework that has been applied in the preparation of the Parent –– valuation of uncertain tax positions, including transfer pricing
company financial statements is applicable law and United Kingdom and updates to the impacts of the US Tax Reform; and
Accounting Standards, including FRS 101 ‘Reduced Disclosure –– IT systems which impact financial reporting.
Framework’ (United Kingdom Generally Accepted Accounting
Practice). Key audit matters considered by the Group’s auditor in the prior
year were broadly aligned with the items identified above, but also
Basis for opinion included consideration of litigations and investigations into the
We conducted our audit in accordance with International Standards Group’s commercial operations, which are less significant in the
on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities current year.
under those standards are further described in the auditor’s Materiality
responsibilities for the audit of the financial statements section of The materiality that we used for the Group financial statements
our report. was £270 million, which was determined on the basis of a
We are independent of the Group and the Parent company in composite benchmarking approach. This approach considers
accordance with the ethical requirements that are relevant to our profit before tax, adjusted profit before tax, revenue and net cash
audit of the financial statements in the UK, including the Financial flows from operations.
Reporting Council’s (the ‘FRC’s’) Ethical Standard as applied to Risk assessment at group level
listed public interest entities, and we have fulfilled our other ethical We applied a top-down risk assessment methodology which
responsibilities in accordance with these requirements. considers the enterprise, industry and financial risks in the context of
the financial statements
 129

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

Report on the audit of the financial statements continued

As part of this process, we spent time understanding the key The coverage obtained from this strategy is summarised as follows:
financial and business processes of the Group and how they are Profit Total
implemented across the organisation. We used our audit analytics Benchmark Revenue before tax assets
tools to analyse client data and the flow of business transactions Covered by market - specific procedures 66% 73% 83%
to inform our fact-based risk assessment. Covered by review at Group level 34% 27% 17%
Audit scope and execution The residual consists of components or legal entities each with
We structured our approach to the audit to reflect how the Group annual revenue (turnover) less than 1.8% of the total Group revenue.
is organised as well as ensuring our audit was both effective and These entities and components are non-significant components that
risk focused. It can be summarised into the following areas which individually and in the aggregate do not present a reasonable
enabled us to obtain the evidence required to form an opinion on possibility of risk of material misstatement.
the Group and Parent company financial statements:
Conclusions relating to going concern, principal risks
–– Risk assessment and audit planning at a Group level.
The central control and common systems throughout most of the and viability statement
Group, enabled us to structure the audit more centrally. In addition Going concern
to appointing partners for each of three businesses, we also had We have reviewed the directors’ statement in notes 1 and A to the
partners coordinate the component and legal entity audits in each financial statements about whether they considered it appropriate
country. These global business partners met regularly with the to adopt the going concern basis of accounting in preparing them
relevant management to understand strategy and matters which and their identification of any material uncertainties to the Group’s
arose throughout the year that could have impacted on the and Company’s ability to continue to do so over a period of at least
financial reporting. The regular meetings we had with members 12 months from the date of approval of the financial statements.
of the Internal Audit, the internal Legal Counsel and the Global
Ethics & Compliance team allowed us to understand their work, We considered as part of our risk assessment the nature of the Group,
to review their reports and to enhance our risk assessment. its business model and related risks including where relevant the
impact of Brexit, the requirements of the applicable financial reporting
–– Audit work performed at global shared service centres. framework and the system of internal control. We evaluated the
A significant amount of the Group’s operational processes which directors’ assessment of the Group’s ability to continue as a going
cover financial reporting are undertaken in shared service centres. concern, including challenging the underlying data and key assumptions
Our central team, which included senior individuals responsible used to make the assessment, and evaluated the directors’ plans for
for each of the global processes, coordinated our audit work at future actions in relation to their going concern assessment.
the shared service centres in scope for the Group audit, to ensure
we developed a good understanding of the end-to-end view of We are required to state whether we have anything material to add
the key processes that supported material account balances, or draw attention to in relation to that statement required by Listing
classes of transactions and disclosures within the Group financial Rule 9.8.6R(3) and report if the statement is materially inconsistent
statements. We then evaluated the effectiveness of internal with our knowledge obtained in the audit.
controls over financial reporting for these processes and We confirm that we have nothing material to report, add or
considered the implications for the remainder of our audit work. draw attention to in respect of these matters.
–– Audit work executed at component and individual
Principal risks and viability statement
legal entities.
Based solely on reading the directors’ statements and considering
The following components were subject to market-specific audit
whether they were consistent with the knowledge we obtained in the
procedures as well as the assessment of the internal controls over
course of the audit, including the knowledge obtained in the evaluation
financial reporting: Belgium; Canada; France; Germany; Italy;
of the directors’ assessment of the Group’s and the Company’s ability
Japan; Spain; Switzerland; United Kingdom and United States.
to continue as a going concern, we are required to state whether we
The Group audit team was in active dialogue throughout the year
have anything material to add or draw attention to in relation to:
with the component audit teams responsible for the audit work
under the direction and supervision of the Group audit team. This –– the disclosures on pages 34 to 36 that describe the principal
included determining whether the work was planned and risks and explain how they are being managed or mitigated;
performed in accordance with the overall Group audit strategy –– the directors’ confirmation on page 87 that they have carried out
and the requirements of our Group audit instructions to the a robust assessment of the principal risks facing the Group,
components. As part of supervising the work of the components, including those that would threaten its business model, future
the Group audit team visited all the component countries, as well performance, solvency or liquidity; or
as locations of all shared service centre audits.
–– the directors’ explanation on page 44 as to how they have
–– Audit procedures undertaken at a Group level and on assessed the prospects of the Group, over what period they have
the Parent company. done so and why they consider that period to be appropriate, and
In addition to the above, we also performed audit work at Group their statement as to whether they have a reasonable expectation
and on the Parent company financial statements, including but not that the Group will be able to continue in operation and meet its
limited to the consolidation of the Group’s results, the preparation liabilities as they fall due over the period of their assessment,
of the financial statements, certain disclosures within the Directors including any related disclosures drawing attention to any
remuneration report, litigation provisions and exposures in addition necessary qualifications or assumptions.
to management’s entity level and oversight controls relevant to
We are also required to report whether the directors’ statement relating
financial reporting. We also carried out analytical procedures to
to the prospects of the Group required by Listing Rule 9.8.6R(3) is
confirm our conclusion that there were no significant risks of
materially inconsistent with our knowledge obtained in the audit.
material misstatement of the aggregated financial information of
the remaining components not subject to the market-specific audit We confirm that we have nothing material to report, add or
procedures. draw attention to in respect of these matters.
130

GSK Annual Report 2018

Independent Auditor’s report continued

Report on the audit of the financial statements continued

Key audit matters
Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of
the current period and include the most significant assessed risks of material misstatement (whether or not due to fraud) that we identified.
These matters included those which had the greatest effect on: the overall audit strategy; the allocation of resources in the audit; and directing
the efforts of the engagement team.
These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we
do not provide a separate opinion on these matters.

Key audit matter description How the scope of our audit responded to the key audit matter

Valuation of acquisition-related liabilities Audit procedures performed

In recent years the Group has completed a number of significant We performed the following audit procedures where relevant:
transactions which resulted in the recognition of material and
–– made enquiries of key individuals from the senior leadership
judgemental acquisition-related liabilities. The most significant
team, commercial strategy team and key personnel involved in
of these liabilities were:
the budgeting and forecasting process, to discuss, challenge
–– ViiV Healthcare Shionogi contingent consideration liability and evaluate management’s evidence to support key inputs
(‘ViiV CCL’): The Group completed the acquisition of the and assumptions;
remaining 50% interest in the Shionogi-ViiV Healthcare joint
–– challenged the business assumptions applied by management
venture in 2012. Upon completion, the Group recognised a
in estimating sales forecasts, including benchmarking of sales
contingent consideration liability for the fair value of the
forecasts to external data. This included analysis of the results
expected future payments to be made to Shionogi. As at
of demand studies conducted by third parties on new drug
31 December 2018, the liability was valued at £5,937 million
launches. We assessed the results of clinical studies and
(2017 – £5,542 million); and
the target medicine profile of new drugs to understand their
–– Pfizer put option: The Group granted Pfizer a put option in relative position in the market and to assess any sources of
2009, enabling Pfizer to put its non-controlling interest in contradictory evidence;
ViiV Healthcare back to the Group in the future. As at
–– assessed the historical accuracy of management’s forecasts
31 December 2018, the liability was valued at £1,240 million
including estimates of the probability of success of pipeline
(2017 – £1,304 million).
products;
In the prior year, the acquisition-related liabilities also included the
–– benchmarked sales forecasts against analyst expectations to,
Consumer Healthcare joint venture put option. The liability
both assess the estimations made by management and, for
represented the present value of the expected redemption price
consideration of any contradictory evidence available;
of a put option over Novartis’ non-controlling interest in Consumer
Healthcare joint venture. On 3 May 2018, the Consumer –– assessed the reasonableness of valuation-specific assumptions
healthcare joint venture put option was de-recognised following used by management, including exchange rates, discount rate,
approval by shareholders of the acquisition of Novartis’ valuation multiples and whether these assumptions were
non-controlling interest in the Consumer healthcare joint venture consistent with how a well-informed independent third party
and therefore this liability did not exist at the year end. would value these liabilities;
The valuations of the liabilities are sensitive to changes in –– assessed the appropriateness of the accounting for acquisition-
exchange rates, discount rates and sales forecasts, which are related liabilities; and
based upon management’s assessment of the probability of –– evaluated the disclosures in respect to these liabilities included
success of pipeline products, expected launch dates, subsequent in the notes to the financial statements to determine whether
sales volumes and pricing. they were compliant with the requirements of the relevant
The key risks in the valuation of the acquisition-related liabilities, accounting standards.
specifically the sales forecast used to value the ViiV CCL and Internal controls over financial reporting
particularly the dolutegravir-based regimens as, in our view, these We tested the design, implementation and operating effectiveness
give rise to the most material source of estimation uncertainty. of key controls identified over the valuation of the acquisition-related
The acquisition related liabilities are disclosed as a key liabilities, such as the review and approval of both the long-range
accounting judgement and estimate in note 3 of the Group forecast and the valuation models.
financial statement with further disclosures provided in notes 27, Key observations communicated to the Audit & Risk Committee
38, 39 and 42. The matter is also discussed in the Audit & Risk
Whilst there are significant commercial risks to the forecasts for the
Committee report within the Corporate Governance section of
future sales of dolutegravir-based regimens and related products,
the Annual Report.
we are satisfied that the valuations of associated liabilities are within
an acceptable range of values.
The approach to valuing the acquisition-related liabilities was
consistent with prior periods and we are satisfied that the valuations
of the acquisition-related liabilities are reasonable and consistent
with IFRS.
 131

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

Report on the audit of the financial statements continued

Key audit matter description How the scope of our audit responded to the key audit matter

Valuation of US Returns and Rebates (RAR) accruals Audit procedures performed

In the US the Group sells to customers under various commercial We performed the following audit procedures:
and government mandated contracts and reimbursement
–– assessed the historical accuracy of management’s estimates
arrangements that include rebates, chargebacks and a right of
against actual outcomes to evaluate the impact and inform our
return for certain products. As such, revenue recognition reflects
assessment of the current year accrual;
gross-to-net sales adjustments which involve significant estimation
and judgement. These adjustments are known as the Returns and –– developed an expectation of the accrual balance for each of the
Rebates (‘RAR’) accruals and are a source of estimation and key channels, based on historical claims received adjusted to
uncertainty which could have a material impact on reported revenue. reflect market changes in the period including an assessment of
The three most significant payer channels within the RAR accrual are the time lag between the initial point of sale and the claim receipt.
managed healthcare organisations, Medicaid and Medicare Part D. We then used this expectation to consider the appropriateness of
management’s ending accrual position;
The two main causes of significant estimation uncertainty are:
–– recalculated the accrual recognised to determine that it is
–– the utilisation rates (the portion of total sales which will be made
consistent with the assumptions determined through
into each payer channel) estimated by management in recording
management’s process;
the accruals. The utilisation assumption is the most challenging
of the key assumptions used to derive the accrual given that it –– substantively tested individual utilisation rates on a sample basis;
is influenced by market demand and other factors outside the –– evaluated, through monitoring of news events and industry
control of the Group; and developments, the appropriateness of period end adjustments
–– the time lag between the point of sale and the point at which to the liability made as part of the ongoing review of the estimated
exact rebate amounts are known to the Group (upon receipt of accrual;
a claim). Those payer channels with the longest time lag result –– evaluated and benchmarked the methodology applied by
in a greater accrued period, and as such a greater level of management in estimating the accrual against industry practice;
estimation uncertainty. and
The level of estimation uncertainty is also impacted by significant –– monitored the market for any significant events in the period, giving
shifts in channel mix driven by changes in the competitive a particular focus to any potential generic competition in respect
landscape. to Advair, one of the Group’s most significant products. A generic
In the US Pharmaceuticals business in 2018, £10,774 million of Advair competitor product was not approved by the US Food and
RAR deductions were made to gross revenue of £18,227 million, Drug Administration (‘FDA’) until the end of January 2019, and
resulting in net revenue of £7,453 million. The balance sheet therefore there was no additional risk associated with market
accrual at 31 December 2018 accrual for the combined events in determining the 2018 Advair RAR liability.
Pharmaceuticals and Vaccines businesses amounted to Internal controls over financial reporting
£4,356 million. We tested the design, implementation and operating effectiveness of
Returns and rebates are disclosed as a key accounting judgement key controls over the estimation of RAR accruals including the review
and estimate in note 3 of the Group financial statement with further of forecasts and monthly accruals.
disclosures provided in note 27. The matter is also discussed in the Key observations communicated to the Audit & Risk Committee
Audit & Risk Committee report within the Corporate Governance
section of the Annual Report. Based on our assessment of the accuracy of historical estimates
made by management by comparing them to actual rebates claimed,
we determined that the estimates have been accurate in the past
giving further assurance over the strength of management’s process
for estimating the liability at the reporting date.
We are satisfied with the appropriateness of the RAR accruals at the
period end, and that management’s estimated liability is reasonable.
132

GSK Annual Report 2018

Independent Auditor’s report continued

Report on the audit of the financial statements continued

Key audit matter description How the scope of our audit responded to the key audit matter

Valuation of intangible assets Audit procedures performed

As at 31 December 2018, the Group held £16,156 million of We assessed the appropriateness of the carrying value of the
intangible assets (including licences, patents, trademarks and intangible assets by performing the following audit procedures:
brand names, but excluding goodwill and computer software).
–– assessed the valuation methodology used by management,
The recoverable value of these intangible assets relies on certain
with involvement of our valuation specialists, and tested the
assumptions and estimates of future trading performance which
mechanical accuracy of the impairment models;
impact the valuation.
–– evaluated the reasonableness of the valuation assumptions,
The assumptions applied by management in determining the
such as discount rates, used by management through reference
recoverable value include the discount rate, future sales growth
to external market data;
rate, the impact of the expiry of patents on the product and
potential product obsolescence. Changes in these assumptions –– reviewed analyst reports and other external sources of
could lead to an impairment to the carrying value of the intangible information to identify any contradictory evidence which
assets. could indicate an impairment is required;
The assets most at risk of material impairment were identified using –– challenged the appropriateness of the business assumptions
sensitivity analysis on key assumptions and a review of potential used by management, such as sales growth and the probability
triggering events that could be indicative of an impairment in the of success of products in development by assessing externally
carrying value of associated assets. available reference data to look for contradictory evidence,
evaluate past performances where relevant and assessing
The disclosures relating to other intangible assets are included in
historical accuracy of the forecast produced by management;
note 19 of the Group financial statements. The matter is also
discussed in the Audit & Risk Committee report within the –– enquired of and challenged management on the commercial
Corporate Governance section of the Annual Report. strategy associated with the products to ensure that it was
consistent with the assumptions used in estimating future
cash flows; and
–– considered whether events or transactions that occurred after
the balance sheet date but before the reporting date affect the
conclusions reached on the carrying values of the assets and
associated disclosures.
Internal controls over financial reporting
We tested the design, implementation and operating effectiveness
of key controls over the impairment review process including the
review and approval of forecasts and review of valuation models.
Key observations communicated to the Audit & Risk Committee
Our audit procedures did not identify any additional impairments.
We are satisfied that management’s intangible impairments
estimates are reasonable and in accordance with IFRS.
 133

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

Report on the audit of the financial statements continued

Key audit matter description How the scope of our audit responded to the key audit matter

Valuation of uncertain tax positions, including transfer pricing Audit procedures performed
and updates to the impacts of the US Tax Reform With the support of tax specialists, we assessed the
The Group operates in numerous jurisdictions and there are appropriateness of the uncertain tax provisions by performing the
open tax and transfer pricing issues and exposures with UK following audit procedures:
and overseas tax authorities that give rise to uncertain tax
–– assessed and challenged provisions for uncertain tax positions,
positions. The range of possible outcomes for provisions and
and focused our work on those jurisdictions where the Group
contingencies can be wide and management is required to make
has the greatest potential exposure and where the highest level
certain judgements in respect of estimates of tax exposures and
of judgement is required;
contingencies in order to assess the adequacy of tax provisions.
–– involved our transfer pricing specialists to review the transfer
At 31 December 2018, the Group has recorded provisions of
pricing methodology of the Group and associated approach
£1,082 million in respect of uncertain tax positions (2017 –
to provisioning;
£1,175 million).
–– involved our UK, US and international tax and transfer specialists
On 22 December 2017, the US Tax Cuts and Jobs Act was
to challenge the conclusions reached by management, both in
enacted. There was limited guidance provided by the US
relation to the expected outcome and the financial impact;
Treasury on how to apply the principles of the reform in practice
and, as such, judgement was required as at 2017 year end. –– considered evidence such as the actual results of previous
Management continued to monitor the impact of the reform outturns, recent and current tax authority audits and enquiries,
on the US business and the associated accounting records. third party tax advice where obtained and our tax specialists
Given the complexity and uncertainty relating to US tax reform, own knowledge of market practice in relevant jurisdictions; and
management is required to make judgements, assumptions and –– involved Deloitte US Tax specialists to determine the
interpretations of the tax law. Following additional guidance reasonableness of the judgements in respect of the US
released by the Internal Revenue Service during 2018, the Tax Reform.
Group reduced its estimate of the 2017 impact of US tax reform
by £125 million. Internal controls over financial reporting
We tested the design, implementation and operating effectiveness
Valuation of uncertain tax positions is disclosed as a key of key controls over preparation of tax packs and tax consolidation.
accounting judgement and estimate in note 3 of the Group
financial statements with further disclosures included in note 14. Key observations communicated to the Audit & Risk Committee
The matter is also discussed in the Audit & Risk Committee We are satisfied that management’s judgements in relation to
report within the Corporate Governance section of the Annual uncertain tax positions and the related disclosures are in
Report. accordance with IFRS. From our work we concluded that
management’s judgements were prudent, consistent with prior
periods, within an acceptable range and continue to be
appropriately recorded.
134

GSK Annual Report 2018

Independent Auditor’s report continued

Report on the audit of the financial statements continued

Key audit matter description How the scope of our audit responded to the key audit matter

IT systems which impact financial reporting Audit procedures performed over IT systems
In our audit plan we set out to place a significant level of reliance We performed the following risk assessment and audit procedures
on the IT systems, underpinned by our ability to rely on effective to test IT controls over the in scope IT systems, which are those
IT controls. The IT systems within the Group form a critical systems that we considered key for financial reporting purposes:
component of the Group’s financial reporting activities and
–– identified the IT risks for each IT system based on our
impact all account balances. IT controls, in the context of our
understanding of the flows of transactions and the IT environment;
scope for the financial audit, primarily relate to user access
security and change control. The purpose of such controls is to –– determined whether each general IT control, individually or
prevent inappropriate changes being made to IT systems in in combination with other controls, is appropriately designed
relation to application functionality, transactional processing and to address the associated IT risk; and
direct changes to underlying data. GSK place significant reliance –– tested the design, implementation and operating effectiveness
on their IT systems and the associated controls. of the relevant general IT controls.
IT control deficiencies were noted around user access
management for certain in scope IT systems and the associated
infrastructure. The existence of these deficiencies in the year
resulted in a heightened risk that data, reports and automated
system functionality (e.g. calculations) from the affected systems
might not be reliable.
We assessesed the impact of the deficiencies noted around user
access management on all account balances to determine the
specific impact on our audit plan.
Key observations communicated to the Audit & Risk Committee
During the year, the Group implemented a remediation plan to
address the user access deficiencies. This primarily involved the
removal of inappropriate access together with the implementation of
appropriate privileged access management processes and controls
which is planned to be fully complete in 2019. The Group has layers
of business process controls at many levels which help to mitigate
this IT risk. An additional programme to identify and validate these
controls, as well as some enhancement to these controls was
completed during 2018.
The IT deficiencies were reported to the Audit & Risk Committee
throughout the year and have been disclosed in the Audit & Risk
Committee section of the Annual Report. The matter is also
discussed in the Audit & Risk Committee report within the
Corporate Governance section of the Annual Report.
We were satisfied that the mitigating business process controls
addressed the risks of material misstatement.
 135

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

Report on the audit of the financial statements continued

Our application of materiality
We define materiality as the magnitude of misstatement in the financial statements that makes it probable that the economic decisions of
a reasonably knowledgeable person would be changed or influenced. We use materiality both in planning the scope of our audit work and
in evaluating the results of our work.
Based on our professional judgement, we determined materiality for the financial statements as a whole as follows:
Group financial statements Parent company financial statements

Materiality £270 million £67 million

Basic for In determining our benchmark for materiality we Materiality was determined using the total assets
determining considered the metrics used by investors and other benchmark.
materiality readers of the financial statements. In particular, we
considered: Statutory profit before tax, Adjusted profit The materiality used by the former auditor in the audit
before tax, Revenue and Net cash flows from of the prior year’s Parent company financial statements
operations. However, given the importance of all these was £70 million.
metrics, we concluded that a composite approach was
most appropriate, based on the range of materiality we
determined using the benchmarks listed above.
Using professional judgement we have determined
preliminary materiality to be £270 million to apply
conservatism to our determination given that this is the
first year of our audit.
Metric %
Statutory profit before tax 5.6
Adjusted profit before tax* 3.3
Revenue 0.9
Net cash inflow from operating activities 3.2
* A reconciliation between the Statutory profit before tax and
Adjusted profit before tax is detailed in the Adjusting Items
section of the Strategic Report.
The materiality used by the former auditor in the audit
of the prior year’s Group financial statements was
£290 million.

Rationale for We calculated the range for each of the relevant The Parent company holds the Group’s investments and
the benchmark benchmarks and used these ranges in exercising our is not in itself profit-oriented. The strength of the balance
applied professional judgement to determine materiality. Our sheet is the key measure of financial health that is
chosen materiality of £270 million was deemed to be important to shareholders since the primary concern for
appropriate taking into account various metrics used by the Parent company is the payment of dividends. Using
investors and other readers of the financial statements. a benchmark of total assets is therefore most
appropriate.
The component materiality allocated to the in-scope
components ranged between £67 million and
£189 million.
The range of materiality allocated across components
by the former auditor in the audit of the prior year’s
Group financial statements was between £15 million
and £154 million.

We agreed with the Audit & Risk Committee that we would report to the Committee all audit differences in excess of £10 million (2017 –
£10 million was used by the previous auditor) as well as differences below that threshold that, in our view, warranted reporting on qualitative
grounds. We also report to the Audit & Risk Committee on disclosure matters that we identified when assessing the overall presentation of
the financial statements.
136

GSK Annual Report 2018

Independent Auditor’s report continued

Other information
The directors are responsible for the other information. The other information comprises the information included in the Annual Report,
other than the financial statements and our auditor’s report thereon.
Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report,
we do not express any form of assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether
the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to
be materially misstated.
If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material
misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we
conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in respect of these matters.

We summarise below our work in relation to areas of the other information including those areas upon which we are specifically required to
report:
Matters we are specifically required to report
Our responsibility Our reporting
Fair, balanced and understandable
Consider whether the statement given by the directors that they consider the We consider that the directors’ statement is materially
Annual Report and financial statements taken as a whole is fair, balanced and consistent with our knowledge obtained from the audit.
understandable and provides the information necessary for shareholders to
assess the Group’s position and performance, business model and strategy
is materially inconsistent with our knowledge obtained from the audit.

Audit & Risk Committee report

Consider whether it deals appropriately with those matters that we reported All matters we reported have been appropriately covered in
to the Audit & Risk Committee. the Audit & Risk Committee report.

Directors’ statement of compliance with the UK Corporate Governance

Code (‘the Code’) We did not identify any such matters.
Consider whether the parts of the Directors’ statement required under the
Listing Rules relating to the Parent company’s compliance with the Code
containing provisions specified for review by the auditor in accordance with
Listing Rule 9.8.10R(2) properly discloses any departure from a relevant
provision of the Code.

Viability statement
Review the confirmation and description in the light of the knowledge As set out in the section ‘Conclusions relating to going
gathered during the audit, including making enquiries and considering the concern, principal risks and viability statement’, we have
directors’ processes used to support the statements made. nothing material to report, add or draw attention to in respect
of these matters.
Consider if the statements are aligned with the relevant provisions of the
UK Corporate Governance Code (the ‘Code’).

Directors’ Remuneration report

Report whether the part of the directors’ remuneration report to be audited As set out in the section ‘Opinions on other matters
is properly prepared and the disclosures specified by the Companies Act prescribed by the Companies Act 2006’, in our opinion, the
have been made. part of the directors’ remuneration report to be audited has
been prepared in accordance with the Companies Act 2006.

Strategic report and Directors’ report

Report whether they are consistent with the audited financial statements As set out in the section ‘Opinions on other matters
and are prepared in accordance with applicable legal requirements. prescribed by the Companies Act 2006’, in our opinion,
Report if we have identified any material misstatements in either report in based on the work undertaken in the course of the audit, the
the light of the knowledge and understanding of the group and of the Parent information in these reports is consistent with the audited
company and their environment obtained in the course of the audit. financial statements and has been prepared in accordance
with applicable legal requirements.
 137

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

Other information continued

Other reporting on other information
Our responsibility Our reporting
Alternative performance measures (APMs)
APMs are measures that are not defined by generally accepted accounting Based on the work undertaken in the course of the audit, in
practice (GAAP) and therefore are not typically included in the financial our opinion:
statement part of the Annual Report. The Group use APMs, such as adjusted
–– the use, calculation and disclosure of APMs is consistent
profit, free cash flow and constant currency growth rates in some of its
with the Group’s published definitions and policies;
quarterly and annual reporting of financial performance.
–– the use of APMs in the Group’s reporting results is
We have reviewed and assessed management’s calculation and reporting of
consistent with the guidelines produced by ESMA
these metrics to assess consistency with the Group’s published definitions
and FRC; and
and policies for these items.
–– there is an appropriate balance between the use of
We have also considered and assessed whether the use of APMs in the
statutory metrics and APMs, together with clear definitions
Group’s reporting results is consistent with the guidelines produced by
and reconciliation for APMs used in financial reporting.
regulators such as the European Securities and Markets Authority (‘ESMA’)
guidelines on the use of APMs and the FRC Alternative Performance Measures
Thematic Review published in November 2017.
We also considered whether there was an appropriate balance between the
use of statutory metrics and APMs, in addition to whether clear definitions and
reconciliation for APMs used in financial reporting.

Approach to Brexit
Consider whether the Brexit risks have been appropriately reflected. Based on the work undertaken in the course of the audit, in
our opinion, the risks in relation to Brexit have been
The Group’s approach to Brexit is outlined in the Strategic report
appropriately reflected.
(page 36).

Dividends and distribution policy

Consider whether the dividends policy is transparent and the dividends paid Based on the work undertaken in the course of the audit, in
are consistent with the policy. our opinion, the dividends policy is appropriately disclosed
and dividends paid are consistent with the policy.
138

GSK Annual Report 2018

Independent Auditor’s report continued

Responsibilities of directors –– discussing among the engagement team including significant

component audit teams and involving relevant internal specialists,
As explained more fully in the directors’ responsibilities statement, including tax, valuations, pensions, IT and industry specialists
the directors are responsible for the preparation of the financial regarding how and where fraud might occur in the financial
statements and for being satisfied that they give a true and fair view, statements and any potential indicators of fraud; and
and for such internal control as the directors determine is necessary
to enable the preparation of financial statements that are free from –– obtaining an understanding of the legal and regulatory frameworks
material misstatement, whether due to fraud or error. that the Group operates in, focusing on those laws and regulations
that had a direct effect on the financial statements, such as
In preparing the financial statements, the directors are responsible provisions of the UK Companies Act, pensions legislation and tax
for assessing the Group’s and the Parent company’s ability to legislations or that had a fundamental effect on the operations of
continue as a going concern, disclosing as applicable, matters the Group, including the Good Clinical Practice, the FDA
related to going concern and using the going concern basis of regulations, General Data Protection requirements, Anti-bribery
accounting unless the directors either intend to liquidate the Group and corruption policy and the Foreign Corrupt Practices Act.
or the Parent company or to cease operations, or have no realistic
alternative but to do so. Audit response to risks identified
Our procedures to respond to risks identified included the following:
Auditor’s responsibilities for the audit of the financial
–– reviewing the financial statement disclosures and testing to
statements supporting documentation to assess compliance with relevant
Our objectives are to obtain reasonable assurance about whether laws and regulations discussed above;
the financial statements as a whole are free from material –– enquiring of management, the Audit & Risk Committee and
misstatement, whether due to fraud or error, and to issue an auditor’s in-house and external legal counsel concerning actual and
report that includes our opinion. Reasonable assurance is a high level potential litigation and claims;
of assurance, but is not a guarantee that an audit conducted in
accordance with ISAs (UK) will always detect a material –– performing analytical procedures to identify any unusual or
misstatement when it exists. Misstatements can arise from fraud or unexpected relationships that may indicate risks of material
error and are considered material if, individually or in the aggregate, misstatement due to fraud; and
they could reasonably be expected to influence the economic –– reading minutes of meetings of those charged with governance
decisions of users taken on the basis of these financial statements. and reviewing internal audit reports.
Details of the extent to which the audit was considered capable of We have also considered the risks noted above in addressing the risk
detecting irregularities, including fraud are set out below. of fraud through management override of controls:
A further description of our responsibilities for the audit of the –– testing the appropriateness of journal entries and other
financial statements is located on the FRC’s website at: www.frc.org. adjustments;
uk/auditorsresponsibilities. This description forms part of our
–– assessing whether the judgements made in making accounting
auditor’s report.
estimates are indicative of a potential bias; and
Extent to which the audit was considered capable of –– evaluating the business rationale of any significant transactions
detecting irregularities, including fraud that are unusual or outside the normal course of business.
We identify and assess the risks of material misstatement of the We also communicated relevant identified laws and regulations and
financial statements, whether due to fraud or error, and then design potential fraud risks to all engagement team members and significant
and perform audit procedures responsive to those risks, including component audit teams, and remained alert to any indications of
obtaining audit evidence that is sufficient and appropriate to provide fraud or non-compliance with laws and regulations throughout
a basis for our opinion. the audit.
Identifying and assessing potential risks related to Report on other legal and regulatory requirements
irregularities
In identifying and assessing the risks of material misstatement in Opinions on other matters prescribed by the Companies Act
respect of irregularities, including fraud and non-compliance with 2006
laws and regulations, our procedures included the following: In our opinion, the part of the directors’ remuneration report to be
audited has been properly prepared in accordance with the
–– enquiring of management, internal audit and the Audit & Risk Companies Act 2006.
Committee, including obtaining and reviewing supporting
documentation, concerning the Group’s policies and procedures In our opinion, based on the work undertaken in the course of the
relating to: audit:

–– identifying, evaluating and complying with laws and regulations –– the information given in the Strategic report and the Directors’
and whether they were aware of any instances of non- report for the financial year for which the financial statements are
compliance; prepared is consistent with the financial statements; and

–– detecting and responding to the risks of fraud and whether they –– the Strategic report and the Directors’ report have been prepared
have knowledge of any actual, suspected or alleged fraud; in accordance with applicable legal requirements.

–– the internal controls established to mitigate risks related to fraud In the light of the knowledge and understanding of the Group and of
or non-compliance with laws and regulations; the Parent company and their environment obtained in the course of
the audit, we have not identified any material misstatements in the
strategic report or the directors’ report.
 139

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

Matters on which we are required to report by

exception
Adequacy of explanations received and accounting records
Under the Companies Act 2006 we are required to report to you if,
in our opinion:
–– we have not received all the information and explanations we
require for our audit; or
–– adequate accounting records have not been kept by the Parent
company, or returns adequate for our audit have not been received
from branches not visited by us; or
–– the Parent company financial statements are not in agreement with
the accounting records and returns.
We have nothing to report in respect of these matters.
Directors’ remuneration
Under the Companies Act 2006 we are also required to report if in
our opinion certain disclosures of directors’ remuneration have not
been made or the part of the directors’ remuneration report to be
audited is not in agreement with the accounting records and returns.
We have nothing to report in respect of these matters.
Other matters
Auditor tenure
Following the recommendation of the Audit & Risk Committee, we
were appointed by the Company at its annual general meeting on 3
May 2018 to audit the financial statements of GlaxoSmithKline plc for
the year ending 31 December 2018 and subsequent financial
periods. The period of uninterrupted engagement including previous
renewals and reappointments of the firm is accordingly one year.
Consistency of the audit report with the additional report to the
Audit & Risk Committee
Our audit opinion is consistent with the additional report to the Audit
& Risk Committee we are required to provide in accordance with
ISAs (UK).
Use of our report
This report is made solely to the Company’s members, as a body, in
accordance with Chapter 3 of Part 16 of the Companies Act 2006.
Our audit work has been undertaken so that we might state to the
Company’s members those matters we are required to state to them
in an auditor’s report and for no other purpose. To the fullest extent
permitted by law, we do not accept or assume responsibility to
anyone other than the Company and the Company’s members as a
body, for our audit work, for this report, or for the opinions we have
formed.
The Parent company has passed a resolution in accordance with
section 506 of the Companies Act that the senior statutory auditor’s
name should not be stated.

Deloitte LLP
Statutory Auditor
London, United Kingdom
11 March 2019
140

GSK Annual Report 2018

Consolidated income statement

for the year ended 31 December 2018

2018 2017 2016

Notes £m £m £m
Turnover 6 30,821 30,186 27,889
Cost of sales (10,241) (10,342) (9,290)
Gross profit 20,580 19,844 18,599
Selling, general and administration (9,915) (9,672) (9,366)
Research and development (3,893) (4,476) (3,628)
Royalty income 299 356 398
Other operating income/(expense) 7 (1,588) (1,965) (3,405)
Operating profit 8 5,483 4,087 2,598
Finance income 11 81 65 72
Finance expense 12 (798) (734) (736)
Profit on disposal of interest in associates 3 94 –
Share of after tax profits of associates and joint ventures 13 31 13 5
Profit before taxation 4,800 3,525 1,939
Taxation 14 (754) (1,356) (877)

Profit after taxation for the year 4,046 2,169 1,062

Profit attributable to non-controlling interests 423 637 150
Profit attributable to shareholders 3,623 1,532 912
4,046 2,169 1,062
Basic earnings per share (pence) 15 73.7p 31.4p 18.8p
Diluted earnings per share (pence) 15 72.9p 31.0p 18.6p

Consolidated statement of comprehensive income

for the year ended 31 December 2018
2018 2017 2016
£m £m £m
Profit for the year 4,046 2,169 1,062
Items that may be subsequently reclassified to income statement:
Exchange movements on overseas net assets and net investment hedges 34 (480) 462 646
Reclassification of exchange on liquidation or disposal of overseas subsidiaries 34 – 109 –
Fair value movements on equity investments (14) 251
Deferred tax on fair value movements on equity investments 47 –
Reclassification of fair value movements on equity investments – (42) (245)
Deferred tax reversed on reclassification of equity investments – (18) 51
Fair value movements on cash flow hedges 140 (10) 2
Deferred tax on fair value movements on cash flow hedges (22) – 2
Reclassification of cash flow hedges to income statement (175) – 1
Deferred tax reversed on reclassification of cash flow hedges 20 – –
(517) 534 708

Items that will not be reclassified to income statement:

Exchange movements on overseas net assets of non-controlling interests 34 (1) (149) 603
Fair value movements on equity investments 180
Deferred tax on fair value movements on equity investments 10
Remeasurement gains/(losses) on defined benefit plans 728 549 (475)
Tax on remeasurement of defined benefit plans (146) (221) 126
771 179 254
Other comprehensive income for the year 34 254 713 962
Total comprehensive income for the year 4,300 2,882 2,024
Total comprehensive income for the year attributable to:
Shareholders 3,878 2,394 1,271
Non-controlling interests 422 488 753
Total comprehensive income for the year 4,300 2,882 2,024
 141

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Consolidated balance sheet Investor information

as at 31 December 2018

2018 2017
Notes £m £m
Non-current assets
Property, plant and equipment 17 11,058 10,860
Goodwill 18 5,789 5,734
Other intangible assets 19 17,202 17,562
Investments in associates and joint ventures 20 236 183
Other investments 21 1,322 918
Deferred tax assets 14 3,887 3,796
Derivative financial instruments 42 69 8
Other non-current assets 22 1,576 1,413
Total non-current assets 41,139 40,474

Current assets
Inventories 23 5,476 5,557
Current tax recoverable 14 229 258
Trade and other receivables 24 6,423 6,000
Derivative financial instruments 42 188 68
Liquid investments 31 84 78
Cash and cash equivalents 25 3,874 3,833
Assets held for sale 26 653 113
Total current assets 16,927 15,907
Total assets 58,066 56,381

Current liabilities
Short-term borrowings 31 (5,793) (2,825)
Contingent consideration liabilities 39 (837) (1,076)
Trade and other payables 27 (14,037) (20,970)
Derivative financial instruments 42 (127) (74)
Current tax payable 14 (965) (995)
Short-term provisions 29 (732) (629)
Total current liabilities (22,491) (26,569)

Non-current liabilities
Long-term borrowings 31 (20,271) (14,264)
Corporation tax payable 14 (272) (411)
Deferred tax liabilities 14 (1,156) (1,396)
Pensions and other post-employment benefits 28 (3,125) (3,539)
Other provisions 29 (691) (636)
Derivative financial instruments 42 (1) –
Contingent consideration liabilities 39 (5,449) (5,096)
Other non-current liabilities 30 (938) (981)
Total non-current liabilities (31,903) (26,323)
Total liabilities (54,394) (52,892)
Net assets 3,672 3,489

Equity
Share capital 33 1,345 1,343
Share premium account 33 3,091 3,019
Retained earnings 34 (2,137) (6,477)
Other reserves 34 2,061 2,047
Shareholders’ equity 4,360 (68)
Non-controlling interests (688) 3,557
Total equity 3,672 3,489

The financial statements on pages 140 to 218 were approved by the Board on 11 March 2019 and signed on its behalf by
Philip Hampton
Chairman
142

GSK Annual Report 2018

Consolidated statement of changes in equity

for the year ended 31 December 2018

Shareholders’ equity
Share Share Retained Other Non-controlling Total
capital premium earnings reserves Total interests equity
£m £m £m £m £m £m £m
At 1 January 2016 1,340 2,831 (1,397) 2,340 5,114 3,764 8,878
Profit for the year – – 912 – 912 150 1,062
Other comprehensive income for the year – – 284 75 359 603 962
Total comprehensive income for the year – – 1,196 75 1,271 753 2,024
Distributions to non-controlling interests – – – – – (534) (534)
Dividends to shareholders – – (4,850) – (4,850) – (4,850)
Recognition of liabilities with non-controlling interests – – (2,013) – (2,013) (159) (2,172)
Derecognition of liabilities with non-controlling interests – – 1,244 – 1,244 – 1,244
Changes in non-controlling interests – – 17 – 17 15 32
Shares issued 2 87 – – 89 – 89
Shares acquired by ESOP Trusts – 36 466 (576) (74) – (74)
Write-down of shares held by ESOP Trusts – – (381) 381 – – –
Share-based incentive plans – – 319 – 319 – 319
Tax on share-based incentive plans – – 7 – 7 – 7
At 31 December 2016 1,342 2,954 (5,392) 2,220 1,124 3,839 4,963
Profit for the year – – 1,532 – 1,532 637 2,169
Other comprehensive income for the year – – 899 (37) 862 (149) 713
Total comprehensive income for the year – – 2,431 (37) 2,394 488 2,882
Distributions to non-controlling interests – – – – – (789) (789)
Contribution from non-controlling interests – – – – – 21 21
Dividends to shareholders – – (3,906) – (3,906) – (3,906)
Changes in non-controlling interests – – – – – (2) (2)
Shares issued 1 55 – – 56 – 56
Shares acquired by ESOP Trusts – 10 581 (656) (65) – (65)
Write-down of shares held by ESOP Trusts – – (520) 520 – – –
Share-based incentive plans – – 333 – 333 – 333
Tax on share-based incentive plans – – (4) – (4) – (4)
At 31 December 2017 1,343 3,019 (6,477) 2,047 (68) 3,557 3,489
Implementation of IFRS 15 – – (4) – (4) – (4)
Implementation of IFRS 9 – – 277 (288) (11) – (11)
At 31 December 2017, as adjusted 1,343 3,019 (6,204) 1,759 (83) 3,557 3,474
Profit for the year – – 3,623 – 3,623 423 4,046
Other comprehensive income for the year – – 124 131 255 (1) 254
Total comprehensive income for the year – – 3,747 131 3,878 422 4,300
Distributions to non-controlling interests – – – – – (570) (570)
Contribution from non-controlling interests – – – – – 21 21
Derecognition of non-controlling interests in Consumer
Healthcare Joint Venture – – 4,056 – 4,056 (4,118) (62)
Dividends to shareholders – – (3,927) – (3,927) – (3,927)
Realised profits on disposal of equity investments – – 56 (56) – – –
Share of associates and joint ventures realised profits on
disposal of equity investments – – 38 (38) – – –
Shares issued 2 72 – – 74 – 74
Write-down of shares held by ESOP Trusts – – (265) 265 – – –
Share-based incentive plans – – 360 – 360 – 360
Tax on share-based incentive plans – – 2 – 2 – 2
At 31 December 2018 1,345 3,091 (2,137) 2,061 4,360 (688) 3,672
 143

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Consolidated cash flow statement Investor information

for the year ended 31 December 2018

2018 2017 2016

Notes £m £m £m
Cash flow from operating activities
Profit after taxation for the year 4,046 2,169 1,062
Adjustments reconciling profit after tax to operating cash flows 36 5,701 6,089 7,044
Cash generated from operations 9,747 8,258 8,106
Taxation paid (1,326) (1,340) (1,609)
Net cash inflow from operating activities 8,421 6,918 6,497

Cash flow from investing activities

Purchase of property, plant and equipment (1,344) (1,545) (1,543)
Proceeds from sale of property, plant and equipment 168 281 98
Purchase of intangible assets (452) (657) (809)
Proceeds from sale of intangible assets 256 48 283
Purchase of equity investments (309) (80) (96)
Proceeds from sale of equity investments 151 64 683
Contingent consideration paid (153) (91) (73)
Purchase of businesses, net of cash acquired 38 – – 17
Disposal of businesses 38 26 282 72
Investments in associates and joint ventures 20 (10) (15) (11)
Proceeds from disposal of interests in associates 38 3 196 –
Decrease in liquid investments – 4 –
Interest received 72 64 68
Dividends from associates, joint ventures and equity investments 39 6 42
Net cash outflow from investing activities (1,553) (1,443) (1,269)

Cash flow from financing activities

Shares acquired by ESOP Trusts – (65) (74)
Issue of share capital 33 74 56 89
Purchase of non-controlling interests (9,320) (29) –
Increase in long-term loans 10,138 2,233 –
Repayment of short-term Notes (2,067) (2,636) (865)
Increase in/(repayment of) other short-term loans 81 (564) 1,013
Net repayment of obligations under finance leases (28) (23) (18)
Interest paid (766) (781) (732)
Dividends paid to shareholders (3,927) (3,906) (4,850)
Distributions to non-controlling interests (570) (779) (534)
Contributions from non-controlling interests 21 21 –
Other financing cash flows (25) 93 (421)
Net cash outflow from financing activities (6,389) (6,380) (6,392)

Increase/(decrease) in cash and bank overdrafts 37 479 (905) (1,164)

Cash and bank overdrafts at beginning of year 3,600 4,605 5,486

Exchange adjustments 8 (100) 283
Increase/(decrease) in cash and bank overdrafts 479 (905) (1,164)
Cash and bank overdrafts at end of year 4,087 3,600 4,605

Cash and bank overdrafts at end of year comprise:

Cash and cash equivalents 3,874 3,833 4,897
Cash and cash equivalents reported in assets held for sale 485 – –
4,359 3,833 4,897
Overdrafts (272) (233) (292)
4,087 3,600 4,605
144

GSK Annual Report 2018

Notes to the financial statements

1. Presentation of the financial statements
Description of business Implementation of IFRS 9 ‘Financial instruments’
GSK is a major global healthcare group which is engaged in the The Group has applied IFRS 9 ‘Financial instruments’ with effect
creation and discovery, development, manufacture and marketing from 1 January 2018. IFRS 9 introduces new requirements for the
of pharmaceutical products, vaccines, over‑the-counter (OTC) classification and measurement of financial assets and financial
medicines and health-related consumer products. GSK’s principal liabilities, impairments for financial assets and general hedge
pharmaceutical products include medicines in the following accounting.
therapeutic areas: respiratory, HIV, immuno-inflammation, anti-virals,
Details of these new requirements as well as their impact on the
central nervous system, cardiovascular and urogenital, metabolic,
Group’s consolidated financial statements are described below.
anti-bacterials and dermatology.
The Group has adopted IFRS 9 retrospectively but with certain
Compliance with applicable law and IFRS permitted exceptions as detailed below.

The financial statements have been prepared in accordance with Classification and measurement of financial assets
the Companies Act 2006, Article 4 of the IAS Regulation and The date of initial application was 1 January 2018. The Group has
International Financial Reporting Standards (IFRS) and related not applied the requirements of IFRS 9 to instruments that were
interpretations, as adopted by the European Union. derecognised prior to 1 January 2018 and has not restated prior
years. Any difference between the previous carrying amount and the
The financial statements are also in compliance with IFRS as issued revised carrying amount at 1 January 2018 has been recognised as
by the International Accounting Standards Board. an adjustment to opening retained earnings at 1 January 2018.
Composition of financial statements All financial assets that are within the scope of IFRS 9 are required to
be measured at amortised cost or fair value, with movements through
 he consolidated financial statements are drawn up in Sterling,
T
other comprehensive income or the income statement on the basis of
the functional currency of GlaxoSmithKline plc, and in accordance
GSK’s business model for managing the financial assets and the
with IFRS accounting presentation. The financial statements
contractual cash flow characteristics of the financial assets.
comprise:
IFRS 9 had the following impact on the Group’s assets:
–– Consolidated income statement
–– The Group has elected to recognise movements in the fair value of
–– Consolidated statement of comprehensive income
equity investments in other comprehensive income under IFRS 9.
–– Consolidated balance sheet Investments in equity instruments that were previously classified as
–– Consolidated statement of changes in equity available-for-sale financial assets measured at fair value have been
designated as measured at fair value through other comprehensive
–– Consolidated cash flow statement income (FVTOCI) under IFRS 9. As a result, fair value movements
–– Notes to the financial statements. are now recorded in other comprehensive income along with gains
or losses on disposal of the investments.
Composition of the Group
–– The Group’s investments in limited life funds included in Other
A list of the subsidiaries and associates which, in the opinion of investments that were previously classified as available-for-sale
the Directors, principally affected the amount of profit or net assets financial assets under IAS 39 and measured at fair value have
of the Group is given in Note 44, ‘Principal Group companies’. been classified as measured at fair value through profit or loss
(FVTPL) under IFRS 9 as the contractual cash flows are not solely
Financial period payments of principal and interest on the principal amount
These financial statements cover the financial year from 1 January to outstanding.
31 December 2018, with comparative figures for the financial years –– Liquid investments that were classified as available-for-sale
from 1 January to 31 December 2017 and, where appropriate, from financial assets measured at fair value under IAS 39 have been
1 January to 31 December 2016. classified as measured at amortised cost under IFRS 9 as they are
Accounting principles and policies held within a business model, the objective of which is to collect
the contractual cash flows.
The financial statements have been prepared using the historical
–– Investments in money market funds included in Cash and cash
cost convention modified by the revaluation of certain items, as
equivalents that were classified as amortised cost financial assets
stated in the accounting policies, and on a going concern basis.
under IAS 39 have been classified as FVTPL under IFRS 9 as the
The financial statements have been prepared in accordance contractual cash flows are not solely payments of principal and
with the Group’s accounting policies approved by the Board interest on the principal amount outstanding.
and described in Note 2, ‘Accounting principles and policies’.
–– The Group’s trade receivables were all classified as financial
Information on the application of these accounting policies,
assets measured at amortised cost under IAS 39. Under IFRS 9,
including areas of estimation and judgement is given in Note 3,
the business model under which each portfolio of trade
‘Key accounting judgements and estimates’.
receivables held has been assessed. The Group has portfolios
The preparation of the financial statements in conformity with in each of the three business models under IFRS 9: to collect the
generally accepted accounting principles requires management contractual cash flows (measured at amortised cost), to sell the
to make estimates and assumptions that affect the reported contractual cash flows (measured at FVTPL), and both to collect
amounts of assets and liabilities and disclosure of contingent and to sell the contractual cash flows (measured at FVTOCI).
assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reporting
period. Actual results could differ from those estimates.
 145

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

1. Presentation of the financial statements continued

–– Amounts receivable under insurance contracts included in Other Impact of new standards on each financial
non-current assets were held at FVTPL or amortised cost under statement line item
IAS 39. Under IFRS 9, as the contractual cash flows are not
solely payments of principal and interest on the principal amount The table below shows the amount of adjustment for each financial
outstanding, the amounts receivable are classified as measured statement line item affected by the application of IFRS 9 and IFRS 15
at FVTPL. at 1 January 2018.
There were no material changes in carrying value of financial assets As previously IFRS 9 IFRS 15
as a result of these changes in measurement basis. reported adjustments adjustments As restated
£m £m £m £m
Impairment of financial assets Trade and other receivables 6,000 (15) – 5,985
IFRS 9 requires an expected credit loss (ECL) model to be applied Liquid investments 78 1 – 79
to financial assets rather than the incurred credit loss model required
Other payables - returns (3,463) – (29) (3,492)
under IAS 39. The expected credit loss model requires the Group and rebates
to account for expected losses as a result of credit risk on initial
Other payables - deferred (240) – 27 (213)
recognition of financial assets and to recognise changes in those income
expected credit losses at each reporting date. Deferred tax assets 3,796 3 (2) 3,797
12-month ECLs are applied to all financial assets not measured
at FVTPL except for net trade receivables which are measured Total effect on net assets 3,489 (11) (4) 3,474
reflecting lifetime ECLs using the simplified approach. An additional
ECL allowance of £15 million for trade receivables was recognised
Fair value reserve 329 (288) – 41
on transition to IFRS 9. There were no other transition adjustments
arising from the change in impairment basis. Retained earnings (6,477) 277 (4) (6,204)

The additional ECL allowance of £15 million at 1 January 2018 has

Total effect on equity 3,489 (11) (4) 3,474
been recognised against opening retained earnings, together with
a related deferred tax impact of £3 million. The £288 million transfer between retained earnings and the
General hedge accounting fair value reserve resulted from the reclassification of previous
The new general hedge accounting requirements retain the three impairment losses on equity investments now designated as
types of hedge accounting which were available under IAS 39: measured at FVTOCI under IFRS 9 from retained earnings to
fair value hedges, cash flow hedges and net investment hedges. the fair value reserve.
However, the effectiveness testing requirements have been The application of IFRS 9 and IFRS 15 has had no impact on the
simplified. consolidated cash flows of the Group.
The Group has applied the IFRS 9 hedge accounting requirements Parent company financial statements
prospectively from the date of initial application of 1 January 2018.
All existing hedging relationships are eligible, and continued to be The financial statements of the parent company, GlaxoSmithKline
effective, under IFRS 9. plc, have been prepared in accordance with UK GAAP and with UK
accounting presentation. The company balance sheet is presented
Implementation of IFRS 15 ‘Revenue from contracts on page 219 and the accounting policies are given on page 220.­
with customers’
The Group has applied IFRS 15 ‘Revenue from contracts with
customers’ with effect from 1 January 2018. IFRS 15 provides a
single, principles-based approach to the recognition of revenue
from all contracts with customers. It focuses on the identification
of performance obligations in a contract and requires revenue to be
recognised when or as those performance obligations are satisfied.
GSK adopted IFRS 15 applying the modified retrospective
approach. IFRS 15 did not have a material impact on the amount
or timing of recognition of reported revenue. At 1 January 2018, a
cumulative adjustment to decrease retained earnings of £4 million
was recognised. In accordance with the requirements of IFRS 15
where the modified retrospective approach is adopted, prior year
results have not been restated.
146

GSK Annual Report 2018

Notes to the financial statements continued

2. Accounting principles and policies

Consolidation Where the consideration transferred, together with the non-controlling
interest, exceeds the fair value of the net assets, liabilities and
The consolidated financial statements include: contingent liabilities acquired, the excess is recorded as goodwill.
–– the assets and liabilities, and the results and cash flows, of the The costs of acquisition are charged to the income statement in the
company and its subsidiaries, including ESOP Trusts period in which they are incurred.
–– the Group’s share of the results and net assets of associates Goodwill is capitalised as a separate item in the case of subsidiaries
and joint ventures and as part of the cost of investment in the case of joint ventures and
associates. Goodwill is denominated in the currency of the operation
–– the Group’s share of assets, liabilities, revenue and expenses
acquired.
of joint operations.
Where the cost of acquisition is below the fair value of the net assets
The financial statements of entities consolidated are made up to
acquired, the difference is recognised directly in the income statement.
31 December each year.
Where not all of the equity of a subsidiary is acquired the non-
Entities over which the Group has the power to direct the relevant
controlling interest is recognised either at fair value or at the non-
activities so as to affect the returns to the Group, generally through
controlling interest’s share of the net assets of the subsidiary, on a
control over the financial and operating policies, are accounted for
case-by-case basis. Changes in the Group’s ownership percentage
as subsidiaries.
of subsidiaries are accounted for within equity.
Where the Group has the ability to exercise joint control over, and
rights to the net assets of, entities, the entities are accounted for Foreign currency translation
as joint ventures. Where the Group has the ability to exercise joint  oreign currency transactions are booked in the functional currency
F
control over an arrangement, but has rights to specified assets of the Group company at the exchange rate ruling on the date of
and obligations for specified liabilities of the arrangement, the transaction. Foreign currency monetary assets and liabilities are
arrangement is accounted for as a joint operation. Where the Group retranslated into the functional currency at rates of exchange ruling
has the ability to exercise significant influence over entities, they are at the balance sheet date. Exchange differences are included in the
accounted for as associates. The results and assets and liabilities of income statement.
associates and joint ventures are incorporated into the consolidated
financial statements using the equity method of accounting. The On consolidation, assets and liabilities, including related goodwill,
Group’s rights to assets, liabilities, revenue and expenses of joint of overseas subsidiaries, associates and joint ventures, are translated
operations are included in the consolidated financial statements in into Sterling at rates of exchange ruling at the balance sheet date. The
accordance with those rights and obligations. results and cash flows of overseas subsidiaries, associates and joint
ventures are translated into Sterling using average rates of exchange.
Interests acquired in entities are consolidated from the date the
Group acquires control and interests sold are de-consolidated from Exchange adjustments arising when the opening net assets and the
the date control ceases. profits for the year retained by overseas subsidiaries, associates and
joint ventures are translated into Sterling, less exchange differences
Transactions and balances between subsidiaries are eliminated and arising on related foreign currency borrowings which hedge the
no profit before tax is taken on sales between subsidiaries until the Group’s net investment in these operations, are taken to a separate
products are sold to customers outside the Group. The relevant component of equity.
proportion of profits on transactions with joint ventures, joint
operations and associates is also deferred until the products are When translating into Sterling the assets, liabilities, results and cash
sold to third parties. Transactions with non-controlling interests are flows of overseas subsidiaries, associates and joint ventures which
recorded directly in equity. Deferred tax relief on unrealised intra- are reported in currencies of hyper-inflationary economies,
Group profit is accounted for only to the extent that it is considered adjustments are made where material to reflect current price levels.
recoverable. Any loss on net monetary assets is charged to the consolidated
income statement.
Business combinations
Revenue (applicable from 1 January 2018)
Business combinations are accounted for using the acquisition
accounting method. Identifiable assets, liabilities and contingent The Group receives revenue for supply of goods to external
liabilities acquired are measured at fair value at acquisition date. customers against orders received. The majority of contracts that
The consideration transferred is measured at fair value and includes GSK enters into relate to sales orders containing single performance
the fair value of any contingent consideration. obligations for the delivery of pharmaceutical, vaccine and consumer
healthcare products. The average duration of a sales order is less
The fair value of contingent consideration liabilities are re-assessed than 12 months.
at each balance sheet date with changes recognised in the income
statement. Payments of contingent consideration reduce the balance Product revenue is recognised when control of the goods is passed
sheet liability and as a result are not recorded in the income statement. to the customer. The point at which control passes is determined by
each customer arrangement, but generally occurs on delivery to the
The part of each payment relating to the original estimate of the fair customer.
value of the contingent consideration on acquisition is reported within
investing activities in the cash flow statement and the part of each Product revenue represents net invoice value including fixed and
payment relating to the increase in the liability since the acquisition variable consideration. Variable consideration arises on the sale of
date is reported within operating cash flows. goods as a result of discounts and allowances given and accruals for
estimated future returns and rebates. Revenue is not recognised in
full until it is highly probable that a significant reversal in the amount
of cumulative revenue recognised will not occur.
 147

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

2. Accounting principles and policies continued

The methodology and assumptions used to estimate rebates and Legal and other disputes
returns are monitored and adjusted regularly in the light of contractual
and legal obligations, historical trends, past experience and Provision is made for the anticipated settlement costs of legal or
projected market conditions. Once the uncertainty associated with other disputes against the Group where an outflow of resources is
the returns and rebates is resolved, revenue is adjusted accordingly. considered probable and a reliable estimate can be made of the likely
outcome. In addition, provision is made for legal or other expenses
GSK enters into development and marketing collaborations and arising from claims received or other disputes. In respect of product
out-licences of the Group’s compounds or products to other parties. liability claims related to certain products, there is sufficient history
These contracts give rise to fixed and variable consideration from of claims made and settlements to enable management to make a
upfront payments, development milestones, sales-based milestones reliable estimate of the provision required to cover unasserted claims.
and royalties. In certain cases, an incurred but not reported (IBNR) actuarial
Income dependent on the achievement of a development milestone technique is used to determine this estimate.
is recognised when it is highly probable that a significant reversal in The Group may become involved in legal proceedings, in respect of
the amount of cumulative revenue recognised will not occur, which which it is not possible to make a reliable estimate of the expected
is usually when the related event occurs. Sales-based milestone financial effect, if any, that could result from ultimate resolution of the
income is recognised when it is highly probable that the sales proceedings.
threshold will be reached.
In these cases, appropriate disclosure about such cases would be
Sales-based royalties on a licence of intellectual property are not included but no provision would be made. Costs associated with
recognised until the relevant product sale occurs. claims made by the Group against third parties are charged to the
If the time between the recognition of revenue and payment from income statement as they are incurred.
the customer is expected to be more than one year and the impact
Pensions and other post-employment benefits
is material, the amount of consideration is discounted using
appropriate discount rates. The costs of providing pensions under defined benefit schemes are
Value added tax and other sales taxes are excluded from revenue. calculated using the projected unit credit method and spread over
the period during which benefit is expected to be derived from the
Expenditure employees’ services, consistent with the advice of qualified actuaries.
Pension obligations are measured as the present value of estimated
Expenditure is recognised in respect of goods and services received future cash flows discounted at rates reflecting the yields of high-
when supplied in accordance with contractual terms. Provision is quality corporate bonds. Pension scheme assets are measured at
made when an obligation exists for a future liability in respect of a fair value at the balance sheet date.
past event and where the amount of the obligation can be reliably
estimated. Manufacturing start-up costs between validation and The costs of other post-employment liabilities are calculated in a
the achievement of normal production are expensed as incurred. similar way to defined benefit pension schemes and spread over
Advertising and promotion expenditure is charged to the income the period during which benefit is expected to be derived from the
statement as incurred. Shipment costs on inter-company transfers employees’ services, in accordance with the advice of qualified
are charged to cost of sales; distribution costs on sales to customers actuaries.
are included in selling, general and administrative expenditure. Actuarial gains and losses and the effect of changes in actuarial
Restructuring costs are recognised and provided for, where assumptions, are recognised in the statement of comprehensive
appropriate, in respect of the direct expenditure of a business income in the year in which they arise.
reorganisation where the plans are sufficiently detailed and well The Group’s contributions to defined contribution plans are charged
advanced, and where appropriate communication to those affected to the income statement as incurred.
has been undertaken.
Employee share plans
Research and development
Incentives in the form of shares are provided to employees under
Research and development expenditure is charged to the income share option and share award schemes.
statement in the period in which it is incurred. Development
expenditure is capitalised when the criteria for recognising an asset The fair values of these options and awards are calculated at their
are met, usually when a regulatory filing has been made in a major grant dates using a Black-Scholes option pricing model and charged
market and approval is considered highly probable. Property, plant to the income statement over the relevant vesting periods.
and equipment used for research and development is capitalised The Group provides finance to ESOP Trusts to purchase company
and depreciated in accordance with the Group’s policy. shares to meet the obligation to provide shares when employees
exercise their options or awards. Costs of running the ESOP Trusts
Environmental expenditure are charged to the income statement. Shares held by the ESOP
Environmental expenditure related to existing conditions resulting Trusts are deducted from other reserves. A transfer is made between
from past or current operations and from which no current or future other reserves and retained earnings over the vesting periods of the
benefit is discernible is charged to the income statement. The Group related share options or awards to reflect the ultimate proceeds
recognises its liability on a site-by-site basis when it can be reliably receivable from employees on exercise.
estimated. This liability includes the Group’s portion of the total costs
and also a portion of other potentially responsible parties’ costs
when it is probable that they will not be able to satisfy their respective
shares of the clean-up obligation. Recoveries of reimbursements are
recorded as assets when virtually certain.
148

GSK Annual Report 2018

Notes to the financial statements continued

2. Accounting principles and policies continued

Property, plant and equipment Contingent milestone payments are recognised at the point that
the contingent event becomes probable. Any development costs
Property, plant and equipment (PP&E) is stated at the cost of incurred by the Group and associated with acquired licences,
purchase or construction, less provisions for depreciation and patents, know-how or marketing rights are written off to the income
impairment. Financing costs are capitalised within the cost of statement when incurred, unless the criteria for recognition of
qualifying assets in construction. an internally generated intangible asset are met, usually when a
Depreciation is calculated to write off the cost less residual value regulatory filing has been made in a major market and approval
of PP&E, excluding freehold land, using the straight-line basis over is considered highly probable.
the expected useful life. Residual values and lives are reviewed, and Acquired brands are valued independently as part of the fair value of
where appropriate adjusted annually. The normal expected useful businesses acquired from third parties where the brand has a value
lives of the major categories of PP&E are: which is substantial and long term and where the brands either are
contractual or legal in nature or can be sold separately from the rest
Freehold buildings 20 to 50 years
of the businesses acquired. Brands are amortised over their
Leasehold land and buildings Lease term or 20 to 50 years estimated useful lives of up to 20 years, except where it is considered
Plant and machinery 10 to 20 years that the useful economic life is indefinite.
Equipment and vehicles 3 to 10 years
The costs of acquiring and developing computer software for internal
On disposal of PP&E, the cost and related accumulated depreciation use and internet sites for external use are capitalised as intangible
and impairments are removed from the financial statements and the fixed assets where the software or site supports a significant
net amount, less any proceeds, is taken to the income statement. business system and the expenditure leads to the creation of a
durable asset. ERP systems software is amortised over seven to
Leases ten years and other computer software over three to five years.
Leasing agreements which transfer to the Group substantially all the Impairment of non-current assets
benefits and risks of ownership of an asset are treated as finance
leases, as if the asset had been purchased outright. The assets are The carrying values of all non-current assets are reviewed for
included in PP&E or computer software and the capital elements of impairment, either on a stand-alone basis or as part of a larger cash
the leasing commitments are shown as obligations under finance generating unit, when there is an indication that the assets might
leases. Assets held under finance leases are depreciated on a basis be impaired. Additionally, goodwill, intangible assets with indefinite
consistent with similar owned assets or the lease term, if shorter. useful lives and intangible assets which are not yet available for use
The interest element of the lease rental is included in the income are tested for impairment annually. Any provision for impairment is
statement. All other leases are operating leases and the rental costs charged to the income statement in the year concerned.
are charged to the income statement on a straight-line basis over Impairments of goodwill are not reversed. Impairment losses on other
the lease term. non-current assets are only reversed if there has been a change in
estimates used to determine recoverable amounts and only to the
Goodwill extent that the revised recoverable amounts do not exceed the
Goodwill is stated at cost less impairments. Goodwill is deemed carrying values that would have existed, net of depreciation or
to have an indefinite useful life and is tested for impairment at least amortisation, had no impairments been recognised.
annually.
Investments in associates, joint ventures and joint
Where the fair value of the interest acquired in an entity’s assets, operations
liabilities and contingent liabilities exceeds the consideration paid,
this excess is recognised immediately as a gain in the income Investments in associates and joint ventures are carried in the
statement. consolidated balance sheet at the Group’s share of their net assets
at date of acquisition and of their post-acquisition retained profits
Other intangible assets or losses together with any goodwill arising on the acquisition. The
Intangible assets are stated at cost less provisions for amortisation Group recognises its rights to assets, liabilities, revenue and
and impairments. expenses of joint operations.

Licences, patents, know-how and marketing rights separately Expected credit losses are recognised in the income statement on
acquired or acquired as part of a business combination are financial assets measured at amortised cost and at fair value through
amortised over their estimated useful lives, generally not exceeding other comprehensive income apart from equity investments.
20 years, using the straight-line basis, from the time they are available Inventories
for use. The estimated useful lives for determining the amortisation
charge take into account patent lives, where applicable, as well as Inventories are included in the financial statements at the lower of
the value obtained from periods of non-exclusivity. Asset lives are cost (including raw materials, direct labour, other direct costs and
reviewed, and where appropriate adjusted, annually. related production overheads) and net realisable value. Cost is
generally determined on a first in, first out basis. Pre-launch inventory
is held as an asset when there is a high probability of regulatory
approval for the product. Before that point a provision is made
against the carrying value to its recoverable amount; the provision
is then reversed at the point when a high probability of regulatory
approval is determined.
 149

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

2. Accounting principles and policies continued

Financial instruments (applicable from 1 January 2018) Borrowings
All borrowings are initially recorded at the amount of proceeds
Financial assets received, net of transaction costs. Borrowings are subsequently
Financial assets are measured at amortised cost, fair value through carried at amortised cost, with the difference between the proceeds,
other comprehensive income (FVTOCI) or fair value through profit net of transaction costs, and the amount due on redemption being
or loss (FVTPL). The measurement basis is determined by reference recognised as a charge to the income statement over the period of
to both the business model for managing the financial asset and the relevant borrowing.
the contractual cash flow characteristics of the financial asset. For
financial assets other than trade receivables a 12-month expected Derivative financial instruments
credit loss (ECL) allowance is recorded on initial recognition. If there Derivative financial instruments are used to manage exposure to
is subsequent evidence of a significant increase in the credit risk of market risks. The principal derivative instruments used by GSK are
an asset, the allowance is increased to reflect the full lifetime ECL. foreign currency swaps, interest rate swaps, foreign exchange
If there is no realistic prospect of recovery, the asset is written off. forward contracts and options. The Group does not hold or issue
derivative financial instruments for trading or speculative purposes.
Other investments
Other investments comprise equity investments and investments Derivative financial assets and liabilities, including derivatives
in limited life funds. The Group has elected to designate equity embedded in host contracts which have been separated from the
investments as measured at FVTOCI. They are initially recorded at host contract, are classified as held-for-trading and are measured at
fair value plus transaction costs and then remeasured at subsequent fair value. Changes in the fair value of any derivative instruments that
reporting dates to fair value. Unrealised gains and losses are do not qualify for hedge accounting are recognised immediately in
recognised in other comprehensive income. the income statement.
On disposal of the equity investment, gains and losses that have Hedge accounting
been deferred in other comprehensive Income are transferred directly Derivatives designated as hedging instruments are classified on
to retained earnings. Investments in limited life funds are measured at inception as cash flow hedges, net investment hedges or fair value
FVTPL. They are initially recorded at fair value and then remeasured hedges.
at subsequent reporting dates to fair value. Unrealised gains and Changes in the fair value of derivatives designated as cash flow
losses are recognised in the income statement. hedges are recognised in other comprehensive income to the extent
Dividends on equity investments and distributions from funds are that the hedges are effective. Ineffective portions are recognised in
recognised in the income statement when the Group’s right to profit or loss immediately. Amounts deferred in other comprehensive
receive payment is established. income are reclassified to the income statement when the hedged
item affects profit or loss.
Purchases and sales of Other investments are accounted for on
the trade date. Net investment hedges are accounted for in a similar way to cash
flow hedges.
Trade receivables
Trade receivables are measured in accordance with the business Changes in the fair value of derivatives designated as fair value
model under which each portfolio of trade receivables is held. The hedges are recorded in the income statement, together with the
Group has portfolios in each of the three business models under IFRS changes in the fair value of the hedged asset or liability.
9: to collect the contractual cash flows (measured at amortised cost), Taxation
to sell the contractual cash flows (measured at FVTPL), and both to
collect and to sell the contractual cash flows (measured at FVTOCI). Current tax is provided at the amounts expected to be paid applying
Trade receivables measured at amortised cost are carried at the tax rates that have been enacted or substantively enacted by the
original invoice amount less allowances for expected credit losses. balance sheet date.
Expected credit losses are calculated in accordance with the simplified Deferred tax is provided in full, on temporary differences arising
approach permitted by IFRS 9, using a provision matrix applying between the tax bases of assets and liabilities and their carrying
lifetime historical credit loss experience to the trade receivables. The amounts in the financial statements. Deferred tax assets are
expected credit loss rate varies depending on whether and the extent recognised to the extent that it is probable that future taxable profits
to which settlement of the trade receivables is overdue and it is also will be available against which the temporary differences can be
adjusted as appropriate to reflect current economic conditions and utilised. Deferred tax is provided on temporary differences arising
estimates of future conditions. For the purpose of determining credit on investments in subsidiaries, associates and joint ventures, except
loss rates, customers are classified into groupings that have similar where the timing of the reversal of the temporary difference can be
loss patterns. The key drivers of the loss rate are the nature of the controlled and it is probable that the temporary difference will not
business unit and the location and type of customer. reverse in the foreseeable future. Deferred tax is provided using rates
of tax that have been enacted or substantively enacted by the
When a trade receivable is determined to have no reasonable
balance sheet date.
expectation of recovery it is written off, firstly against any expected
credit loss allowance available and then to the income statement. Where an uncertain tax position is identified, management will make
a judgement as to what the probable outcome will be. Where it is
Subsequent recoveries of amounts previously provided for or written
assessed that an economic outflow is probable to arise a provision
off are credited to the income statement. Long-term receivables are
is made for the best estimate of the liability. In estimating any such
discounted where the effect is material.
liability GSK applies a risk-based approach which takes into account,
Cash and cash equivalents as appropriate, the probability that the Group would be able to obtain
Cash held in deposit accounts is measured at amortised cost. compensatory adjustments under international tax treaties. These
Investments in money market funds are held at fair value through estimates take into account the specific circumstances of each
profit or loss. dispute and relevant external advice.
150

GSK Annual Report 2018

Notes to the financial statements continued

2. Accounting principles and policies continued

Discounting Trade receivables
Trade receivables are carried at original invoice amount less any
Where the time value of money is material, balances are discounted provisions for doubtful debts. Provisions are made where there is
to current values using appropriate discount rates. The unwinding of evidence of a risk of non-payment, taking into account ageing,
the discounts is recorded in finance income and finance expense. previous experience and general economic conditions. When a trade
Revenue (applicable up to 31 December 2017) receivable is determined to be uncollectable it is written off, firstly
against any provision available and then to the income statement.
Revenue is recognised in the income statement when goods or
services are supplied or made available to external customers against Subsequent recoveries of amounts previously provided for are
orders received, title and risk of loss is passed to the customer, credited to the income statement. Long-term receivables are
reliable estimates can be made of relevant deductions and all relevant discounted where the effect is material.
obligations have been fulfilled, such that the earnings process is Borrowings
regarded as being complete. All borrowings are initially recorded at the amount of proceeds
Turnover represents net invoice value after the deduction of received, net of transaction costs. Borrowings are subsequently
discounts and allowances given and accruals for estimated future carried at amortised cost, with the difference between the proceeds,
rebates and returns. The methodology and assumptions used to net of transaction costs, and the amount due on redemption being
estimate rebates and returns are monitored and adjusted regularly recognised as a charge to the income statement over the period of
in the light of contractual and legal obligations, historical trends, past the relevant borrowing.
experience and projected market conditions. Market conditions are Derivative financial instruments and hedging
evaluated using wholesaler and other third-party analyses, market Derivative financial instruments are used to manage exposure to
research data and internally generated information. Value added tax market risks. The principal derivative instruments used by GSK are
and other sales taxes are excluded from revenue. foreign currency swaps, interest rate swaps, foreign exchange
Where the Group co-promotes a product and the counterparty forward contracts and options. The Group does not hold or issue
records the sale, the Group records its share of revenue as derivative financial instruments for trading or speculative purposes.
co-promotion income within turnover. The nature of co-promotion Derivative financial instruments are classified as held-for-trading and
activities is such that the Group records no costs of sales. In are carried in the balance sheet at fair value. Derivatives designated
addition, initial or event-based milestone income (excluding royalty as hedging instruments are classified on inception as cash flow
income) arising on development or marketing collaborations of the hedges, net investment hedges or fair value hedges.
Group’s compounds or products with other parties is recognised
Changes in the fair value of derivatives designated as cash flow
in turnover.
hedges are recognised in other comprehensive income to the extent
Royalty income is recognised on an accruals basis in accordance that the hedges are effective. Ineffective portions are recognised in
with the terms of the relevant licensing agreements. profit or loss immediately. Amounts deferred in other comprehensive
income are reclassified to the income statement when the hedged
Financial instruments (applicable up to 31 December 2017) item affects profit or loss.
Available-for-sale investments Net investment hedges are accounted for in a similar way to cash
Liquid investments and other investments are classified as available- flow hedges.
for-sale investments and are initially recorded at fair value plus
transaction costs and then remeasured at subsequent reporting Changes in the fair value of derivatives designated as fair value
dates to fair value. Unrealised gains and losses on available-for-sale hedges are recorded in the income statement, together with the
investments are recognised directly in other comprehensive income. changes in the fair value of the hedged asset or liability.
Impairments arising from the significant or prolonged decline in fair Changes in the fair value of any derivative instruments that do not
value of an equity investment reduce the carrying amount of the asset qualify for hedge accounting are recognised immediately in the
directly and are charged to the income statement. income statement.
On disposal or impairment of the investments, any gains and
losses that have been deferred in other comprehensive income
are reclassified to the income statement. Dividends on equity
investments are recognised in the income statement when the
Group’s right to receive payment is established. Equity investments
are recorded in non-current assets unless they are expected to be
sold within one year.
Purchases and sales of equity investments are accounted for on the
trade date and purchases and sales of other available-for-sale
investments are accounted for on settlement date.
 151

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

3. Key accounting judgements and estimates

In preparing the financial statements, management is required to Estimates
make judgements about when or how items should be recognised in If sufficient information is available, in estimating a potential tax
the financial statements and estimates and assumptions that affect liability GSK applies a risk-based approach which takes into account,
the amounts of assets, liabilities, revenue and expenses reported in as appropriate, the probability that the Group would be able to obtain
the financial statements. Actual amounts and results could differ from compensatory adjustments under international tax treaties. These
those estimates. The following are considered to be the critical estimates take into account the specific circumstances of each
accounting judgements and key sources of estimation uncertainty. dispute and relevant external advice, are inherently judgemental and
could change substantially over time as each dispute progresses and
Turnover new facts emerge.
Reported Group turnover for 2018 was £30,821 million (2017 – At 31 December 2018, the Group had recognised provisions
£30,186 million). of £1,082 million in respect of uncertain tax positions (2017 –
Estimates £1,175 million). Because of the nature of these uncertain positions,
Gross turnover is reduced by rebates, discounts, allowances it is not practicable to give meaningful sensitivity estimates.
and product returns given or expected to be given, which vary by Factors affecting the tax charge in future years are set out in Note 14,
product arrangements and buying groups. These arrangements with ‘Taxation’. GSK continues to believe that it has made adequate
purchasing organisations are dependent upon the submission of provision for the liabilities likely to arise from open assessments.
claims some time after the initial recognition of the sale. Accruals Where open issues exist the ultimate liability for such matters may
are made at the time of sale for the estimated rebates, discounts or vary from the amounts provided and is dependent upon the outcome
allowances payable or returns to be made, based on available market of negotiations with the relevant tax authorities or, if necessary,
information and historical experience. litigation proceedings.
Because the amounts are estimated they may not fully reflect the
Legal and other disputes
final outcome, and the amounts are subject to change dependent
upon, amongst other things, the types of buying group and product Legal costs for the year were £117 million (2017 – £166 million).
sales mix. At 31 December 2018 provisions for legal and other disputes
The level of accrual for rebates and returns is reviewed and adjusted amounted to £219 million (2017 – £186 million).
regularly in the light of contractual and legal obligations, historical Judgement
trends, past experience and projected market conditions. Market Management makes a judgement of whether there is sufficient
conditions are evaluated using wholesaler and other third-party information to be able to make a reliable estimate of the likely
analyses, market research data and internally generated information. outcome of the dispute and legal and other expenses arising from
Revenue is not recognised in full until it is highly probable that a claims against the Group. If insufficient information is available,
significant reversal in the amount of cumulative revenue recognised no provision is made and disclosure of the claim is given.
will not occur. The amount of turnover recognised in the year from
Estimates
performance obligations satisfied in previous periods is set out in
The estimated provisions take into account the specific
Note 6, ‘Turnover and segment information’.
circumstances of each dispute and relevant external advice, are
Future events could cause the assumptions on which the accruals inherently judgemental and could change substantially over time
are based to change, which could affect the future results of the as each dispute progresses and new facts emerge. Details of the
Group. status and various uncertainties involved in the significant unresolved
disputes are set out in Note 45, ‘Legal proceedings’.
Taxation
The company’s Directors, having taken legal advice, have
The tax charge for the year was £754 million (2017 – £1,356 million). established provisions after taking into account the relevant facts
At December 2018, current tax payable was £965 million (2017 – and circumstances of each matter and in accordance with
£995 million), non-current corporation tax payable was £272 million accounting requirements. In respect of product liability claims related
(2017 – £411 million) and current tax recoverable was £229 million to certain products there is sufficient history of claims made and
(2017 – £258 million). settlements to enable management to make a reliable estimate of
Judgement the provision required to cover unasserted claims. The Group may
The Group has open tax issues with a number of revenue authorities. become involved in legal proceedings, in respect of which it is not
Management makes a judgement of whether there is sufficient possible to make a reliable estimate of the expected financial effect,
information to be able to make a reliable estimate of the outcome if any, that could result from ultimate resolution of the proceedings.
of the dispute. If insufficient information is available, no provision In these cases, appropriate disclosure about such cases would be
is made. provided, but no provision would be made and no contingent liability
can be quantified.
The ultimate liability for legal claims may vary from the amounts
provided and is dependent upon the outcome of litigation
proceedings, investigations and possible settlement negotiations.
The position could change over time and, therefore, there can be no
assurance that any losses that result from the outcome of any legal
proceedings will not exceed the amount of the provisions reported
in the Group’s financial statements by a material amount.
152

GSK Annual Report 2018

Notes to the financial statements continued

3. Key accounting judgements and estimates continued

Contingent consideration and put option liabilities Pensions and other post-employment benefits
The 2018 income statement charge for contingent consideration Judgement
and put option liabilities was £1,851 million (2017 – £2,134 million). Where a surplus on a defined benefit scheme arises, or there is
potential for a surplus to arise from committed future contributions,
At 31 December 2018, the liability for contingent consideration
the rights of the Trustees to prevent the Group obtaining a refund of
amounted to £6,286 million (2017 – £6,172 million). Of this amount,
that surplus in the future are considered in determining whether it is
£5,937 million (2017 – £5,542 million) related to the acquisition
necessary to restrict the amount of the surplus that is recognised.
of the former Shionogi-ViiV Healthcare joint venture in 2012 and
Four UK schemes are in surplus, with a combined surplus of £711
£296 million (2017 – £584 million) related to the acquisition of the
million at 31 December 2018 (2017 – £470 million). GSK has made
Vaccines business from Novartis in 2015.
the judgement that these amounts meet the requirements of
Estimates recoverability.
Any contingent consideration included in the consideration payable
for a business combination is recorded at fair value at the date of
Estimates
The costs of providing pensions and other post-employment benefits
acquisition. These fair values are generally based on risk-adjusted
are assessed on the basis of assumptions selected by management.
future cash flows discounted using appropriate post-tax discount
These assumptions include future earnings and pension increases,
rates. The fair values are reviewed on a regular basis, at least
discount rates, expected long-term rates of return on assets and
annually, and any changes are reflected in the income statement.
mortality rates, and are disclosed in Note 28, ‘Pensions and other
See Note 39, ‘Contingent consideration liabilities’.
post-employment benefits’.
In June 2018, GSK acquired Novartis’ shareholding in the Consumer
Discount rates are derived from AA rated corporate bond yields
Healthcare Joint Venture for $13 billion. This resulted in a net charge
except in countries where there is no deep market in corporate
in the period of £658 million to remeasure the Consumer Healthcare
bonds where government bond yields are used. A sensitivity analysis
Joint Venture put option to the agreed valuation.
is provided in Note 28, ‘Pensions and other post-employment
Pfizer may request an IPO of ViiV Healthcare at any time and if either benefits’, but a 0.25% reduction in the discount rate would lead to an
GSK does not consent to such IPO or an offering is not completed increase in the net pension deficit of approximately £707 million and
within nine months, Pfizer could require GSK to acquire its an increase in the annual pension cost of approximately £28 million.
shareholding. The liability for the Pfizer put option, which is derived The selection of different assumptions could affect the future results
from an internal valuation of the ViiV Healthcare business, utilising of the Group.
both discounted forecast future cash flow and multiples-based
methodologies amounted to £1,240 million at 31 December 2018
(2017 – £1,304 million). Sensitivity analysis is given in Note 27,
‘Trade and other payables’.

4. New accounting requirements

The following new and amended accounting standards have been GSK will implement IFRS 16 applying the modified retrospective
issued by the IASB and are likely to affect future Annual Reports. approach. For larger leases, the right of use asset at 1 January 2019
will be calculated based on the original lease inception date and for
IFRS 16 ‘Leases’ was issued in January 2016 and will be
smaller leases the right of use asset will be set equal to the lease
implemented by the Group from 1 January 2019. The Standard will
liability, adjusted for any prepaid or accrued lease payments, onerous
replace IAS 17 ‘Leases’ and will require lease liabilities and ‘right of
lease provisions and business combination fair value adjustments.
use’ assets to be recognised on the balance sheet for almost all
On the transition date of 1 January 2019, the Group expects to
leases. This is expected to result in a significant increase in both
recognise right of use assets of £1.1 billion and a lease liability of
assets and liabilities recognised. The costs of operating leases
£1.3 billion, including existing finance leases. The implementation
currently included within operating costs will be split and the
is expected to reduce net assets and total equity by £0.1 billion.
financing element of the charge will be reported within finance
expense. The overall impact on earnings is not expected to be
material. Finance lease obligations at 31 December 2018 are set
out in Note 31, ‘Net debt’ and the undiscounted commitments
under non-cancellable operating leases are set out in Note 41,
‘Commitments’.
 153

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

5. Exchange rates
The Group uses the average of exchange rates prevailing during the period to translate the results and cash flows of overseas subsidiaries,
joint ventures and associates into Sterling and period end rates to translate the net assets of those entities. The currencies which most
influence these translations and the relevant exchange rates were:

2018 2017 2016 2018 2017 2016

Average rates: Period end rates:
US$/£ 1.33 1.30 1.36 US$/£ 1.27 1.35 1.24
Euro/£ 1.13 1.15 1.23 Euro/£ 1.11 1.13 1.17
Yen/£ 147 145 149 Yen/£ 140 152 144

6. Turnover and segment information

Operating segments are reported based on the financial information provided to the Chief Executive Officer and the responsibilities of the
Corporate Executive Team (CET). GSK reports results under four segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and
Consumer Healthcare, and individual members of the CET are responsible for each segment.
The Group’s management reporting process allocates intra-Group profit on a product sale to the market in which that sale is recorded,
and the profit analyses below have been presented on that basis.
Corporate and other unallocated costs included the costs of corporate functions.
Revenue recognised in the year from performance obligations satisfied in previous periods totalled £426 million and included £122 million
reported in turnover arising from changes to prior year estimates of RAR accruals and £299 million of royalty income.
2018 2017 2016
Turnover by segment £m £m £m
Pharmaceuticals 17,269 17,276 16,104
Vaccines 5,894 5,160 4,592
Consumer Healthcare 7,658 7,750 7,193
30,821 30,186 27,889

2018 2017 2016

Pharmaceuticals turnover by therapeutic area £m £m £m
Respiratory 6,928 6,991 6,510
HIV 4,722 4,350 3,556
Immuno-inflammation 472 377 340
Established Pharmaceuticals 5,147 5,558 5,698
17,269 17,276 16,104

2018 2017 2016

Vaccines turnover by category £m £m £m
Meningitis 881 890 662
Influenza 523 488 414
Shingles 784 22 –
Established Vaccines 3,706 3,760 3,516
5,894 5,160 4,592

During 2018, the US operations of the Pharmaceuticals and Vaccines businesses made sales to three wholesalers of approximately
£2,709 million (2017 – £2,449 million; 2016 – £2,139 million), £2,962 million (2017 – £3,043 million; 2016 – £2,691 million) and
£2,656 million (2017 – £2,356 million; 2016 – £2,129 million) respectively, after allocating final-customer discounts to the wholesalers.
2018 2017 2016
Consumer Healthcare turnover by category £m £m £m
Wellness 3,940 4,001 3,726
Oral care 2,496 2,466 2,223
Nutrition 643 680 674
Skin health 579 603 570
7,658 7,750 7,193
154

GSK Annual Report 2018

Notes to the financial statements continued

6. Turnover and segment information continued

2018 2017 2016
Segment profit £m £m £m
Pharmaceuticals 8,420 8,667 7,976
Pharmaceuticals R&D (2,676) (2,740) (2,488)
Pharmaceuticals, including R&D 5,744 5,927 5,488
Vaccines 1,943 1,644 1,429
Consumer Healthcare 1,517 1,373 1,116
Segment profit 9,204 8,944 8,033
Corporate and other unallocated costs (459) (376) (362)
Other reconciling items between segment profit and operating profit (3,262) (4,481) (5,073)
Operating profit 5,483 4,087 2,598

Finance income 81 65 72
Finance costs (798) (734) (736)
Profit on disposal of interest in associates 3 94 –
Share of after tax profits of associates and joint ventures 31 13 5
Profit before taxation 4,800 3,525 1,939
Taxation (754) (1,356) (877)
Profit after taxation for the year 4,046 2,169 1,062

Other reconciling items between segment profit and operating profit comprise items not specifically allocated to segment profit. These
include impairment and amortisation of intangible assets; major restructuring costs, which include impairments of tangible assets and
computer software; transaction-related adjustments related to significant acquisitions; proceeds and costs of disposals of associates,
products and businesses, significant legal charges and expenses on the settlement of litigation and government investigations, other
operating income other than royalty income and other items, and the pre-tax impact of the enactment of the US Tax Cuts and Jobs Act.
2018 2017 2016
Depreciation and amortisation by segment £m £m £m
Pharmaceuticals 506 551 440
Pharmaceuticals R&D 123 96 211
Pharmaceuticals, including R&D 629 647 651
Vaccines 395 405 315
Consumer Healthcare 146 135 126
Segment depreciation and amortisation 1,170 1,187 1,092
Corporate and other unallocated depreciation and amortisation 106 144 94
Other reconciling items between segment depreciation and amortisation and
total depreciation and amortisation 580 591 588
Total depreciation and amortisation 1,856 1,922 1,774
 155

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

6. Turnover and segment information continued

2018 2017 2016
PP&E, intangible asset and goodwill impairment by segment £m £m £m
Pharmaceuticals 51 38 29
Pharmaceuticals R&D 15 10 88
Pharmaceuticals, including R&D 66 48 117
Vaccines 5 13 34
Consumer Healthcare 4 10 46
Segment impairment 75 71 197
Corporate and other unallocated impairment 14 3 24
Other reconciling items between segment impairment and total impairment 261 995 68
Total impairment 350 1,069 289

PP&E and intangible asset impairment reversals by segment

Pharmaceuticals (4) (13) (15)
Pharmaceuticals R&D (1) (2) (10)
Pharmaceuticals, including R&D (5) (15) (25)
Vaccines – – (19)
Consumer Healthcare – (1) (8)
Segment impairment reversals (5) (16) (52)
Corporate and other unallocated impairment reversals – – (26)
Other reconciling items between segment impairment reversals and total impairment reversals (8) (36) (9)
Total impairment reversals (13) (52) (87)

2018 2017
Net assets by segment £m £m
Pharmaceuticals 869 2,017
Pharmaceuticals R&D 502 522
Pharmaceuticals, including R&D 1,371 2,539
Vaccines 9,966 9,707
Consumer Healthcare 10,559 2,003
Segment net operating assets 21,896 14,249
Corporate and other unallocated net operating assets 1,141 868
Net operating assets 23,037 15,117

Net debt (21,621) (13,178)

Investments in associates and joint ventures 236 183
Derivative financial instruments 129 2
Current and deferred taxation 1,723 1,252
Assets held for sale (excluding cash and cash equivalents) 168 113
Net assets 3,672 3,489

The Pharmaceuticals segment includes the Shionogi-ViiV Healthcare contingent consideration liability of £5,937 million (2017 –
£5,542 million) and the Pfizer put option of £1,240 million (2017 – £1,304 million). The put option liability (2017 – £8,606 million)
related to the Consumer Healthcare segment was extinguished during 2018.
156

GSK Annual Report 2018

Notes to the financial statements continued

6. Turnover and segment information continued

Geographical information
The UK is regarded as being the Group’s country of domicile.
2018 2017 2016
Turnover by location of customer £m £m £m
UK 923 940 1,056
US 11,982 11,263 10,197
Rest of World 17,916 17,983 16,636
External turnover 30,821 30,186 27,889

2018 2017
Non-current assets by location of subsidiary £m £m
UK 6,118 6,824
US 7,540 6,841
Rest of World 20,768 20,901
Non-current assets 34,426 34,566

Non-current assets by location excludes amounts relating to other investments, deferred tax assets, derivative financial instruments, pension
assets, amounts receivable under insurance contracts and certain other non-current receivables.

7. Other operating income/(expense)

2018 2017 2016
£m £m £m
Fair value remeasurements of equity investments under IFRS 9 16
Disposal of businesses and assets 258 195 283
Fair value remeasurements on contingent consideration recognised in business combinations (1,252) (1,012) (2,205)
Remeasurement of ViiV Healthcare put option liabilities and preferential dividends 58 13 (577)
Remeasurement of Consumer Healthcare put option liability (658) (1,186) (1,133)
Fair value adjustments on derivative financial instruments (3) 9 (3)
Other (expense)/income (7) 9 23
Impairment of available-for-sale equity investments under IAS 39 (30) (47)
Disposal of available-for-sale equity investments under IAS 39 37 254
(1,588) (1,965) (3,405)

Disposal of businesses and assets in 2018 included a profit of £119 million on the disposal of tapinarof to Dermavant Sciences, a profit of
£33 million on the disposal of Consumer Healthcare tail brands in the US and a gain arising from the increase in value of the shares in
Hindustan Unilever Limited to be received on the disposal of Horlicks and other Consumer Healthcare brands, which is expected to complete
by the end of 2019, net of disposal costs.
Fair value remeasurements on contingent consideration recognised in business combinations included £1,188 million related to the
acquisition of the former Shionogi-ViiV Healthcare joint venture and £56 million payable to Novartis related to the Vaccines acquisition and
fair value movements on derivatives hedging foreign exchange exposure.
 157

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

8. Operating profit
2018 2017 2016
The following items have been included in operating profit: £m £m £m
Employee costs (Note 9) 9,440 9,122 8,212
Advertising 1,376 1,351 1,265
Distribution costs 389 405 395
Depreciation of property, plant and equipment 954 988 978
Impairment of property, plant and equipment, net of reversals 203 327 180
Amortisation of intangible assets 902 934 796
Impairment of intangible assets, net of reversals 134 690 22
Net foreign exchange losses 81 215 53
Inventories:
Cost of inventories included in cost of sales 8,713 8,526 8,093
Write-down of inventories 695 701 533
Reversal of prior year write-down of inventories (302) (352) (145)
Operating lease rentals:
Minimum lease payments 188 110 91
Contingent rents 12 4 4
Sub-lease payments 5 5 4
Fees payable to the company’s auditor and its associates in relation to the Group (see below) 29.8 29.2 29.7

The reversals of prior year write-downs of inventories principally arise from the reassessment of usage or demand expectations prior to
inventory expiration.
Net foreign exchange losses include a net loss of £nil (2017 – £109 million; 2016 – £nil) of exchange arising on the reclassification
of exchange on liquidation or disposal of overseas subsidiaries.
Included within operating profit are major restructuring charges of £809 million (2017 – £1,056 million; 2016 – £970 million), see Note 10,
‘Major restructuring costs’.
2018 2017 2016
Fees payable to the company’s auditor and its associates: £m £m £m
Audit of parent company and consolidated financial statements 6.7 7.0 5.8
Audit of the company’s subsidiaries 12.9 16.2 16.4
Attestation under s.404 of Sarbanes-Oxley Act 2002 6.6 4.5 4.4
Audit and audit-related services 26.2 27.7 26.6
Taxation compliance 0.1 0.2 0.2
Taxation advice – 0.1 1.8
Other assurance services 3.0 1.0 0.3
All other services 0.5 0.2 0.8
29.8 29.2 29.7

The other assurance services provided by the auditor relate to agreed upon procedures and other assurance services outside of statutory
audit requirements. All other services provided by the auditor primarily related to advisory services for the year ended 31 December 2018.

In addition to the above, fees paid in respect of the GSK pension schemes were:
2018 2017 2016
£m £m £m
Audit 0.3 0.3 0.4
Other services – 0.1 –
158

GSK Annual Report 2018

Notes to the financial statements continued

9. Employee costs
2018 2017 2016
£m £m £m
Wages and salaries 7,203 7,116 6,391
Social security costs 795 802 733
Pension and other post-employment costs, including augmentations (Note 28) 586 616 541
Cost of share-based incentive plans 393 347 338
Severance and other costs from integration and restructuring activities 463 241 209
9,440 9,122 8,212

The increase in wages and salaries included the impact of movements in exchange rates. The Group provides benefits to employees,
commensurate with local practice in individual countries, including, in some markets, healthcare insurance, subsidised car schemes and
personal life assurance.
The cost of share-based incentive plans is analysed as follows:
2018 2017 2016
£m £m £m
Share Value Plan 304 276 271
Performance Share Plan 49 47 39
Share option plans 4 4 4
Cash settled and other plans 36 20 24
393 347 338

The average monthly number of persons employed by the Group (including Directors) during the year was:
2018 2017 2016
Number Number Number
Manufacturing 37,296 38,632 38,611
Selling, general and administration 47,887 49,141 49,961
Research and development 11,668 11,576 11,255
96,851 99,349 99,827

The average monthly number of Group employees excludes temporary and contract staff. The numbers of Group employees at the end of
each financial year are given in the financial record on page 231. The monthly average number of persons employed by GlaxoSmithKline plc
in 2018 was nil (2017 – nil).
The compensation of the Directors and Senior Management (members of the CET) in aggregate, was as follows:
2018 2017 2016
£m £m £m
Wages and salaries 29 26 25
Social security costs 3 4 4
Pension and other post-employment costs 3 3 2
Cost of share-based incentive plans 20 22 15
55 55 46

Further information on the remuneration of the Directors is given in the Remuneration report on pages 96 to 124.

10. Major restructuring costs

Within the Pharmaceuticals sector, the highly regulated manufacturing operations and supply chains and long lifecycle of the business mean
that restructuring programmes, particularly those that involve the rationalisation or closure of manufacturing or R&D sites, are likely to take
several years to complete.
Major restructuring costs are those related to specific Board approved Major restructuring programmes, including integration costs following
material acquisitions, which are structural and are of a significant scale where the costs of individual or related projects exceed £25 million.
The existing Combined restructuring and integration programme incorporates the previous Major Change programme, the Pharmaceuticals
restructuring programme and the restructuring and integration programme following the Novartis transaction in 2015. In July 2018, the Board
approved a new Major restructuring programme, which is designed to significantly improve the competitiveness and efficiency of the Group’s
cost base with savings delivered primarily through supply chain optimisation and reductions in administrative costs.
 159

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

10. Major restructuring costs continued

The total restructuring costs of £809 million in 2018 were incurred in a number of areas, including the following:
–– Restructuring of the commercial operating model, including staff reductions in the US, Europe and International Pharmaceutical commercial
operations and the US Respiratory field sales force
–– Manufacturing site restructuring, including the GSK steriles manufacturing facility at Ulverston, United Kingdom
–– Vaccines transformation and remediation
–– Restructuring of the Pharmaceutical and Consumer Healthcare supply chains leading to simplification of the operating model and
improved resource allocation
–– Transformation of central functions, including GSK technology platforms and interfaces, to deliver greater digital synergies, simplification
of applications and staff reductions.
The analysis of the costs charged to operating profit under these programmes was as follows:
2018 2017 2016
£m £m £m
Increase in provision for Major restructuring programmes (see Note 29) 450 259 163
Amount of provision reversed unused (see Note 29) (99) (43) (140)
Impairment losses recognised 130 278 158
Other non-cash charges 72 247 108
Other cash costs 256 315 681
809 1,056 970

Asset impairments and other non-cash charges principally comprise fixed asset write-downs across support function, manufacturing and
research facilities and accelerated depreciation where asset lives in R&D and manufacturing have been shortened as a result of the major
restructuring programmes. All other charges have been or will be settled in cash and include the termination of leases, site closure costs
and consultancy and project management fees.
The analysis of Major restructuring charges by income statement line was as follows:
2018 2017 2016
£m £m £m
Cost of sales 443 545 297
Selling, general and administration 315 248 514
Research and development 49 263 159
Other operating income/(expense) 2 – –
809 1,056 970

11. Finance income

2018 2017 2016
£m £m £m
Year to 31 December 2018 under IFRS 9
Finance income arising from:
Financial assets measured at amortised cost 73
Financial assets measured at fair value through profit or loss 1
Net gains arising from hedge ineffectiveness on net investment hedges 7

Years to 31 December 2017 and 31 December 2016 under IAS 39

Interest income arising from:
Cash and cash equivalents 60 67
Available-for-sale investments 2 1
Loans and receivables 1 2
Fair value adjustments on derivatives at fair value through profit or loss 2 2
81 65 72

Interest income arising from financial assets measured at amortised cost in 2018 includes interest income arising from assets which would
have been classified as available-for-sale investments and loans and receivables in prior years under IAS 39. This also includes interest
income arising from certain cash and cash equivalents. Interest income arising from financial assets measured at fair value through profit or
loss in 2018 includes interest income arising from other cash and cash equivalents.
Net gains arising from hedge ineffectiveness on net investment hedges were recorded in ‘Fair value adjustments on derivatives at fair value
through profit or loss’ in 2017 and 2016. All derivatives accounted for at fair value through profit or loss other than designated and effective
hedging instruments (see Note 42, ‘Financial instruments and related disclosures’) are classified as held-for-trading financial instruments.
160

GSK Annual Report 2018

Notes to the financial statements continued

12. Finance expense

2018 2017 2016
£m £m £m
Finance expense arising on:
Financial liabilities at amortised cost (677) (698) (671)
Derivatives at fair value through profit or loss (38) (22) (30)
Net losses arising from:
Financial instruments mandatorily measured at fair value through profit or loss 3 (4) (3)
Reclassification of hedges from other comprehensive income (2) – (1)
Unwinding of discounts on provisions (15) (16) (16)
Other finance expense (69) 6 (15)
(798) (734) (736)

All derivatives accounted for at fair value through profit or loss, other than designated and effective hedging instruments (see Note 42,
‘Financial instruments and related disclosures’), are classified as held-for-trading financial instruments. Interest expense arising on
derivatives at fair value through profit or loss relates to swap interest expense. Other finance expense in 2018 includes a £39 million charge
(2017 – £24 million credit) for interest relating to historical income tax settlements.

13. Associates and joint ventures

The Group’s share of after tax profits and losses of associates and joint ventures is set out below:

2018 2017 2016

£m £m £m
Share of after tax profits of associates 28 16 9
Share of after tax profits/(losses) of joint ventures 3 (3) (4)
31 13 5

At 31 December 2018, the Group held one significant associate, Innoviva, Inc.
Summarised income statement information in respect of Innoviva is set out below for the periods in which the Group accounted for its
investment in Innoviva as an associate. The Group’s 2018 share of after tax profits of associates and other comprehensive income includes
a profit of £33 million and other comprehensive income of £nil in respect of Innoviva.
2018 2017 2016
£m £m £m
Turnover 183 165 98
Profit after taxation 134 103 44
Other comprehensive income – – –
Total comprehensive income 134 103 44

The results of Innoviva included in the summarised income statement information above represent the estimated earnings of Innoviva in the
relevant periods, based on publicly available information. Innoviva’s turnover is from royalty income from GSK in relation to Relvar/Breo Ellipta,
Anoro Ellipta and Trelegy Ellipta sales.

Aggregated financial information in respect of GSK’s share of other associated undertakings and joint ventures is set out below:
2018 2017 2016
£m £m £m
Share of turnover 242 252 133
Share of after tax (losses)/profits (2) (5) (1)
Share of other comprehensive income – – –
Share of total comprehensive (expense)/income (2) (5) (1)

The Group’s sales to associates and joint ventures were £43 million in 2018 (2017 – £41 million; 2016 – £43 million).
 161

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

14. Taxation
The Group’s tax charge is the sum of the total current and deferred tax expense.
2018 2017 2016
Taxation charge based on profits for the year £m £m £m
UK current year charge 234 199 241
Rest of World current year charge 1,426 1,928 1,326
Credit in respect of prior periods (492) (508) (149)
Total current taxation 1,168 1,619 1,418
Total deferred taxation (414) (263) (541)
Total tax 754 1,356 877

In 2018, GSK made payments of £113 million in UK corporation tax to HMRC. These amounts are for UK corporation tax only, and do not
include the various other business taxes borne in the UK by GSK each year.
The deferred tax credit in 2018 reflected the origination of current year tax losses, where offset against taxable profits in future periods is
probable, as well as an uplift in the tax carrying value of certain Consumer Healthcare brands as a result of the acquisition of Novartis’ interest
in the former Consumer Healthcare Joint Venture.
The deferred tax credit in 2017 reflected the revaluation of existing deferred tax liabilities to reflect a lower Swiss tax rate applicable following
Swiss tax reform, and an increase in deferred tax assets related to intra-Group profit on inventory. The impact of these items was partly offset
by the revaluation of existing deferred tax assets to reflect the lower US tax rate applicable following the enactment of US tax reform. In 2016,
the net deferred tax credit was impacted to a greater extent by remeasurement of the contingent consideration in relation to the former
Shionogi-ViiV Healthcare Joint Venture.
The following table reconciles the tax charge calculated at the UK statutory rate on the Group profit before tax with the actual tax charge for
the year.
2018 2018 2017 2017 2016 2016
Reconciliation of taxation on Group profits £m % £m % £m %
Profit before tax 4,800 3,525 1,939
UK statutory rate of taxation 912 19.0 679 19.25 388 20.0
Differences in overseas taxation rates 675 14.1 635 18.0 593 30.6
Benefit of intellectual property incentives (522) (10.9) (458) (13.0) (321) (16.5)
R&D credits (73) (1.5) (75) (2.1) (93) (4.8)
FV remeasurement of non-taxable put options 221 4.6 227 6.4 340 17.5
Tax losses where no benefit is recognised 24 0.5 28 0.8 (15) (0.8)
Permanent differences on disposals and acquisitions (7) (0.1) 4 0.1 (21) (1.1)
Other permanent differences 85 1.7 196 5.6 122 6.3
Re-assessments of prior year estimates (436) (9.1) (475) (13.5) (116) (6.0)
US and Swiss Tax Reform (125) (2.6) 595 16.9
Tax charge/tax rate 754 15.7 1,356 38.5 877 45.2

GSK has a substantial business presence in many countries around the world. The impact of differences in overseas taxation rates arose from
profits being earned in countries with tax rates higher than the UK statutory rate, the most significant of which in 2018 were the US, Belgium,
India and Japan. The adverse impact was partly offset by the increased benefit of intellectual property incentives such as the UK Patent box
and Belgian Patent income deduction regimes. Such regimes provide a reduced rate of corporate income tax on profits earned from qualifying
patents.
The Group’s 2018 tax rate of 15.7% has been influenced by the reassessment of open issues with tax authorities in various jurisdictions,
together with the £125 million credit related to a reduced estimate of the 2017 impact of US Tax Reform following additional guidance being
released by the US tax authorities and the transaction related charges arising on the Group’s put option liabilities to ViiV Healthcare and the
former Consumer Healthcare Joint Venture with Novartis.
Future tax charges, and therefore the Group’s effective tax rate, may be affected by factors such as acquisitions, disposals, restructuring, the
location of research and development activity, tax regime reforms and resolution of open matters as tax affairs are brought up to date around
the world.
162

GSK Annual Report 2018

Notes to the financial statements continued

14. Taxation continued

2018 2017 2016
Tax on items charged to equity and statement of comprehensive income £m £m £m
Current taxation
Share-based payments – – 7
Defined benefit plans (2) 26 32
(2) 26 39
Deferred taxation
Share-based payments 2 (4) –
Defined benefit plans (144) (247) 94
Fair value movements on cash flow hedges (2) – 2
Fair value movements on equity investments 10 29 51
(134) (222) 147
Total (charge)/credit to equity and statement of comprehensive income (136) (196) 186

All of the above items have been charged to the statement of comprehensive income except for tax on share-based payments.
Issues relating to taxation
The integrated nature of the Group’s worldwide operations involves significant investment in research and strategic manufacture at a limited
number of locations, with consequential cross-border supply routes into numerous end-markets. In line with current OECD guidelines GSK
bases its transfer pricing policy on the ‘arm’s length’ principle. However, different tax authorities may seek to attribute further profit to activities
being undertaken in their jurisdiction potentially resulting in double taxation. The Group also has open items in several jurisdictions concerning
such matters as the deductibility of particular expenses and the tax treatment of certain business transactions. GSK applies a risk-based
approach to determine the transactions most likely to be subject to challenge and the probability that the Group would be able to obtain
compensatory adjustments under international tax treaties.
The calculation of the Group’s total tax charge therefore necessarily involves a degree of estimation and judgement in respect of certain items
whose tax treatment cannot be finally determined until resolution has been reached with the relevant tax authority or, as appropriate, through a
formal legal process. At 31 December 2018 the Group had recognised provisions of £1,082 million in respect of such uncertain tax positions
(2017 – £1,175 million). The decrease in recognised provisions during 2018 was driven by the reassessment of estimates and the utilisation
of provisions for uncertain tax positions following the settlement of a number of open issues with tax authorities in various jurisdictions. Whilst
the ultimate liability for such matters may vary from the amounts provided and is dependent upon the outcome of agreements with the relevant
tax authorities, or litigation where appropriate, the Group continues to believe that it has made appropriate provision for periods which are
open and not yet agreed by the tax authorities. GSK does not currently anticipate any material changes to the amounts provided for transfer
pricing or tax contingencies during the next 12 months.
A provision for deferred tax liabilities of £185 million as at 31 December 2018 (2017 – £209 million) has been made in respect of withholding
taxation that would be payable on the remittance of profits by certain overseas subsidiaries. Whilst the aggregate amount of unremitted profits
at the balance sheet date was approximately £18 billion (2017 – £17 billion), the majority of these unremitted profits would not be subject to
tax (including withholding tax) on repatriation, as UK legislation relating to company distributions provides for exemption from tax for most
overseas profits, subject to certain exceptions. Deferred tax is not provided on temporary differences of £231 million (2017 – £nil) arising
on unremitted profits as management has the ability to control any future reversal and does not consider such a reversal to be probable.
 163

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

14. Taxation continued

Movement in deferred tax assets and liabilities
Pensions & Share Other
Accelerated other post option net
capital Intangible Contingent Intra-Group employment Tax and award temporary
allowances assets consideration profit benefits losses schemes differences Total
£m £m £m £m £m £m £m £m £m
At 1 January 2017 (377) (2,324) 1,138 1,054 1,262 227 110 1,350 2,440
Exchange adjustments (7) 75 – (58) (48) (5) (4) (18) (65)
Credit/(charge) to income statement 62 330 (52) 256 3 59 (1) (88) 569
Credit/(charge) to income statement
associated with US tax reform 5 116 (218) (235) (210) (20) (27) (216) (805)
Credit to income statement
associated with Swiss tax reform – 483 – – – – – – 483
(Charge)/credit to statement of
comprehensive income and equity – – – – (247) – (4) 29 (222)
At 1 January 2018 (317) (1,320) 868 1,017 760 261 74 1,057 2,400
Exchange adjustments (6) (4) – 43 38 2 2 9 84
Credit/(charge) to income statement (12) 365 (34) (31) 33 183 (7) (101) 396
Credit/(charge) to statement of
comprehensive income and equity – – – – (144) – 2 8 (134)
Reclassification on disposal – – – – 7 1 – (23) (15)
At 31 December 2018 (335) (959) 834 1,029 694 447 71 950 2,731

The net credit to the income statement of £396 million included an £18 million charge related to R&D incentives recognised within Operating
profit (and not the taxation charge) in the income statement.
Deferred tax liabilities provided in relation to intangible assets predominately relate to temporary differences arising on assets and liabilities
acquired as part of historic business combinations.
The Group continues to recognise deferred tax assets on future obligations in respect of contingent consideration amounts payable to
minority shareholders. These payments are tax deductible at the point in time at which payment is made.
A deferred tax asset is recognised on intra-Group profits arising on inter-company inventory which are eliminated within the consolidated
accounts. As intra-Group profits are not eliminated from the individual entities’ tax returns a temporary difference arises that will reverse at the
point in time inventory is sold externally.
The deferred tax asset recognised on tax losses of £447 million (2017 – £261 million) related to trading losses. Other net temporary
differences included accrued expenses for which a tax deduction is only available on a paid basis, such as for pensions.
Deferred tax asset and liabilities are recognised on the balance sheet as follows:
2018 2017
£m £m
Deferred tax assets 3,887 3,796
Deferred tax liabilities (1,156) (1,396)
2,731 2,400

Deferred tax assets are recognised on US foreign tax credits only where it is probable that future taxable profits will be available. The net
amount of foreign tax credits on which deferred tax has not been provided was £114 million at 31 December 2018 (2017 – £151 million).
2018 2017
Unrecognised Unrecognised
deferred tax deferred tax
Tax losses asset Tax losses asset
Unrecognised tax losses £m £m £m £m
Trading losses expiring:
Within 10 years 678 148 802 187
More than 10 years 957 93 872 99
Available indefinitely 89 15 86 14
At 31 December 1,724 256 1,760 300

Capital losses expiring:

Available indefinitely 2,042 399 1,924 372
At 31 December 2,042 399 1,924 372

Deferred tax assets are only recognised where it is probable that future taxable profit will be available to utilise losses.
164

GSK Annual Report 2018

Notes to the financial statements continued

15. Earnings per share

2018 2017 2016
pence pence pence
Basic earnings per share 73.7 31.4 18.8
Diluted earnings per share 72.9 31.0 18.6

Basic earnings per share has been calculated by dividing the profit attributable to shareholders by the weighted average number of shares
in issue during the period after deducting shares held by the ESOP Trusts and Treasury shares. The trustees have waived their rights to
dividends on the shares held by the ESOP Trusts.
Diluted earnings per share has been calculated after adjusting the weighted average number of shares used in the basic calculation to
assume the conversion of all potentially dilutive shares. A potentially dilutive share forms part of the employee share schemes where its
exercise price is below the average market price of GSK shares during the period and any performance conditions attaching to the scheme
have been met at the balance sheet date.
The numbers of shares used in calculating basic and diluted earnings per share are reconciled below.
2018 2017 2016
Weighted average number of shares in issue millions millions millions
Basic 4,914 4,886 4,860
Dilution for share options and awards 57 55 49
Diluted 4,971 4,941 4,909

16. Dividends
2018 2017 2016
Dividend Total Dividend Total Dividend Total
per share dividend per share dividend per share dividend
Paid/payable (pence) £m Paid (pence) £m Paid (pence) £m
First interim 12 July 2018 19 934 13 July 2017 19 928 14 July 2016 19 923
Second interim 11 October 2018 19 934 12 October 2017 19 929 13 October 2016 19 925
Third interim 10 January 2019 19 935 11 January 2018 19 929 12 January 2017 19 925
Fourth interim 11 April 2019 23 1,132 12 April 2018 23 1,130 13 April 2017 23 1,124
Total 80 3,935 80 3,916 80 3,897

Under IFRS, interim dividends are only recognised in the financial statements when paid and not when declared. GSK normally pays a
dividend two quarters after the quarter to which it relates and one quarter after it is declared. The 2018 financial statements recognise those
dividends paid in 2018, namely the third and fourth interim dividends for 2017, and the first and second interim dividends for 2018.
The amounts recognised in each year were as follows:
2018 2017 2016
£m £m £m
Dividends to shareholders 3,927 3,906 4,850
 165

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

17. Property, plant and equipment

Plant,
Land and equipment Assets in
buildings and vehicles construction Total
£m £m £m £m
Cost at 1 January 2017 7,761 11,235 3,168 22,164
Exchange adjustments (127) (62) (45) (234)
Other additions 69 296 1,219 1,584
Capitalised borrowing costs – – 30 30
Disposals and write-offs (376) (685) (31) (1,092)
Reclassifications 602 1,186 (1,826) (38)
Transfer to assets held for sale (462) (219) (14) (695)
Cost at 31 December 2017 7,467 11,751 2,501 21,719
Exchange adjustments 150 187 25 362
Other additions 33 190 1,135 1,358
Capitalised borrowing costs – – 21 21
Disposals and write-offs (90) (440) (53) (583)
Reclassifications 403 1,016 (1,486) (67)
Transfer to assets held for sale (152) (167) (3) (322)
Cost at 31 December 2018 7,811 12,537 2,140 22,488

Depreciation at 1 January 2017 (3,259) (7,410) – (10,669)

Exchange adjustments 50 110 – 160
Charge for the year (299) (689) – (988)
Disposals and write-offs 158 539 – 697
Transfer to assets held for sale 314 190 – 504
Depreciation at 31 December 2017 (3,036) (7,260) – (10,296)
Exchange adjustments (61) (111) – (172)
Charge for the year (268) (686) – (954)
Disposals and write-offs 77 401 – 478
Transfer to assets held for sale 55 122 – 177
Depreciation at 31 December 2018 (3,233) (7,534) – (10,767)

Impairment at 1 January 2017 (279) (344) (64) (687)

Exchange adjustments 8 2 (2) 8
Disposals and write-offs 210 104 28 342
Impairment losses (194) (138) (17) (349)
Reversal of impairments 7 9 1 17
Transfer to assets held for sale 87 8 11 106
Impairment at 31 December 2017 (161) (359) (43) (563)
Exchange adjustments (8) (4) (1) (13)
Disposals and write-offs 10 59 22 91
Impairment losses (16) (143) (46) (205)
Reversal of impairments 1 6 – 7
Transfer to assets held for sale – 20 – 20
Impairment at 31 December 2018 (174) (421) (68) (663)

Total depreciation and impairment at 31 December 2017 (3,197) (7,619) (43) (10,859)
Total depreciation and impairment at 31 December 2018 (3,407) (7,955) (68) (11,430)

Net book value at 1 January 2017 4,223 3,481 3,104 10,808

Net book value at 31 December 2017 4,270 4,132 2,458 10,860

Net book value at 31 December 2018 4,404 4,582 2,072 11,058

The weighted average interest rate for capitalised borrowing costs in the year was 3% (2017 – 4%). Disposals and write-offs in the year
included a number of assets with nil net book value that are no longer in use in the business.
166

GSK Annual Report 2018

Notes to the financial statements continued

17. Property, plant and equipment continued

The net book value at 31 December 2018 of the Group’s land and buildings included £24 million (2017 – £27 million) held under finance
leases. In addition, the net book value of plant, equipment and vehicles held under finance lease at 31 December 2018 was £59 million
(2017 – £55 million).
The impairment losses principally arose from decisions to rationalise facilities and are calculated based on either fair value less costs
of disposal or value in use. The fair value less costs of disposal valuation methodology uses significant inputs which are not based on
observable market data, and therefore this valuation technique is classified as level 3 of the fair value hierarchy. These calculations
determine the net present value of the projected risk-adjusted, post-tax cash flows of the relevant asset or cash generating unit, applying
a discount rate of the Group post-tax weighted average cost of capital (WACC) of 7%, adjusted where appropriate for specific segment,
country and currency risk. For value in use calculations, where an impairment is indicated and a pre-tax cash flow calculation is expected
to give a materially different result, the test would be reperformed using pre-tax cash flows and a pre-tax discount rate. The Group WACC
is equivalent to a pre-tax discount rate of approximately 9%. The net impairment losses have been charged to cost of sales £142 million
(2017 – £198 million), R&D £9 million (2017 – £93 million) and SG&A £54 million (2017 – £36 million), and included £138 million
(2017 – £278 million) arising from the major restructuring programmes.
Reversals of impairment arose from subsequent reviews of the impaired assets where the conditions which gave rise to the original
impairments were deemed no longer to apply. All of the reversals have been credited to cost of sales.
The carrying value at 31 December 2018 of assets for which impairments have been charged or reversed in the year was £95 million
(2017 – £33 million).
During 2018, £67 million (2017 – £38 million) of computer software was reclassified from assets in construction to intangible assets
on becoming ready for use.

18. Goodwill
2018 2017
£m £m
Cost at 1 January 5,734 5,965
Exchange adjustments 199 (228)
Transfer to assets held for sale (144) (3)
Cost at 31 December 5,789 5,734

Net book value at 1 January 5,734 5,965

Net book value at 31 December 5,789 5,734

Goodwill is allocated to the Group’s segments as follows:

2018 2017
£m £m
Pharmaceuticals 3,273 3,172
Vaccines 1,342 1,302
Consumer Healthcare 1,174 1,260
Net book value at 31 December 5,789 5,734
 167

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

18. Goodwill continued

The recoverable amounts of the cash generating units are assessed using a fair value less costs of disposal model. Fair value less costs of
disposal is calculated using a discounted cash flow approach, with a post-tax discount rate applied to the projected risk-adjusted post-tax
cash flows and terminal value.
The discount rate used is based on the Group WACC of 7%, as most cash generating units have integrated operations across large parts of
the Group. The discount rate is adjusted where appropriate for specific segment, country and currency risks. The valuation methodology uses
significant inputs which are not based on observable market data, therefore this valuation technique is classified as level 3 in the fair value
hierarchy.
Details relating to the discounted cash flow models used in the impairment tests of the Pharmaceuticals, Vaccines and Consumer Healthcare
cash generating units are as follows:

Valuation basis Fair value less costs of disposal

Key assumptions Sales growth rates

Profit margins
Terminal growth rate
Discount rate
Taxation rate

Determination of assumptions Growth rates are internal forecasts based on both internal and external market information.
Margins reflect past experience, adjusted for expected changes.
Terminal growth rates based on management’s estimate of future long-term average growth rates.
Discount rates based on Group WACC, adjusted where appropriate.
Taxation rates based on appropriate rates for each region.

Period of specific projected cash flows Five years

Terminal growth rate and discount rate Terminal growth rate Discount rate

Pharmaceuticals 1% p.a. 7.5%

Vaccines 1% p.a. 7.5%
Consumer Healthcare 2% p.a. 6%

The terminal growth rates do not exceed the long-term projected growth rates for the relevant markets, reflect the impact of future generic
competition and take account of new product launches.
In each case the valuations indicated sufficient headroom such that a reasonably possible change to key assumptions is unlikely to result in
an impairment of the related goodwill. Goodwill is monitored at the segmental level.
The Pharmaceuticals cash generating unit comprises a collection of smaller cash generating units including assets with indefinite lives with
a carrying value of £236 million (2017 – £228 million). The Consumer Healthcare cash generating unit also comprises a collection of smaller
cash generating units including brands with indefinite lives with a carrying value of £8.5 billion (2017 – £8.5 billion).
Details of indefinite life brands are given in Note 19, ‘Other intangible assets’.
168

GSK Annual Report 2018

Notes to the financial statements continued

19. Other intangible assets

Computer Licences, Amortised Indefinite life
software patents, etc. brands brands Total
£m £m £m £m £m
Cost at 1 January 2017 2,156 15,143 427 9,375 27,101
Exchange adjustments (37) (215) (4) (272) (528)
Capitalised development costs – 251 – – 251
Capitalised borrowing costs 2 3 – – 5
Other additions 233 221 – – 454
Disposals and asset write-offs (217) (38) – – (255)
Transfer to assets held for sale (1) (90) – (44) (135)
Reclassifications 38 – 66 (66) 38
Cost at 31 December 2017 2,174 15,275 489 8,993 26,931
Exchange adjustments 32 235 29 63 359
Capitalised development costs – 203 – – 203
Capitalised borrowing costs 1 – – – 1
Other additions 173 154 – – 327
Disposals and asset write-offs (80) (129) – – (209)
Transfer to assets held for sale (2) (81) (9) – (92)
Reclassifications 67 – – – 67
Cost at 31 December 2018 2,365 15,657 509 9,056 27,587
Amortisation at 1 January 2017 (1,184) (4,983) (224) – (6,391)
Exchange adjustments 25 141 – – 166
Charge for the year (163) (761) (10) – (934)
Disposals and asset write-offs 210 25 – – 235
Transfer to assets held for sale 1 25 – – 26
Amortisation at 31 December 2017 (1,111) (5,553) (234) – (6,898)
Exchange adjustments (24) (104) (3) – (131)
Charge for the year (240) (645) (17) – (902)
Disposals and asset write-offs 67 124 – – 191
Transfer to assets held for sale 1 18 1 – 20
Amortisation at 31 December 2018 (1,307) (6,160) (253) – (7,720)
Impairment at 1 January 2017 (9) (1,652) (143) (130) (1,934)
Exchange adjustments – 110 – 3 113
Impairment losses (2) (546) – (132) (680)
Disposals and asset write-offs 2 5 – – 7
Transfer to assets held for sale – 19 – 4 23
Impairment at 31 December 2017 (9) (2,064) (143) (255) (2,471)
Exchange adjustments – (69) (20) – (89)
Impairment losses (17) (51) – (69) (137)
Reversal of impairments – 3 – – 3
Disposals and asset write-offs 14 4 – – 18
Transfer to assets held for sale – 11 – – 11
Impairment at 31 December 2018 (12) (2,166) (163) (324) (2,665)
Total amortisation and impairment at 31 December 2017 (1,120) (7,617) (377) (255) (9,369)
Total amortisation and impairment at 31 December 2018 (1,319) (8,326) (416) (324) (10,385)

Net book value at 1 January 2017 963 8,508 60 9,245 18,776

Net book value at 31 December 2017 1,054 7,658 112 8,738 17,562
Net book value at 31 December 2018 1,046 7,331 93 8,732 17,202

The weighted average interest rate for capitalised borrowing costs in the year was 3% (2017 – 4%).
The net book value of computer software included £578 million (2017 – £669 million) of internally generated costs.
The carrying value at 31 December 2018 of intangible assets, for which impairments have been charged or reversed in the year, following
those impairments or reversals, was £73 million (2017 – £300 million).
The patent expiry dates of the Group’s most significant assets, where relevant, are set out on pages 238 and 239.
 169

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

19. Other intangible assets continued

Amortisation and impairment losses, net of reversals, have been charged in the income statement as follows:
Amortisation Net impairment losses
2018 2017 2018 2017
£m £m £m £m
Cost of sales 593 578 69 400
Selling, general and administration 178 116 19 2
Research and development 131 240 46 278
902 934 134 680

Licences, patents, etc. includes a large number of acquired licences, patents, know-how agreements and marketing rights, which are either
marketed or in use, or still in development. Note 38, ‘Acquisitions and disposals’ gives details of additions through business combinations in
the year. The book values of the largest individual items are as follows:
2018 2017
£m £m
Meningitis portfolio 2,363 2,450
Dolutegravir 1,319 1,389
Benlysta 905 965
Fluarix/FluLaval 274 321
HIV assets acquired from BMS 277 277
Selzentry 136 162
Okairos technology platform 205 202
Others 1,852 1,892
7,331 7,658

The Meningitis portfolio includes Menveo, Bexsero, Men ABCWY and Menjugate.
Indefinite life brands comprise a portfolio of Consumer Healthcare products primarily acquired with the acquisitions of Sterling Winthrop, Inc.
in 1994, Block Drug Company, Inc. in 2001, CNS, Inc. in 2006 and the Novartis Consumer Healthcare business in 2015, together with a
number of pharmaceutical brands from the acquisition of Stiefel Laboratories, Inc. in 2009. The book values of the major brands are as follows:
2018 2017
£m £m
Voltaren 2,735 2,716
Otrivin 1,385 1,380
Fenistil 651 648
Theraflu 449 441
Panadol 388 386
Sensodyne 265 265
Lamisil 293 289
Breathe Right 262 236
Stiefel trade name 236 228
Excedrin 193 185
Physiogel 150 166
Polident 112 112
Others 1,613 1,686
8,732 8,738

Each of these brands is considered to have an indefinite life, given the strength and durability of the brand and the level of marketing support.
The brands are in relatively similar stable and profitable market sectors, with similar risk profiles, and their size, diversification and market
shares mean that the risk of market-related factors causing a reduction in the lives of the brands is considered to be relatively low. The
Group is not aware of any material legal, regulatory, contractual, competitive, economic or other factors which could limit their useful lives.
Accordingly, they are not amortised.
Each brand is tested annually for impairment and other amortised intangible assets are tested when indicators of impairment arise. This
testing applies a fair value less costs of disposal methodology, generally using post-tax cash flow forecasts with a terminal value calculation
and a discount rate equal to the Group post-tax WACC of 7%, adjusted where appropriate for specific segment, country and currency risks.
This valuation methodology uses significant inputs which are not based on observable market data, and therefore this valuation technique is
classified as level 3 of the fair value hierarchy. The main assumptions include future sales price and volume growth, product contribution,
the future expenditure required to maintain the product’s marketability and registration in the relevant jurisdictions and exchange rates. These
assumptions are based on past experience and are reviewed as part of management’s budgeting and strategic planning cycle for changes
in market conditions and sales erosion through competition. The terminal growth rates applied of between nil% and 3% are management’s
estimates of future long-term average growth rates of the relevant markets. In each case the valuations indicate sufficient headroom such
that a reasonably possible change to key assumptions is unlikely to result in an impairment of these intangible assets.
170

GSK Annual Report 2018

Notes to the financial statements continued

20. Investments in associates and joint ventures

Joint 2018 Joint 2017

ventures Associates Total ventures Associates Total
£m £m £m £m £m £m
At 1 January 13 170 183 19 244 263
Exchange adjustments 1 11 12 (2) (10) (12)
Additions 1 9 10 – 15 15
Disposals – – – – (92) (92)
Distributions received – (40) (40) (1) (1) (2)
Other movements 1 39 40 – (2) (2)
Profit/(loss) after tax recognised in the consolidated income statement 3 28 31 (3) 16 13
At 31 December 19 217 236 13 170 183

The Group held one significant associate at 31 December 2018, Innoviva, Inc. At 31 December 2018, the Group owned 32 million shares
or 31.7% of Innoviva, which is a biopharmaceutical company listed on NASDAQ. Innoviva partnered with GSK in the development of the long
acting beta agonist vilanterol and currently receives royalty income from sales of products that contain this component, namely Relvar/Breo
Ellipta and Anoro Ellipta. It also has a 15% economic interest in royalties paid by GSK on sales of Trelegy Ellipta. The remaining 85% of the
economic interest in these royalties is held by Theravance Biopharma Inc., in which the Group holds 17.4% of the common stock. The
investment in Innoviva had a market value of £440 million at 31 December 2018 (2017 – £336 million).
Summarised balance sheet information, based on published information, in respect of Innoviva is set out below:
At 31 December At 31 December
2018 2017
£m £m
Non-current assets 275 124
Current assets 157 148

Current liabilities (4) (26)

Non-current liabilities (302) (426)

Net assets/(liabilities) 126 (180)

2018 2017
£m £m
Interest in associated undertaking 40 (57)
Goodwill 91 86
Fair value and other adjustments 58 118

Carrying value at 31 December 189 147

21. Other investments

Investments
designated as Investments
measured at measured at
FVTOCI FVTPL 2018 2017
£m £m £m £m
At 1 January 869 49 918 985
Exchange adjustments 48 4 52 (64)
Additions 363 9 372 80
Net fair value movements through Other comprehensive income 118 – 118 11
Net fair value movements through profit or loss – 16 16 –
Impairment losses – – – (30)
Disposals and settlements (89) (6) (95) (64)
Transfers to Assets held for sale (59) – (59) –
At 31 December 1,250 72 1,322 918

Other investments comprise non-current equity investments which are recorded at fair value at each balance sheet date. For investments
traded in an active market, the fair value is determined by reference to the relevant stock exchange quoted bid price. For other investments, the
fair value is estimated by management with reference to relevant available information, including the current market value of similar instruments
and discounted cash flows of the underlying net assets. Other investments include listed investments of £656 million (2017 – £535 million).
 171

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

21. Other investments continued

GSK has elected to designate the majority of its equity investments as measured at fair value through other comprehensive income (FVTOCI).
The most significant of these investments held at 31 December 2018 were in Theravance Biopharma, Inc. in which the Group holds 17.4%
of the common stock, Orchard in which the group holds 14.5% and 23andMe in which the Group holds 14.5%. These investments had a
fair value at 31 December 2018 of £194 million (2017 – £199 million), £154 million and £229 million respectively. No other investment is
individually material. The other investments include equity stakes in companies with which GSK has research collaborations and in companies
which provide access to biotechnology developments of potential interest. Information on dividends received from investments measured at
FVTOCI is provided in Note 7 ‘Other operating income/(expense)’.
On disposal of equity investments measured at FVTOCI, the accumulated fair value movements are reclassified from the fair value reserve to
retained earnings. Investments with a fair value of £148 million were disposed of during the year. The cumulative gain on these investments
after tax was £56 million.
Certain other investments, such as investments in funds with limited lives, are measured at fair value through profit or loss (FVTPL). The
cumulative gain/loss on investments measured at FVTPL which were disposed of during the year was £nil. The fair value of these investments
on derecognition was £nil.
In 2017, prior to the Group’s implementation of IFRS 9, the cumulative fair value movements, based on average cost for shares acquired at
different times, for all other investments disposed of during the period were reclassified from the fair value reserve to the income statement.
The impairment losses recorded above for the prior year were recognised in the income statement within Other operating income, together
with amounts reclassified from the fair value reserve on recognition of the impairments. These impairments resulted from prolonged or
significant declines in the fair value of the equity investments below acquisition cost.
The carrying value at 31 December 2017 of Other investments which had been impaired was as follows:
2017
£m
Original cost 475
Cumulative impairments recognised in the income statement (283)
Subsequent fair value increases 210
Carrying value at 31 December 2017 402

Cumulative impairments on those Other investments designated as measured at FVTOCI under IFRS 9 were transferred from retained
earnings to the fair value reserve on 1 January 2018 on adoption of IFRS 9.

22. Other non-current assets

2018 2017
£m £m
Amounts receivable under insurance contracts 675 648
Pension schemes in surplus 760 538
Other receivables 141 227
1,576 1,413

Amounts receivable under insurance contacts are held at fair value through profit or loss.

In regards to the other receivables of £141 million, £89 million is classified as financial assets of which £41 million is classified as fair value
through profit or loss. Of the remaining balance of £48 million, the expected credit loss allowance was immaterial at 31 December 2018.

23. Inventories
2018 2017
£m £m
Raw materials and consumables 1,122 1,193
Work in progress 2,286 2,381
Finished goods 2,068 1,983
5,476 5,557
172

GSK Annual Report 2018

Notes to the financial statements continued

24. Trade and other receivables

2018 2017
£m £m
Trade receivables, net of loss allowance 5,176 4,672
Accrued income 9 21
Other prepayments 330 308
Interest receivable 4 10
Employee loans and advances 14 19
Other receivables 890 970
6,423 6,000

Trade receivables included £15 million (2017 – £11 million) due from associates and joint ventures. Other receivables included £nil
(2017 – £7 million) due from associates and joint ventures.
2018 2017
Loss allowance £m £m
At 1 January 140 207
Implementation of IFRS 9 15 –
At 1 January, as adjusted 155 –
Exchange adjustments – (4)
Charge for the year 7 31
Subsequent recoveries of amounts provided for (30) (79)
Utilised (4) (15)
At 31 December 128 140

Of the total trade receivables balance, £71 million was considered credit impaired, against which a £7 million expected credit loss allowance
has been applied. No amount was purchased or originated credit impaired.
Of the other receivables of £890 million, £376 million was classified as financial assets of which £41 million was classified as at fair value
through profit and loss. On the remaining balance of £335 million, an expected credit loss allowance of £5 million was recognised at
31 December 2018 with no charge reported in profit or loss during the year.
For more discussion on credit risk practices, please refer to Note 42.

25. Cash and cash equivalents

2018 2017
£m £m
Cash at bank and in hand 569 826
Short-term deposits 3,305 3,007
3,874 3,833

In addition, £485 million of cash and cash equivalents has been reported in Assets held for sale, see Note 26, ‘Assets held for sale’.
Cash and cash equivalents included £0.2 billion (2017 – £0.8 billion) not available for general use due to restrictions applying in the
subsidiaries where it is held. Restrictions include exchange controls and taxes on repatriation.
 173

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

26. Assets held for sale

2018 2017
£m £m
Property, plant and equipment 109 57
Goodwill 144 –
Other intangibles 1 49
Inventory 50 7
Cash and cash equivalents 485 –
Other (136) –
653 113

Non-current assets and disposal groups are transferred to assets held for sale when it is expected that their carrying amounts will be
recovered principally through disposal and a sale is considered highly probable. They are held at the lower of carrying amount and fair
value less costs to sell.
Assets held for sale primarily reflect the disposal group arising from GSK’s agreement to divest Horlicks and other Consumer Healthcare
nutritional brands to Unilever plc announced in December 2018, and which is expected to complete by the end of 2019. See Note 38,
‘Acquisitions and disposals’.
Included within assets held for sale are assets which were written down to fair value less costs to sell of £51 million (2017 – £63 million).
The valuation methodology used significant inputs which were not based on observable market data and therefore this valuation is classified
as level 3 in the fair value hierarchy.

27. Trade and other payables

2018 2017
£m £m
Trade payables 3,645 3,528
Wages and salaries 1,355 1,228
Social security 139 166
Consumer Healthcare put option – 8,606
ViiV Healthcare put option 1,240 1,304
Other payables 401 363
Deferred income 216 240
Customer return and rebate accruals 5,064 3,463
Other accruals 1,977 2,072
14,037 20,970

Trade and other payables included £64 million (2017 – £53 million) due to associates and joint ventures. The Group provides limited supplier
financing arrangements to certain customers. The amounts involved at 31 December 2018 were not material.
Revenue recognised in the year that was included in deferred income at 1 January 2018 was £66 million. Of the remaining balance, £64 million
related to proceeds from a site disposal in India, which was expected to complete in 2018, but is now expected to complete in 2019.
Customer return and rebate accruals are provided for by the Group at the point of sale in respect of the estimated rebates, discounts or
allowances payable to customers, and included £4,356 million (2017 – £2,837 million) in respect of US Pharmaceuticals and Vaccines, as
more fully described in the Group financial review on page 63. Accruals are made at the time of sale but the actual amounts paid are based
on claims made some time after the initial recognition of the sale. As the amounts are estimated, they may not fully reflect the final outcome
and are subject to change dependent upon, amongst other things, the types of buying group and product sales mix. The level of accrual is
reviewed and adjusted quarterly in light of historical experience of actual amounts paid and any changes in arrangements. Future events could
cause the assumptions on which the accruals are based to change, which could affect the future results of the Group.
Pfizer’s put option over its shareholding in ViiV Healthcare is currently exercisable. The amount of the liability recognised is derived from
several valuation methodologies, including reference to market multiples of comparable companies. The table below shows on an indicative
basis the income statement and balance sheet sensitivity of the Pfizer put option to reasonably possible changes in key assumptions.
2018
Increase/(decrease) in financial liability and loss/(gain) in Income statement £m
10% increase in sales forecasts 140
10% decrease in sales forecasts (140)
10 cent appreciation of US Dollar 75
10 cent depreciation of US Dollar (64)
10 cent appreciation of Euro 44
10 cent depreciation of Euro (37)

An explanation of the accounting for ViiV Healthcare is set out on page 41.
174

GSK Annual Report 2018

Notes to the financial statements continued

28. Pensions and other post-employment benefits

2018 2017 2016
Pension and other post-employment costs £m £m £m
UK pension schemes 246 198 205
US pension schemes 100 113 106
Other overseas pension schemes 190 218 140
Unfunded post-retirement healthcare schemes 50 87 90
586 616 541
Analysed as:
Funded defined benefit/hybrid pension schemes 369 335 304
Unfunded defined benefit pension schemes 43 55 43
Unfunded post-retirement healthcare schemes 50 87 90
Defined benefit schemes 462 477 437
Defined contribution pension schemes 124 139 104
586 616 541

The costs of the defined benefit pension and post-retirement healthcare schemes are charged in the income statement as follows:
2018 2017 2016
£m £m £m
Cost of sales 160 162 135
Selling, general and administration 228 238 221
Research and development 74 77 81
462 477 437

GSK entities operate pension arrangements which cover the Group’s material obligations to provide pensions to retired employees. These
arrangements have been developed in accordance with local practices in the countries concerned. Pension benefits can be provided by state
schemes; by defined contribution schemes, whereby retirement benefits are determined by the value of funds arising from contributions paid
in respect of each employee; or by defined benefit schemes, whereby retirement benefits are based on employee pensionable remuneration
and length of service.
Pension costs of defined benefit schemes for accounting purposes have been calculated using the projected unit method. In certain countries
pension benefits are provided on an unfunded basis, some administered by trustee companies. Formal, independent, actuarial valuations of
the Group’s main plans are undertaken regularly, normally at least every three years.
Actuarial movements in the year are recognised through the statement of comprehensive income. Discount rates are derived from AA
rated corporate bond yields except in countries where there is no deep market in corporate bonds where government bond yields are used.
Discount rates are selected to reflect the term of the expected benefit payments. Projected inflation rate and pension increases are long-term
predictions based on the yield gap between long-term index-linked and fixed interest Gilts. In the UK, mortality rates are determined by
adjusting the SAPS S2 standard mortality tables to reflect recent scheme experience. These rates are then projected to reflect improvements
in life expectancy in line with the CMI 2017 projections with a long-term rate of improvement of 1.25% per year for both males and females.
In the US, mortality rates are calculated using the RP2014 white collar table adjusted to reflect recent experience. These rates are projected
using MP-2017 to allow for future improvements in life expectancy.
 175

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

28. Pensions and other post-employment benefits continued

The average life expectancy assumed now for an individual at the age of 60 and projected to apply in 2038 for an individual then at the age of
60 is as follows:

UK US
Male Female Male Female
Years Years Years Years
Current 27.5 29.1 27.0 28.7
Projected for 2038 29.0 30.6 28.7 30.3

The assets of funded schemes are generally held in separately administered trusts, either as specific assets or as a proportion of a general
fund, or are insurance contracts. Assets are invested in different classes in order to maintain a balance between risk and return. Investments
are diversified to limit the financial effect of the failure of any individual investment. The physical asset allocation strategy for three of the four
UK plans remains unchanged, with 55% in return-seeking assets and 45% in liability-matching assets. The remaining plan has materially
de-risked given its relative higher maturity as well as improved funding position. The asset allocation of the US plans is currently set at 55%
return-seeking assets and 45% liability-matching assets.

The pension plans are exposed to risk that arises because the estimated market value of the plans’ assets might decline, the investment
returns might reduce, or the estimated value of the plans’ liabilities might increase.

In line with the agreed mix of return-seeking assets to generate future returns and liability-matching assets to better match future pension
obligations, the Group has defined an overall long-term investment strategy for the plans, with investments across a broad range of assets.
The main market risks within the asset and hedging portfolio are against credit risk, interest rates, long-term inflation, equities, property,
currency and bank counterparty risk.

The plan liabilities are a series of future cash flows with relatively long duration. On an IAS 19 basis, these cash flows are sensitive to
changes in the expected long-term inflation rate and the discount rate (AA corporate bond yield curve) where an increase in long-term
inflation corresponds with an increase in the liabilities, and an increase in the discount rate corresponds with a decrease in the liabilities.

The interest rate risk and credit rate risk in the US are partially hedged. The targets are based on an accounting measure of the plan liabilities.

For the UK plans, there is an interest rate and inflation hedging strategy in place. The targets are based on an economic measure of the plan
liabilities. Furthermore, the plans also currently hedge a portion of their equity exposure with a staggered maturity profile.

In the UK, the defined benefit pension schemes operated for the benefit of former Glaxo Wellcome employees and former SmithKline
Beecham employees remain separate. These schemes were closed to new entrants in 2001 and subsequent UK employees are entitled to
join a defined contribution scheme. In addition, the Group operates a number of post-retirement healthcare schemes, the principal one of
which is in the US.
The Group has applied the following financial assumptions in assessing the defined benefit liabilities:
UK US Rest of World
2018 2017 2016 2018 2017 2016 2018 2017 2016
% pa % pa % pa % pa % pa % pa % pa % pa % pa
Rate of increase of future earnings 2.00 2.00 2.00 4.00 4.00 4.00 2.70 2.80 2.70
Discount rate 2.90 2.50 2.70 4.20 3.60 3.90 1.80 1.60 1.60
Expected pension increases 3.20 3.20 3.20 n/a n/a n/a 2.10 2.20 2.10
Cash balance credit/conversion rate n/a n/a n/a 3.20 2.90 3.20 0.40 0.30 0.30
Inflation rate 3.20 3.20 3.20 2.25 2.25 2.25 1.50 1.70 1.50

Sensitivity analysis detailing the effect of changes in assumptions is provided on page 182. The analysis provided reflects the assumption
changes which have the most material impact on the results of the Group.
176

GSK Annual Report 2018

Notes to the financial statements continued

28. Pensions and other post-employment benefits continued

The amounts recorded in the income statement and statement of comprehensive income for the three years ended 31 December 2018
in relation to the defined benefit pension and post-retirement healthcare schemes were as follows:
Post-retirement
Pensions benefits
UK US Rest of World Group Group
2018 £m £m £m £m £m
Amounts charged to operating profit
Current service cost 75 72 134 281 29
Past service cost/(credit) 93 1 – 94 (27)
Net interest (income)/cost (3) 20 19 36 49
Gains from settlements – – (14) (14) (1)
Expenses 8 7 – 15 –
173 100 139 412 50

Remeasurement gains/(losses) recorded in the statement of

comprehensive income 495 (108) 196 583 145

Post-retirement
Pensions benefits
UK US Rest of World Group Group
2017 £m £m £m £m £m
Amounts charged to operating profit
Current service cost 79 70 131 280 30
Past service cost/(credit) 37 – – 37 (2)
Net interest cost 7 31 16 54 59
Expenses 7 12 – 19 –
130 113 147 390 87

Remeasurement gains/(losses) recorded in the statement of

comprehensive income 259 240 (14) 485 64

Post-retirement
Pensions benefits
UK US Rest of World Group Group
2016 £m £m £m £m £m
Amounts charged to operating profit
Current service cost 70 66 110 246 31
Past service cost 52 1 1 54 3
Net interest cost 9 27 20 56 56
Gains from settlements – – (28) (28) –
Expenses 7 12 – 19 –
138 106 103 347 90

Remeasurement losses recorded in the statement of

comprehensive income (165) (27) (224) (416) (59)

The amounts included within past service costs in the UK include a charge of £40 million in relation to the estimated impact of GMP
equalisation and £43 million (2017 – £37 million; 2016 – £52 million) of augmentation costs of which £21 million is arising from major
restructuring programmes (see Note 29, ‘Other provisions’).
 177

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

28. Pensions and other post-employment benefits continued

A summarised balance sheet presentation of the Group defined benefit pension schemes and other post-retirement benefits is set out in the
table below:
2018 2017 2016
£m £m £m
Recognised in Other non-current assets:
Pension schemes in surplus 760 538 313
Recognised in Assets held for sale:
Post-retirement benefits (9) – –
Recognised in Pensions and other post-employment benefits:
Pension schemes in deficit (1,755) (2,043) (2,397)
Post-retirement benefits (1,370) (1,496) (1,693)
(3,125) (3,539) (4,090)

In the event of a plan wind-up, GSK believes the UK pension scheme rules provide the company with the right to a refund of surplus assets
following the full settlement of plan liabilities. As a result, the net surplus in the UK defined benefit pension schemes is recognised in full.
The fair values of the assets and liabilities of the UK and US defined benefit pension schemes, together with aggregated data for other
defined benefit pension schemes in the Group are as follows:
UK US Rest of World Group
At 31 December 2018 £m £m £m £m
Equities: – listed 3,257 1,280 518 5,055
– unlisted – – 7 7
Multi-asset funds 2,997 – – 2,997
Property: – listed – – 33 33
– unlisted 423 231 4 658
Corporate bonds: – listed 404 783 111 1,298
– unlisted 306 – 25 331
Government bonds: – listed 3,835 286 795 4,916
Insurance contracts 770 – 831 1,601
Other assets 589 228 66 883
Fair value of assets 12,581 2,808 2,390 17,779
Present value of scheme obligations (12,087) (3,474) (3,213) (18,774)
Net surplus/(obligation) 494 (666) (823) (995)

Included in Other non-current assets 711 – 49 760

Included in Pensions and other post-employment benefits (217) (666) (872) (1,755)
494 (666) (823) (995)

Actual return on plan assets (88) (123) 55 (156)

The multi-asset funds comprise investments in pooled investment vehicles that are invested across a range of asset classes, increasing
diversification within the growth portfolio. The ‘Other assets’ category comprises cash and mark to market values of derivative positions.
In previous years, index-linked gilts held as part of a UK repo programme were included in government bonds. The related loan was
included within ‘Other assets’ at a value of £(773) million at 31 December 2017 (2016 – £(1,686) million). This programme was cancelled
during 2018.
178

GSK Annual Report 2018

Notes to the financial statements continued

28. Pensions and other post-employment benefits continued

UK US Rest of World Group
At 31 December 2017 £m £m £m £m
Equities: – listed 4,902 1,448 544 6,894
– unlisted – – 13 13
Multi-asset funds 2,517 – – 2,517
Property: – unlisted 352 209 32 593
Corporate bonds: – listed 297 820 103 1,220
– unlisted 326 – 20 346
Government bonds: – listed 5,127 239 762 6,128
Insurance contracts 849 – 707 1,556
Other assets (1,216) 158 71 (987)
Fair value of assets 13,154 2,874 2,252 18,280
Present value of scheme obligations (13,101) (3,445) (3,239) (19,785)
Net surplus/(obligation) 53 (571) (987) (1,505)

Included in Other non-current assets 470 – 68 538

Included in Pensions and other post-employment benefits (417) (571) (1,055) (2,043)
53 (571) (987) (1,505)

Actual return on plan assets 893 394 82 1,369

UK US Rest of World Group

At 31 December 2016 £m £m £m £m
Equities: – listed 5,357 1,358 486 7,201
– unlisted – – 14 14
Multi-asset funds 1,545 – – 1,545
Property: – unlisted 314 216 28 558
Corporate bonds: – listed 292 213 96 601
– unlisted 321 – 24 345
Government bonds: – listed 6,165 815 739 7,719
Insurance contracts 856 – 637 1,493
Other assets (2,267) 288 73 (1,906)
Fair value of assets 12,583 2,890 2,097 17,570
Present value of scheme obligations (12,884) (3,752) (3,018) (19,654)
Net obligation (301) (862) (921) (2,084)

Included in Other non-current assets 276 – 37 313

Included in Pensions and other post-employment benefits (577) (862) (958) (2,397)
(301) (862) (921) (2,084)

Actual return on plan assets 2,473 153 99 2,725

 179

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

28. Pensions and other post-employment benefits continued

Post-retirement
Pensions benefits
UK US Rest of World Group Group
Movements in fair values of assets £m £m £m £m £m
Assets at 1 January 2016 10,284 2,501 1,750 14,535 –
Exchange adjustments – 459 305 764 –
Interest income 385 108 37 530 –
Expenses (7) (12) – (19) –
Settlements and curtailments – – (110) (110) –
Remeasurement 2,088 45 62 2,195 –
Employer contributions 319 31 131 481 91
Scheme participants’ contributions 4 – 14 18 17
Benefits paid (490) (242) (92) (824) (108)
Assets at 31 December 2016 12,583 2,890 2,097 17,570 –
Exchange adjustments – (244) 24 (220) –
Interest income 333 104 33 470 –
Expenses (7) (12) – (19) –
Settlements and curtailments – – (4) (4) –
Remeasurement 560 290 49 899 –
Employer contributions 225 103 116 444 101
Scheme participants’ contributions 4 – 17 21 17
Benefits paid (544) (257) (80) (881) (118)
Assets at 31 December 2017 13,154 2,874 2,252 18,280 –
Exchange adjustments – 171 53 224 –
Interest income 323 102 29 454 –
Expenses (8) (7) – (15) –
Settlements and curtailments – – (14) (14) –
Remeasurement (411) (225) 26 (610) –
Employer contributions 119 150 117 386 93
Scheme participants’ contributions 4 – 16 20 16
Benefits paid (600) (257) (89) (946) (109)
Assets at 31 December 2018 12,581 2,808 2,390 17,779 –

During 2018, the Group made no special funding contributions to the UK pension schemes (2017 – £136 million; 2016 – £191 million) but
£125 million (2017 – £78 million; 2016 – £nil) to the US scheme. In 2018, GSK reached a revised agreement with the trustees of the UK
pension schemes to make additional contributions to eliminate the pension deficits identified within the schemes at the 31 December 2017
actuarial funding valuation. Based on these funding agreements, the additional contributions to eliminate the pension deficit are expected to
be £75 million in 2019. Further payments have been agreed for the years 2020 to 2022 and these are included within Note 41, ‘Commitments’
on page 197. This funding commitment supersedes the previous agreement made in 2016. The contributions were based on a government
bond yield curve approach to selecting the discount rate; the rate chosen included an allowance for expected investment returns which
reflected the asset mix of the schemes.
Employer contributions for 2019, including special funding contributions, are estimated to be approximately £420 million in respect of defined
benefit pension schemes and £100 million in respect of post-retirement benefits.
180

GSK Annual Report 2018

Notes to the financial statements continued

28. Pensions and other post-employment benefits continued

Post-retirement
Pensions benefits
UK US Rest of World Group Group
Movements in defined benefit obligations £m £m £m £m £m
Obligations at 1 January 2016 (10,601) (3,134) (2,384) (16,119) (1,387)
Exchange adjustments – (586) (396) (982) (248)
Service cost (70) (66) (110) (246) (31)
Past service cost (52) (1) (1) (54) (3)
Interest cost (394) (135) (57) (586) (56)
Settlements and curtailments – – 138 138 –
Remeasurement (2,253) (72) (286) (2,611) (59)
Scheme participants’ contributions (4) – (14) (18) (17)
Benefits paid 490 242 92 824 108
Obligations at 31 December 2016 (12,884) (3,752) (3,018) (19,654) (1,693)
Exchange adjustments – 305 (45) 260 119
Service cost (79) (70) (131) (280) (30)
Past service cost/(credit) (37) – – (37) 2
Interest cost (340) (135) (49) (524) (59)
Settlements and curtailments – – 4 4 –
Remeasurement (301) (50) (63) (414) 64
Scheme participants’ contributions (4) – (17) (21) (17)
Benefits paid 544 257 80 881 118
Obligations at 31 December 2017 (13,101) (3,445) (3,239) (19,785) (1,496)
Exchange adjustments – (208) (63) (271) (71)
Service cost (75) (72) (134) (281) (29)
Past service cost (93) (1) – (94) 27
Interest cost (320) (122) (48) (490) (49)
Settlements and curtailments – – 28 28 1
Remeasurement 906 117 170 1,193 145
Scheme participants’ contributions (4) – (16) (20) (16)
Benefits paid 600 257 89 946 109
Obligations at 31 December 2018 (12,087) (3,474) (3,213) (18,774) (1,379)

The defined benefit pension obligation is analysed as follows:

2018 2017 2016
£m £m £m
Funded (18,025) (19,052) (18,974)
Unfunded (749) (733) (680)
(18,774) (19,785) (19,654)

The liability for the US post-retirement healthcare scheme has been assessed using the same assumptions as for the US pension scheme,
together with the assumption for future medical inflation of 6.50% (2017 – 6.75%), grading down to 5.0% in 2025 and thereafter. At
31 December 2018, the US post-retirement healthcare scheme obligation was £1,179 million (2017 – £1,254 million; 2016 – £1,463 million).
Post-retirement benefits are unfunded.
 181

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

28. Pensions and other post-employment benefits continued

The movement in the net defined benefit liability is as follows:
2018 2017 2016
£m £m £m
At 1 January (1,505) (2,084) (1,584)
Exchange adjustments (47) 40 (218)
Service cost (281) (280) (246)
Past service cost (94) (37) (54)
Interest cost (36) (54) (56)
Settlements and curtailments 14 – 28
Remeasurements:
Return on plan assets, excluding amounts included in interest (610) 899 2,195
Gain from change in demographic assumptions 131 209 85
Gain/(loss) from change in financial assumptions 1,149 (555) (2,770)
Experience (losses)/gains (87) (68) 74
Employer contributions 386 444 481
Expenses (15) (19) (19)
At 31 December (995) (1,505) (2,084)

The remeasurements included within post-retirement benefits are detailed below:

2018 2017 2016
£m £m £m
Gain from change in demographic assumptions 6 47 –
Gain/(loss) from change in financial assumptions 100 (1) (81)
Experience gains 39 18 22
145 64 (59)
182

GSK Annual Report 2018

Notes to the financial statements continued

28. Pensions and other post-employment benefits continued

The defined benefit pension obligation analysed by membership category is as follows:
2018 2017 2016
£m £m £m
Active 4,427 4,611 4,576
Retired 9,542 9,805 9,574
Deferred 4,805 5,369 5,504
18,774 19,785 19,654

The post-retirement benefit obligation analysed by membership category is as follows:

2018 2017 2016
£m £m £m
Active 499 514 594
Retired 879 981 1,099
Deferred 1 1 –
1,379 1,496 1,693

The weighted average duration of the defined benefit obligation is as follows:

2018 2017 2016
years years years
Pension benefits 15 16 16
Post-retirement benefits 11 11 12

Sensitivity analysis
The effect of changes in assumptions used on the benefit obligations and on the 2019 annual defined benefit pension and post-retirement
costs are detailed below. This information has been determined by taking into account the duration of the liabilities and the overall profile of
the plan memberships.

£m

A 0.25% decrease in discount rate would have the following approximate effect:

Increase in annual pension cost 28

Decrease in annual post-retirement benefits cost (1)
Increase in pension obligation 707
Increase in post-retirement benefits obligation 34

A one-year increase in life expectancy would have the following approximate effect:

Increase in annual pension cost 21

Increase in annual post-retirement benefits cost 2
Increase in pension obligation 592
Increase in post-retirement benefits obligation 33

A 1% increase in the rate of future healthcare inflation would have the following approximate effect:

Increase in annual post-retirement benefits cost 1

Increase in post-retirement benefits obligation 38

A 0.25% increase in inflation would have the following approximate effect:

Increase in annual pension cost 18

Increase in pension obligation 447
 183

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

29. Other provisions

Legal Major Employee
and other restructuring -related Other
disputes programmes provisions provisions Total
£m £m £m £m £m
At 1 January 2018 186 504 304 271 1,265
Exchange adjustments 13 17 9 5 44
Charge for the year 119 450 105 50 724
Reversed unused (2) (99) (25) (46) (172)
Unwinding of discount 2 4 – 9 15
Utilised (98) (226) (41) (79) (444)
Reclassifications and other movements (1) 12 (2) 3 12
Transfer to Pension obligations – (21) – – (21)
At 31 December 2018 219 641 350 213 1,423

To be settled within one year 156 362 145 69 732

To be settled after one year 63 279 205 144 691
At 31 December 2018 219 641 350 213 1,423

Legal and other disputes Major restructuring programmes

The Group is involved in a substantial number of legal and other The Group is undertaking two major restructuring programmes:
disputes, including notification of possible claims, as set out in the Combined restructuring and integration programme and the
Note 45 ‘Legal proceedings’. Provisions for legal and other disputes 2018 major restructuring programme. The programmes are focused
include amounts relating to product liability, anti-trust, government primarily on simplifying supply chain processes, rationalising the
investigations, contract terminations, self insurance and Group’s manufacturing network and restructuring the
environmental clean-up. Pharmaceuticals commercial operations.
The charge for the year of £117 million (net of reversals and Provisions for staff severance payments are made when management
estimated insurance recoveries) primarily related to provisions has made a formal decision to eliminate certain positions and this
for product liability cases, commercial disputes and various other has been communicated to the groups of employees affected and
government investigations. appropriate consultation procedures completed, where appropriate.
No provision is made for staff severance payments that are made
The discount on the provisions increased by £2 million in 2018
immediately.
(2017 – increased by £2 million). The discount was calculated
using risk-adjusted projected cash flows and risk-free rates of return. Pension augmentations arising from staff redundancies of
£21 million (2017 – £18 million) have been charged during the
In respect of product liability claims related to certain products,
year and then transferred to the pension obligations provision as
there is sufficient history of claims made and settlements to enable
shown in Note 28, ‘Pensions and other post-employment benefits’.
management to make a reliable estimate of the provision required
Asset write-downs have been recognised as impairments of
to cover unasserted claims. The ultimate liability for such matters
property, plant and equipment in Note 17, ‘Property, plant and
may vary from the amounts provided and is dependent upon the
equipment’. The majority of the amounts provided are expected
outcome of litigation proceedings, investigations and possible
to be utilised in the next two years.
settlement negotiations.
Employee-related provisions
It is in the nature of the Group’s business that a number of these
Employee related provisions include obligations for certain medical
matters may be the subject of negotiation and litigation over
benefits to disabled employees and their spouses in the US. At
many years. Litigation proceedings, including the various appeal
31 December 2018, the provision for these benefits amounted to
procedures, often take many years to reach resolution, and
£87 million (2017 – £108 million). Other employee benefits reflect
out-of-court settlement discussions can also often be protracted.
a variety of provisions for severance costs, jubilee awards and other
Indemnified disputes will recognise a provision charge and a
long-service benefits. Given the nature of these provisions, the
corresponding receivable.
amounts are likely to be settled over many years.
The Group is in potential settlement discussions in a number of
Other provisions
the disputes for which amounts have been provided and, based
Included in other provisions are insurance provisions of £7 million
on its current assessment of the progress of these disputes,
(2017 – £6 million), onerous property lease provisions of
estimates that £156 million of the amount provided at 31 December
£6 million (2017 – £38 million) and a number of other provisions
2018 will be settled within one year. At 31 December 2018, it was
including vehicle insurance and regulatory matters.
expected that £37 million (2017 – £nil) of the provision made for
legal and other disputes will be reimbursed by third parties. For
a discussion of legal issues, see Note 45, ‘Legal proceedings’.
184

GSK Annual Report 2018

Notes to the financial statements continued

30. Other non-current liabilities

2018 2017
£m £m
Accruals 71 82
Deferred Income 19 22
Other payables 848 877
938 981

Other payables includes acquisition accounting market value lease adjustments and a number of employee-related liabilities.

31. Net debt

2018 2017
Listing exchange £m £m
Current assets:
Liquid investments 84 78
Cash and cash equivalents 3,874 3,833
Cash and cash equivalents reported in Assets held for sale 485 –
4,443 3,911
Short-term borrowings:
Commercial paper (630) (529)
Bank loans and overdrafts (290) (236)
Obligations under finance leases (24) (23)
Drawn bank facility (3,500) –
5.650% US$ US Medium Term Note 2018 New York Stock Exchange – (2,037)
0.625% € European Medium Term Note 2019 London Stock Exchange (1,349) –
(5,793) (2,825)
Long-term borrowings:
0.625% € European Medium Term Note 2019 London Stock Exchange – (1,324)
EURIBOR +0.20% € European Medium Term Note 2020 London Stock Exchange (677) –
0.000% € European Medium Term Note 2020 London Stock Exchange (1,079) (1,060)
3.125% US$ US Medium Term Note 2021 New York Stock Exchange (980) –
LIBOR +0.35% US$ US Medium Term Note 2021 New York Stock Exchange (589) –
2.850% US$ US Medium Term Note 2022 New York Stock Exchange (1,568) (1,474)
2.800% US$ US Medium Term Note 2023 New York Stock Exchange (978) (919)
3.375% US$ US Medium Term Note 2023 New York Stock Exchange (977) –
1.375% € European Medium Term Note 2024 London Stock Exchange (893) (876)
4.000% € European Medium Term Note 2025 London Stock Exchange (670) (659)
3.625% US$ US Medium Term Note 2025 New York Stock Exchange (780) –
1.000% € European Medium Term Note 2026 London Stock Exchange (629) (617)
1.250% € European Medium Term Note 2026 London Stock Exchange (897) –
3.375% £ European Medium Term Note 2027 London Stock Exchange (593) (593)
3.875% US$ US Medium Term Note 2028 New York Stock Exchange (1,372) –
1.375% € European Medium Term Note 2029 London Stock Exchange (447) (439)
1.750% € European Medium Term Note 2030 London Stock Exchange (673) –
5.250% £ European Medium Term Note 2033 London Stock Exchange (982) (986)
5.375% US$ US Medium Term Note 2034 New York Stock Exchange (390) (368)
6.375% US$ US Medium Term Note 2038 New York Stock Exchange (2,143) (2,021)
6.375% £ European Medium Term Note 2039 London Stock Exchange (694) (695)
5.250% £ European Medium Term Note 2042 London Stock Exchange (986) (989)
4.200% US$ US Medium Term Note 2043 New York Stock Exchange (386) (363)
4.250% £ European Medium Term Note 2045 London Stock Exchange (788) (789)
Obligations under finance leases (44) (43)
Other long-term borrowings (56) (49)
(20,271) (14,264)
Net debt (21,621) (13,178)
 185

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

31. Net debt continued

Current assets
Liquid investments are classified as financial assets at amortised cost (previously available-for-sale investments in prior years).
At 31 December 2018, they included US Treasury Notes and other government bonds. The effective interest rate on liquid investments
at 31 December 2018 was approximately 1.0% (2017 – approximately 1.0%). Liquid investment balances at 31 December 2018 earning
interest at floating rates amount to £84 million (2017 – £78 million). Liquid investment balances at 31 December 2018 earning interest
at fixed rates amount to £nil (2017 – £nil).
The effective interest rate on cash and cash equivalents at 31 December 2018 was approximately 1.9% (2017 – approximately 1.3%).
Cash and cash equivalents at 31 December 2018 earning interest at floating and fixed rates amount to £4,094 million and £2 million
respectively (2017 – £3,832 million and £1 million) and non-interest bearing holdings amount to £263 million.
GSK’s policy regarding the credit quality of cash and cash equivalents is referred to in Note 42, ‘Financial instruments and related
disclosures’.
Short-term borrowings
GSK has a $10 billion (£7.9 billion) US commercial paper programme, of which $0.8 billion (£0.6 billion) was in issue at 31 December 2018
(2017 – $0.7 billion (£0.5 billion)). GSK has a £1.9 billion five-year committed facility and $2.5 billion (£2.0 billion) under a 364 day
committed facility. The five-year committed facility was agreed in September 2015 and extended by one year to 2021 in September 2016.
The 364 day committed facility was agreed in September 2018. Additional bank facilities were agreed in 2018 to support transactions and
two remained active at 31 December 2018. In June 2018, £3.5 billion was drawn to support the acquisition from Novartis of the remaining
stake in the Consumer Healthcare Joint Venture. In addition, a $5.0 billion bank facility was agreed in December 2018 to support the
acquisition of Tesaro and was undrawn at 31 December 2018. Liquid investments, cash and cash equivalents were as shown in the table
on page 184.
The weighted average interest rate on commercial paper borrowings at 31 December 2018 was 2.5% (2017 – 1.5%).
The weighted average interest rate on current bank loans and overdrafts at 31 December 2018 was 12.0% (2017 – 4.7%). At 31 December
2018, short-term loan rates of 60% in Argentina had a disproportionate effect on the weighted average interest rate. Excluding this impact
the weighted average interest rate on current bank loans and overdrafts stands at 4.4%.
The average effective pre-swap interest rate of notes classified as short term at 31 December 2018 was 0.8% (2017 – 5.9%). The material
decrease in the rate largely reflects the maturity of a 5.65% coupon note in May 2018 and the upcoming maturity of a 0.625% coupon note
in December 2019.
Long-term borrowings
At the year-end, GSK had long-term borrowings of £20.3 billion (2017 – £14.3 billion), of which £13.3 billion (2017 – £10.3 billion) falls
due in more than five years. The average effective pre-swap interest rate of all notes in issue at 31 December 2018 was approximately 4.4%
(2017 – approximately 3.6%).
Long-term borrowings repayable after five years carry interest at effective rates between 1.1% and 6.4%, with repayment dates ranging from
2024 to 2045.
Pledged assets
The Group held pledged investments in US Treasury Notes with a par value of $50 million (£39 million), (2017 – $105 million (£78 million))
as security against irrevocable letters of credit issued on the Group’s behalf in respect of the Group’s self-insurance activity. Provisions
in respect of self-insurance are included within the provisions for legal and other disputes discussed in Note 29, ‘Other provisions’.
In addition, in 2017, £20 million of assets included in Note 22, ‘Other non-current assets’, which do not form part of Net debt, were pledged
as collateral against future rental payments under operating lease arrangements which were previously entered into by Human Genome
Sciences, Inc. prior to its acquisition by the Group, and terminated in 2018.
Finance lease obligations
2018 2017
£m £m
Rental payments due within one year 29 25
Rental payments due between one and two years 20 29
Rental payments due between two and three years 13 9
Rental payments due between three and four years 7 3
Rental payments due between four and five years 4 2
Rental payments due after five years 11 10
Total future rental payments 84 78
Future finance charges (16) (12)
Total finance lease obligations 68 66
186

GSK Annual Report 2018

Notes to the financial statements continued

32. Contingent liabilities

At 31 December 2018, contingent liabilities, comprising guarantees, discounted bills and other items arising in the normal course of business,
amounted to £93 million (2017 – £434 million). At 31 December 2018, £nil (2017 – £2 million) of financial assets were pledged as collateral
for contingent liabilities. Provision is made for the outcome of tax, legal and other disputes where it is both probable that the Group will suffer
an outflow of funds and it is possible to make a reliable estimate of that outflow. At 31 December 2018, other than for those disputes where
provision has been made, it was not possible to make a reliable estimate of the potential outflow of funds that might be required to settle
disputes where the possibility of there being an outflow was more than remote. Descriptions of the significant legal and other disputes to
which the Group is a party are set out in Note 45, ‘Legal proceedings’.

33. Share capital and share premium account

Share
Ordinary Shares of 25p each premium
Number £m £m
Share capital authorised
At 31 December 2016 10,000,000,000 2,500
At 31 December 2017 10,000,000,000 2,500
At 31 December 2018 10,000,000,000 2,500
Share capital issued and fully paid
At 1 January 2016 5,361,307,647 1,340 2,831
Issued under employee share schemes 7,008,415 2 87
Ordinary shares acquired by ESOP Trusts – – 36
At 31 December 2016 5,368,316,062 1,342 2,954
Issued under employee share schemes 4,237,758 1 55
Ordinary shares acquired by ESOP Trusts – – 10
At 31 December 2017 5,372,553,820 1,343 3,019
Issued under employee share schemes 6,513,804 2 72
At 31 December 2018 5,379,067,624 1,345 3,091

31 December 2018 31 December 2017

000 000
Number of shares issuable under employee share schemes 56,723 38,647
Number of unissued shares not under option 4,564,209 4,588,799

At 31 December 2018, of the issued share capital, 41,530,909 shares were held in the ESOP Trusts, 414,605,950 shares were held
as Treasury shares and 4,922,930,765 shares were in free issue. All issued shares are fully paid. The nominal, carrying and market values
of the shares held in the ESOP Trusts are disclosed in Note 43, ‘Employee share schemes’.
 187

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

34. Movements in equity

Retained losses and other reserves amounted to £76 million at 31 December 2018 (2017 – £4,430 million loss; 2016 – £3,172 million loss)
of which £337 million (2017 – £334 million; 2016 – £329 million) relates to joint ventures and associated undertakings. The cumulative
translation exchange in equity is as follows:
Net translation exchange included in:
Non- Total
Retained Fair value controlling translation
earnings reserve interests exchange
£m £m £m £m
At 1 January 2016 (761) 10 (109) (860)
Exchange movements on overseas net assets 633 13 603 1,249
At 31 December 2016 (128) 23 494 389
Exchange movements on overseas net assets 462 – (149) 313
Reclassification of exchange on liquidation or disposal of overseas subsidiaries 109 – – 109
At 31 December 2017 443 23 345 811
Exchange movements on overseas net assets (458) (22) (1) (481)
At 31 December 2018 (15) 1 344 330

The analysis of other comprehensive income by equity category is as follows:

Non-
Retained Other controlling
earnings reserves interests Total
2018 £m £m £m £m
Items that may be subsequently reclassified to income statement:
Exchange movements on overseas net assets and net investment hedges (458) (22) – (480)
Fair value movements on cash flow hedges – 140 – 140
Reclassification of cash flow hedges on income and expense – (175) – (175)
Deferred tax on fair value movements on cash flow hedges – (22) – (22)
Deferred tax reversed on reclassification of cash flow hedges – 20 – 20

Items that will not be reclassified to income statement:

Exchange movements on overseas net assets of non-controlling interests – – (1) (1)
Fair value movements on equity investments – 180 – 180
Deferred tax on fair value movements on equity investments – 10 – 10
Remeasurement gains on defined benefit plans 728 – – 728
Tax on remeasurement gains in defined benefit plans (146) – – (146)
Other comprehensive income/(expense) for the year 124 131 (1) 254

Non-
Retained Other controlling
earnings reserves interests Total
2017 £m £m £m £m
Items that may be subsequently reclassified to income statement:
Exchange movements on overseas net assets and net investment hedges 462 – – 462
Reclassification of exchange on liquidation or disposal of overseas subsidiaries 109 – – 109
Fair value movements on available-for-sale investments – (14) – (14)
Reclassification of fair value movements on available-for-sale investments – (42) – (42)
Deferred tax on fair value movements on available-for-sale investments – 47 – 47
Deferred tax reversed on reclassification of available-for-sale investments – (18) – (18)
Fair value movements on cash flow hedges – (10) – (10)

Items that will not be reclassified to income statement:

Exchange movements on overseas net assets of non-controlling interests – – (149) (149)
Remeasurement gains on defined benefit plans 549 – – 549
Tax on remeasurement gains in defined benefit plans (221) – – (221)
Other comprehensive income/(expense) for the year 899 (37) (149) 713
188

GSK Annual Report 2018

Notes to the financial statements continued

34. Movements in equity continued

Non-
Retained Other controlling
earnings reserves interests Total
2016 £m £m £m £m
Items that may be subsequently reclassified to income statement:
Exchange movements on overseas net assets and net investment hedges 633 13 – 646
Fair value movements on available-for-sale investments – 251 – 251
Reclassification of fair value movements on available-for-sale investments – (245) – (245)
Deferred tax reversed on reclassification of available-for-sale investments – 51 – 51
Reclassification of cash flow hedges to income statement – 1 – 1
Fair value movements on cash flow hedges – 2 – 2
Deferred tax on fair value movements on cash flow hedges – 2 – 2

Items that will not be reclassified to income statement:

Exchange movements on overseas net assets of non-controlling interests – – 603 603
Remeasurement losses on defined benefit plans (475) – – (475)
Tax on remeasurement losses in defined benefit plans 126 – – 126
Other comprehensive income for the year 284 75 603 962

The analysis of other reserves is as follows:

ESOP Trust Fair value Cash flow Other
shares reserve hedge reserve reserves Total
£m £m £m £m £m
At 1 January 2016 (75) 295 (9) 2,129 2,340
Exchange adjustments (16) – – – (16)
Transferred to income and expense in the year on disposals – (268) – – (268)
Transferred to income and expense in the year on impairments – 23 – – 23
Net fair value movement in the year – 330 6 – 336
Ordinary shares acquired by ESOP Trusts (576) – – – (576)
Write-down of shares held by ESOP Trusts 381 – – – 381
At 31 December 2016 (286) 380 (3) 2,129 2,220
Exchange adjustments 22 – – – 22
Transferred to income and expense in the year on disposals – (42) – – (42)
Net fair value movement in the year – (9) (8) – (17)
Ordinary shares acquired by ESOP Trusts (656) – – – (656)
Write-down of shares held by ESOP Trusts 520 – – – 520
At 31 December 2017 (400) 329 (11) 2,129 2,047
Implementation of IFRS 9 – (288) – – (288)
At 31 December, as adjusted (400) 41 (11) 2,129 1,759
Exchange adjustments (26) – – – (26)
Transferred to Retained earnings in the year on disposal of equity investments – (94) – – (94)
Net fair value movement in the year – 193 (36) – 157
Write-down of shares held by ESOP Trusts 265 – – – 265
At 31 December 2018 (161) 140 (47) 2,129 2,061

Other reserves include various non-distributable merger and pre-merger reserves amounting to £1,849 million at 31 December 2018
(2017 – £1,849 million; 2016 – £1,849 million). Other reserves also include the capital redemption reserve created as a result of the
share buy-back programme amounting to £280 million at 31 December 2018 (2017 – £280 million; 2016 – £280 million).
 189

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

35. Related party transactions

At 31 December 2018, GSK owned 32 million shares or 31.7% of Innoviva Inc. which is a biopharmaceutical company listed on NASDAQ.
GSK began recognising Innoviva as an associate on 1 September 2015. The royalties due from GSK to Innoviva in the year were £209 million
(2017 – £173 million). At 31 December 2018, the balance payable by GSK to Innoviva was £64 million (2017 – £53 million).
At 31 December 2018, GSK held a 50% interest in Japan Vaccine Co. Ltd (JVC) through its subsidiary GlaxoSmithKline K.K. This joint
venture with Daiichi Sankyo Co., Ltd is primarily responsible for the development and marketing of certain prophylactic vaccines in Japan.
During 2018, GSK sold £43 million (2017 – £41 million) of its vaccine products into the joint venture. At 31 December 2018, the trading
balance due to GSK from JVC was £15 million (2017 – £11 million) and the balance payable by GSK to JVC was £nil (2017 – £nil).
Loans of £5 million to Medicxi Ventures I LP and £6 million to Index Ventures Life VI (Jersey) LP remained due to GSK at 31 December 2018.
In 2018, GSK increased the equity investment in Kurma Biofund II, FCPR by £3 million, Apollo Therapeutics LLP by £2 million and Longwood
Founders Fund LP by £0.2 million, and reduced a liability with Qura Therapeutics LLC by £3 million. As at 31 December 2018, the
outstanding liability to Qura was £4 million.
The aggregate compensation of the Directors and CET is given in Note 9, ‘Employee costs’.

36. Adjustments reconciling profit after tax to operating cash flows

2018 2017 2016

£m £m £m
Profit after tax 4,046 2,169 1,062

Tax on profits 754 1,356 877

Share of after tax profits of associates and joint ventures (31) (13) (5)
Finance expense net of finance income 717 669 664
Depreciation 954 988 978
Amortisation of intangible assets 902 934 796
Impairment and assets written off 350 1,061 226
Profit on sale of businesses (63) (157) (5)
Profit on sale of intangible assets (201) (46) (178)
Profit on sale of investments in associates (3) (94) –
Profit on sale of equity investments (4) (37) (254)
Gain on Consumer Healthcare Joint Venture put hedging (513) – –
Business acquisition costs 47 – –
Changes in working capital:
Decrease/(increase) in inventories 51 (461) 70
Increase in trade receivables (429) (287) (188)
Increase in trade payables 131 11 96
Decrease in other receivables 18 74 381
Contingent consideration paid (see Note •) (984) (594) (358)
Other non-cash increase in contingent consideration liabilities 1,250 961 2,281
Increase in other payables 2,362 1,741 1,989
Increase/(decrease) in pension and other provisions 102 (255) (621)
Share-based incentive plans 360 333 319
Fair value adjustments (7) – (3)
Other (62) (95) (21)
5,701 6,089 7,044

Cash generated from operations 9,747 8,258 8,106

190

GSK Annual Report 2018

Notes to the financial statements continued

37. Reconciliation of net cash flow to movement in net debt

2018 2017 2016
£m £m £m
Net debt at beginning of year (13,178) (13,804) (10,727)

Increase/(decrease) in cash and bank overdrafts 479 (905) (1,164)

Decrease in liquid investments – (4) –
Net increase in long-term loans (10,138) (2,233) –
Repayment of short-term Notes 2,067 2,636 865
(Increase in)/repayment of other short-term loans (81) 564 (1,013)
Net repayment of obligations under finance leases 28 23 18
Exchange adjustments (776) 585 (1,781)
Other non-cash movements (22) (40) (2)
Movement in net debt (8,443) 626 (3,077)

Net debt at end of year (21,621) (13,178) (13,804)

At 1 January Profit Reclass- At 31 December

2018 Exchange Other and loss ifications Cash flow 2018
Analysis of changes in net debt £m £m £m £m £m £m £m
Liquid investments 78 5 1 – – – 84

Cash and cash equivalents 3,833 4 – – (485) 522 3,874

Cash and cash equivalents – AHFS – 485 485
Overdrafts (233) 4 – – – (43) (272)
3,600 8 – – – 479 4,087

Debt due within one year:

Commercial paper (529) (36) – – – (65) (630)
European/US Medium Term Notes and bank facilities (2,037) (55) – – (4,824) 2,067 (4,849)
Other (26) (1) (11) – (16) 12 (42)
(2,592) (92) (11) – (4,840) 2,014 (5,521)

Debt due after one year:

European/US Medium Term Notes and bank facilities (14,221) (696) – 4 4,824 (10,138) (20,227)
Other (43) (1) (16) – 16 – (44)
(14,264) (697) (16) 4 4,840 (10,138) (20,271)

Net debt (13,178) (776) (26) 4 – (7,645) (21,621)

Analysis of changes in liabilities from financing activities

Debt due within one year (2,592) (92) (11) – (4,840) 2,014 (5,521)
Debt due after one year (14,264) (697) (16) 4 4,840 (10,138) (20,271)

Hedge of borrowings:
Derivative financial instruments 2 1 130 (10) – 6 129
Other financing items – (19) – – – 19 –
Interest payable (203) (2) 2 (802) – 766 (239)
Total liabilities from financing activities (17,057) (809) 105 (808) – (7,333) (25,902)

For further information on significant changes in net debt see Note 31, ‘Net debt’.
 191

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

38. Acquisitions and disposals

Details of the acquisition and disposal of significant subsidiaries and associates, joint ventures and other businesses are given below:
2018
Business acquisitions
There were no business acquisitions during 2018.
Business disposals
GSK made a number of small business disposals during the year for a net cash consideration of £2 million.
Cash flows
Associates Associates
and joint and joint
Business venture venture
disposals investments disposals
£m £m £m
Cash consideration 2 (10) 3
Net deferred consideration received 24 – –
Cash and cash equivalents divested – – –
Cash inflow 26 (10) 3

Transactions signed but not yet completed

In December 2018, GSK agreed to divest Horlicks and other Consumer Healthcare nutrition brands to Unilever plc and to merge
GSK Consumer Healthcare Limited with Hindustan Unilever Limited for a total consideration valued at approximately £3.1 billion. GSK
Consumer Healthcare Limited is a public company listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) in
India, in which GSK holds a 72.5% stake. Hindustan Unilever Limited is a public company listed on the NSE and BSE. Following the merger,
GSK will own approximately 5.7% of Hindustan Unilever Limited. The transaction is expected to complete by the end of 2019, subject to
the fulfilment of certain conditions including the approval of the merger by the shareholders of GSK Consumer Healthcare Limited and
Hindustan Unilever Limited.
The Group has entered into forward foreign exchange contracts which have been designated as a cash flow hedge of part of the foreign
exchange exposure arising on the transaction. In addition, the exposure to share price movements in the forward purchase of shares in
Hindustan Unilever Limited has been recognised as an embedded derivative. The embedded derivative was in an asset position and had
a fair value of £100 million at 31 December 2018.
In December 2018, GSK agreed to acquire 100% of Tesaro, Inc., an oncology-focused biopharmaceutical company, for $5.1 billion
(£4.0 billion) in cash. This transaction completed on 22nd January 2019. The exercise to determine the acquisition fair values of assets
and liabilities is not yet complete. Initial transaction costs were recognised in December 2018.
In December 2018, GSK agreed to form a new Consumer Healthcare Joint Venture by acquiring Pfizer’s consumer health business in
an all-share transaction. Pfizer will hold 32% of the combined business which will be controlled by GSK. The new Consumer Healthcare
Joint Venture is expected to be formed in the second half of 2019, subject to approvals. Initial transaction costs were recognised in
December 2018.
192

GSK Annual Report 2018

Notes to the financial statements continued

38. Acquisitions and disposals continued

2017
Business acquisitions
There were no business acquisitions during 2017.
Business disposals
GSK made a number of small business disposals during the year for a net cash consideration of £342 million, including contingent
consideration receivable of £86 million. The profit on disposal was determined as follows:
Total
£m
Consideration including currency forwards and purchase adjustments 342
Net assets sold:
Goodwill (16)
Intangible assets (21)
Property, plant and equipment (18)
Inventory (11)
Cash and cash equivalents (6)
Other net assets (5)
(77)
Transaction costs (8)
Reclassification of exchange from other comprehensive income (100)
Profit on disposal 157

Investment in associates and joint ventures

During the year, GSK made cash investments of £15 million into associates and joint ventures. In addition, GSK sold its holdings in two
associates for £198 million in cash.
Total
£m
Cash consideration 198
Net book value of shares (92)
Reclassification of exchange from other comprehensive income (7)
Transaction costs (5)
Profit on disposal 94

Cash flows
Associates Associates
and joint and joint
Business venture venture
disposals investments disposals
£m £m £m
Cash consideration 256 (15) 198
Net deferred consideration received 39 – –
Cash and cash equivalents divested (6) – –
Transaction costs paid (7) – (2)
Cash inflow 282 (15) 196
 193

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

38. Acquisitions and disposals continued

2016
Business acquisitions
GSK completed two small business acquisitions during 2016.
Cash consideration of £24 million was paid in the year to acquire the HIV R&D preclinical and discovery stage portfolio from Bristol Myers
Squibb. Further consideration, contingent on commercial milestones and future sales performance, may be due, and an initial estimate of
£40 million was recognised for this contingent consideration. Intangible assets acquired were valued at £57 million and goodwill of £7 million
was recognised.
GSK formed Galvani Bioelectronics Limited during the year and acquired intangible assets of £45 million and cash and cash equivalents
of £41 million from Verily Life Sciences LLC in return for a 45% shareholding in Galvani Bioelectronics. The fair value of this shareholding
was £47 million, and GSK also recognised a credit of £39 million in non-controlling interests representing Verily’s share of the net assets
it contributed.
Business disposals
GSK also made a number of small business disposals in the year for net cash consideration of £72 million. In addition, deferred consideration
receivable of £43 million was recognised.
Cash flows
Business Business
acquisitions disposals
£m £m
Cash consideration (paid)/received after purchase adjustments (24) 72
Cash and cash equivalents acquired 41 –
Cash inflow 17 72

In addition, GSK made cash investments of £11 million into associates and joint ventures.
194

GSK Annual Report 2018

Notes to the financial statements continued

39. Contingent consideration liabilities

The consideration for certain acquisitions includes amounts contingent on future events such as development milestones or sales
performance. The Group has provided for the fair value of this contingent consideration as follows:
Shionogi-
ViiV Novartis
Healthcare Vaccines Other Total
£m £m £m £m
At 1 January 2016 3,409 405 41 3,855
Additions through business combinations 154 – 40 194
Remeasurement through income statement 2,162 152 (33) 2,281
Cash payments: operating cash flows (351) (5) (2) (358)
Cash payments: investing activities (66) (7) – (73)
Other movements (4) – 1 (3)
At 31 December 2016 5,304 545 47 5,896
Remeasurement through income statement 909 53 (1) 961
Cash payments: operating cash flows (587) (7) – (594)
Cash payments: investing activities (84) (7) – (91)
At 31 December 2017 5,542 584 46 6,172
Remeasurement through income statement 1,188 56 7 1,251
Cash payments: operating cash flows (703) (281) – (984)
Cash payments: investing activities (90) (63) – (153)
At 31 December 2018 5,937 296 53 6,286

Of the contingent consideration payable at 31 December 2018, £837 million (2017 – £1,076 million) is expected to be paid within one year.
The contingent consideration payable in respect of the Novartis Vaccines business included a sales milestone of $450 million which was
settled in January 2018.
The consideration payable for the acquisition of the Shionogi-ViiV Healthcare joint venture and the Novartis Vaccines business is
expected to be paid over a number of years. As a result, the total estimated liabilities are discounted to their present values, shown above.
The Shionogi-ViiV Healthcare contingent consideration liability is discounted at 8.5% and the Novartis Vaccines contingent consideration
liability is discounted partly at 8% and partly at 9%.
The Shionogi-ViiV Healthcare and Novartis Vaccines contingent consideration liabilities are calculated principally based on the forecast sales
performance of specified products over the lives of those products.
The table below shows on an indicative basis the income statement and balance sheet sensitivity to reasonably possible changes in key
inputs to the valuations of the contingent consideration liabilities.

Shionogi- Novartis
ViiV Healthcare Vaccines
Increase/(decrease) in financial liability and loss/(gain) in Income statement £m £m
10% increase in sales forecasts 569 62
10% decrease in sales forecasts (569) (62)
1% increase in discount rate (238) (22)
1% decrease in discount rate 256 26
5% increase in probability of milestone success 7
5% decrease in probability of milestone success (7)
10 cent appreciation of US Dollar 367 (13)
10 cent depreciation of US Dollar (313) 11
10 cent appreciation of Euro 114 29
10 cent depreciation of Euro (95) (25)

An explanation of the accounting for ViiV Healthcare is set out on page 41.
 195

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

40. Non-controlling interests

ViiV Healthcare
The ViiV Healthcare subgroup has a material non-controlling interest. Summarised financial information in respect of the ViiV Healthcare
group is as follows:
2018 2017 2016
£m £m £m
Turnover 4,665 4,269 3,527
Profit/(loss) after taxation 560 825 (1,249)
Other comprehensive income 19 20 36
Total comprehensive income/(expense) 579 845 (1,213)

2018 2017
£m £m
Non-current assets 2,787 2,736
Current assets 2,643 2,533
Total assets 5,430 5,269
Current liabilities (2,638) (2,409)
Non-current liabilities (8,895) (8,011)
Total liabilities (11,533) (10,420)
Net liabilities (6,103) (5,151)

2018 2017 2016

£m £m £m
Net cash inflow from operating activities 2,212 2,132 1,750
Net cash outflow from investing activities (237) (207) (326)
Net cash outflow from financing activities (1,982) (1,820) (1,023)
(Decrease)/increase in cash and bank overdrafts in the year (7) 105 401

The above financial information relates to the ViiV Healthcare group on a stand-alone basis, before the impact of Group-related adjustments,
primarily related to the recognition of preferential dividends. The profit after taxation of £560 million (2017 – profit after taxation of
£825 million; 2016 – loss after taxation of £1,249 million) is stated after charging preferential dividends payable to GSK, Shionogi and Pfizer
and after a charge of £1,194 million (2017 – £909 million; 2016 – £2,186 million) for remeasurement of the contingent consideration payable
for the acquisition of the former Shionogi-ViiV Healthcare joint venture. This consideration is expected to be paid over a number of years.
The following amounts attributable to the ViiV Healthcare group are included in GSK’s Consolidated statement of comprehensive income,
Consolidated statement of changes in equity and Consolidated balance sheet:
2018 2017 2016
£m £m £m
Total comprehensive income/(expense) for the year attributable to non-controlling interests 254 187 (83)
Dividends paid to non-controlling interests 332 316 152

Non-controlling interests in the Consolidated balance sheet (543) (476)

196

GSK Annual Report 2018

Notes to the financial statements continued

40. Non-controlling interests continued

Consumer Healthcare Joint Venture
During 2018, the Group acquired Novartis’ interest in the Consumer Healthcare Joint Venture to obtain 100% ownership. The acquisition
became unconditional on 3 May 2018 and completed on 1 June 2018. Summarised financial information in respect of the Consumer
Healthcare Joint Venture is as follows:
Period ended
3 May 2018 2017 2016
£m £m £m
Turnover 2,306 7,003 6,530
Profit after taxation 7 1,211 660
Other comprehensive (expense)/income (79) (387) 1,640
Total comprehensive (expense)/income (72) 824 2,300

2017
£m
Non-current assets 12,771
Current assets 3,282
Total assets 16,053
Current liabilities (2,675)
Non-current liabilities (1,537)
Total liabilities (4,212)
Net assets 11,841

Period ended
3 May 2018 2017 2016
£m £m £m
Net cash inflow from operating activities 65 883 1,496
Net cash inflow/(outflow) from investing activities 442 270 (537)
Net cash outflow from financing activities (504) (1,194) (980)
Increase/(decrease) in cash and bank overdrafts in the year 3 (41) (21)

The above financial information relates to the Consumer Healthcare Joint Venture on a stand-alone basis, before the impact of Group-related
adjustments but after major restructuring charges.
The following amounts attributable to the Consumer Healthcare Joint Venture are included in GSK’s Consolidated statement of
comprehensive income, Consolidated statement of changes in equity and Consolidated balance sheet:

2018 2017 2016

£m £m £m
Total comprehensive income for the year attributable to non-controlling interests 111 296 730
Dividends paid to non-controlling interests 183 420 346

Non-controlling interests in the Consolidated balance sheet – 3,631

 197

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

41. Commitments
2018 2017
Contractual obligations and commitments £m £m
Contracted for but not provided in the financial statements:
Intangible assets 4,762 5,254
Property, plant and equipment 665 584
Investments 82 107
Purchase commitments 561 346
Pensions 238 738
Other commitments – 38
Interest on loans 9,418 8,510
Finance lease charges 16 12
15,742 15,589

The commitments related to intangible assets include milestone payments, which are dependent on successful clinical development or
on meeting specified sales targets, and which represent the maximum that would be paid if all milestones, however unlikely, are achieved.
The amounts are not risk-adjusted or discounted. The decrease in intangible commitments in 2018 is mainly attributable to the reduction
in commitments to third parties such as Nkarta, Inc.
In 2018, GSK reached an agreement with the trustees of the UK pension schemes to make additional contributions to eliminate the pension
deficit identified at the 31 December 2017 actuarial funding valuation. A payment of £75 million is due in both 2019 and 2020 and a payment
of £44 million is due in both 2021 and 2022. The table above includes this commitment, but excludes the normal ongoing annual funding
requirement in the UK of approximately £140 million.
The Group also has other commitments which principally relate to revenue payments to be made under licences and other alliances.
Commitments in respect of future interest payable on loans are disclosed before taking into account the effect of interest rate swaps.
Commitments under non-cancellable operating leases are disclosed below. £161 million (2017 – £117 million) is provided against these
commitments on the Group’s balance sheet.
2018 2017
Commitments under non-cancellable operating leases £m £m
Rental payments due within one year 223 186
Rental payments due between one and two years 173 149
Rental payments due between two and three years 143 122
Rental payments due between three and four years 123 107
Rental payments due between four and five years 105 94
Rental payments due after five years 371 387
Total commitments under non-cancellable operating leases 1,138 1,045
­
198

GSK Annual Report 2018

Notes to the financial statements continued

42. Financial instruments and related disclosures

The objective of our Treasury activity is to minimise the post-tax In addition a $5.0 billion bank facility was agreed in December 2018
net cost of financial operations and reduce its volatility to benefit to support the acquisition of Tesaro and was undrawn at 31
earnings and cash flows. GSK uses a variety of financial instruments December 2018. This 12-month facility includes two six-month
to finance its operations and derivative financial instruments to extension options.
manage market risks from these operations. Derivatives principally
GSK has a £20.0 billion European Medium Term Note programme
comprise of foreign exchange forward contracts and swaps which
and at 31 December 2018, £11.4 billion of notes were in issue under
are used to swap borrowings and liquid assets into currencies
this programme. The Group also had $12.9 billion (£10.2 billion) of
required for Group purposes as well as interest rate swaps which
notes in issue at 31 December 2018 under a US shelf registration.
are used to manage exposure to financial risks from changes in
GSK’s borrowings mature at dates between 2019 and 2045.
interest rates. These financial instruments reduce the uncertainty
of foreign currency transactions and interest payments. The put option owned by Pfizer in ViiV Healthcare is exercisable.
In reviewing liquidity requirements GSK considers that sufficient
Derivatives are used exclusively for hedging purposes in relation
financing options are available should the put option be exercised.
to underlying business activities and not as trading or speculative
instruments. Market risk
Capital management Interest rate risk management
The objective of GSK’s Treasury activity is to minimise the effective
GSK’s financial strategy supports the Group’s strategic priorities
net interest cost and to balance the mix of debt at fixed and floating
and is regularly reviewed by the Board. GSK manages the capital
rates over time.
structure of the Group through an appropriate mix of debt and equity.
The Group’s main interest rate risk arises from borrowings and
The capital structure of the Group consists of net debt of
investments with floating rates and refinancing of maturing fixed rate
£21.6 billion (see Note 31, ‘Net debt’) and total equity, including
debt where any changes in interest rates will affect future cash flows
items related to non-controlling interests, of £3.7 billion (see
or the fair values of financial instruments. The policy on interest rate
‘Consolidated statement of changes in equity’ on page 142).
risk management limits the net amount of floating rate debt to a
Total capital, including that provided by non-controlling interests,
specific cap, reviewed and agreed no less than annually by the
is £25.3 billion.
Board.
The Group continues to manage its financial policies to a credit
The majority of debt is issued at fixed interest rates and changes in
profile that particularly targets short-term credit ratings of A-1 and
the floating rates of interest do not significantly affect the Group’s
P-1 while maintaining single A long-term ratings consistent with
net interest charge. This includes some borrowings for which interest
those targets. The Group’s long-term credit rating with Standard and
rate swaps are in place which removes the impact of the associated
Poor’s is A+ (negative outlook) and with Moody’s Investor Services
periodic repricing. Short-term borrowings including bank facilities
(‘Moody’s’) it is A2 (negative outlook). The Group’s short-term credit
are exposed to the risk of future changes in market interest rate as
ratings are A-1 and P-1 with Standard and Poor’s and Moody’s
are the majority of cash and liquid investments.
respectively.
Foreign exchange risk management
Liquidity risk management Foreign currency transaction exposures arising on external trade
GSK’s policy is to borrow centrally in order to meet anticipated flows are not normally hedged. Foreign currency transaction
funding requirements. The strategy is to diversify liquidity sources exposures arising on internal trade flows are selectively hedged. The
using a range of facilities and to maintain broad access to financial Group’s objective is to minimise the exposure of overseas operating
markets. subsidiaries to transaction risk by matching local currency income
with local currency costs where possible. GSK’s internal trading
At 31 December 2018, GSK had £5.8 billion of borrowings transactions are matched centrally and inter-company payment
repayable within one year and held £4.5 billion of cash and cash terms are managed to reduce foreign currency risk. Foreign currency
equivalents and liquid investments of which £2.9 billion was cash flows can be hedged selectively including hedges of the
held centrally. GSK has access to short-term finance under a foreign exchange risk arising from acquisitions and disposals of
$10.0 billion (£7.9 billion) US commercial paper programme; assets. Where possible, GSK manages the cash surpluses or
$0.8 billion (£0.6 billion) was in issue at 31 December 2018 borrowing requirements of subsidiary companies centrally using
(2017 – $0.7 billion). GSK has a £1.9 billion five-year committed forward contracts to hedge future repayments back into the
facility and a $2.5 billion (£2.0 billion) 364-day committed facility. originating currency.
The five-year committed facility was agreed in September 2015 and
was extended by one year to 2021 in September 2016. The 364-day In order to reduce foreign currency translation exposure, the Group
committed facility was agreed in September 2018. These facilities seeks to denominate borrowings in the currencies of our principal
were undrawn at 31 December 2018. GSK considers this level of assets and cash flows. These are primarily denominated in US
committed facilities to be adequate, given current liquidity Dollars, Euros and Sterling. Borrowings can be swapped into other
requirements. currencies as required.

Additional bank facilities were agreed in 2018 to support Borrowings denominated in, or swapped into, foreign currencies
transactions and two remain active at 31 December 2018. In that match investments in overseas Group assets may be treated
June 2018, £3.5 billion was drawn to support the acquisition from as a hedge against the relevant assets. Forward contracts in major
Novartis of the remaining stake in the Consumer Healthcare Joint currencies are also used to reduce exposure to the Group’s
Venture. This facility, which is due to mature in December 2019 investment in overseas assets (see ‘Net investment hedges’
includes one extension option through to June 2020. section of this note for further details).
 199

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

42. Financial instruments and related disclosures continued

Credit risk GSK actively manages its exposure to credit risk, reducing surplus
cash balances wherever possible. This is part of GSK’s strategy to
Credit risk is the risk that a counterparty will default on its regionalise cash management and to concentrate cash centrally as
contractual obligations resulting in financial loss to the Group much as possible. The table below sets out the credit exposure to
and arises on cash and cash equivalents, favourable derivative counterparties by rating for liquid investments, cash and cash
financial instruments held with banks and financial institutions equivalents and derivatives.
as well as credit exposures to wholesale and retail customers,
including outstanding receivables. The gross asset position on each derivative contract is considered
for the purpose of this table, although, under ISDA agreements, the
The Group considers its maximum credit risk at 31 December amount at risk is the net position with each counterparty. Table (e)
2018 to be £11,080 million (31 December 2017 – £9,988 million) on page 208 sets out the Group’s financial assets and liabilities on
which is the total of the Group’s financial assets with the exception an offset basis.
of ’Other investments’ (comprising equity investments) which bear
equity risk rather than credit risk. See page 201 for details on the At 31 December 2018, £20 million of cash is categorised as held
Group’s total financial assets. At 31 December 2018, GSK’s with unrated or sub-investment grade rated counterparties (lower
greatest concentration of credit risk was £0.7 billion with Citibank than BBB-/Baa3) of which £1 million is cash in transit. The remaining
(A+/A1) (2017 – £0.5 billion with Citibank (A/A1) and £0.5 billion exposure is concentrated in overseas banks used for local cash
with one US wholesaler (BBB+/Baa2)). management or investment purposes, including £6 million in Nigeria
held with United Bank for Africa, Zenith Bank, Stanbic IBTC Bank and
There has been no change in the estimation techniques or First Bank of Nigeria, £3 million with BTV in Austria, £2 million with
significant assumptions made during the current reporting period in Nacion Argentina bank, and £2 million with Banco de la Republica in
assessing the loss allowance for financial assets at amortised cost Uruguay. Of the £381 million of bank balances and deposits held
since the adoption of IFRS 9 at the start of the current reporting with BBB/Baa rated counterparties, £22 million was held with BBB-/
period. Baa3 rated counterparties, including balances or deposits of £20
Treasury-related credit risk million with HDFC Bank in India and £1 million with State Bank of
GSK sets global counterparty limits for each of GSK’s banking India. These banks are used for local investment purposes.
and investment counterparties based on long-term credit ratings GSK measures expected credit losses over cash and cash
from Moody’s and Standard and Poor’s. Usage of these limits is equivalents as a function of individual counterparty credit ratings
monitored daily. and associated 12 month default rates. Expected credit losses over
cash and cash equivalents and third-party financial derivatives are
deemed to be immaterial and no such loss has been experienced
during 2018.

BB+/Ba1
and below
AAA/Aaa AA/Aa A/A BBB/Baa /unrated Total
2018 £m £m £m £m £m £m
Bank balances and deposits – 662 1,275 381 20 2,338
US Treasury and Treasury repo only money market funds 449 – – – – 449
Liquidity funds 1,572 – – – – 1,572
Government securities – 83 – 1 – 84
3rd party financial derivatives – 19 127 4 – 150
Total 2,021 764 1,402 386 20 4,593

BB+/Ba1
and below
AAA/Aaa AA/Aa A/A BBB/Baa /unrated Total
2017 £m £m £m £m £m £m
Bank balances and deposits – 423 1,167 80 45 1,715
US Treasury and Treasury repo only money market funds 1,715 – – – – 1,715
Liquidity funds 403 – – – – 403
Government securities – 77 – 1 – 78
3rd party financial derivatives – 26 42 – – 68
Total 2,118 526 1,209 81 45 3,979

Credit ratings are assigned by Standard and Poor’s and Moody’s respectively. Where the opinions of the two rating agencies differ, GSK
assigns the lower rating of the two to the counterparty. Where local rating agency or Fitch data is the only source available, the ratings are
converted to global ratings equivalent to those of Standard and Poor’s or Moody’s using published conversion tables. These credit ratings
form the basis of the assessment of the expected credit loss on Treasury related balances held at amortised cost being bank balances and
deposits and Government securities.
200

GSK Annual Report 2018

Notes to the financial statements continued

42. Financial instruments and related disclosures continued

GSK’s centrally managed cash reserves amounted to £2.9 billion Credit enhancements
at 31 December 2018, all available within three months. This The Group uses credit enhancements including factoring and
includes £1.7 billion of cash managed by the Group for ViiV credit insurance to minimise credit risk of the trade receivables in
Healthcare, a 78.3% owned subsidiary. The Group has invested the Group. During 2018, a new Global Insurance Programme was
centrally managed liquid assets in bank deposits, Aaa/AAA rated launched in order to consolidate all locally negotiated programmes
US Treasury and Treasury repo only money market funds and Aaa/ and to expand the use of credit insurance to new markets. At
AAA rated liquidity funds. 31 December 2018, £240 million of GSK trade receivables were
Wholesale and retail credit risk insured protecting GSK’s account receivables balance from loss
Outside the US, no customer accounts for more than 5% of the due to credit risks such as default, insolvency and bankruptcy.
Group’s trade receivables balance. Each Group entity assesses the credit risk of its private customers
In the US, in line with other pharmaceutical companies, the Group to determine if credit insurance is required.
sells its products through a small number of wholesalers in addition Factoring arrangements are managed locally by entities and are
to hospitals, pharmacies, physicians and other groups. Sales to the used to mitigate risk arising from large credit risk concentrations.
three largest wholesalers amounted to approximately 82% of the All factoring arrangements are non-recourse.
sales of the US Pharmaceuticals and Vaccines businesses in 2018.
At 31 December 2018, the Group had trade receivables due from Fair value of financial assets and liabilities
these three wholesalers totalling £2,134 million (2017 – £1,265 The table on pages 201 and 202 presents the carrying amounts
million). The Group is exposed to a concentration of credit risk in and the fair values of the Group’s financial assets and liabilities at
respect of these wholesalers such that, if one or more of them 31 December 2018 and 31 December 2017.
encounters financial difficulty, it could materially and adversely
affect the Group’s financial results. The fair values of the financial assets and liabilities are included at
the price that would be received to sell an asset or paid to transfer
The Group’s credit risk monitoring activities relating to these a liability in an orderly transaction between market participants at
wholesalers include a review of their quarterly financial information the measurement date.
and Standard & Poor’s credit ratings, development of GSK internal
risk ratings, and establishment and periodic review of credit limits. The following methods and assumptions were used to estimate
the fair values:
All new customers are subject to a credit vetting process and
existing customers will be subject to a review at least annually. –– Cash and cash equivalents – approximates to the carrying amount
The vetting process and subsequent reviews involves obtaining –– Liquid investments – approximates to the carrying amount
information including the customer’s status as a government or
–– Other investments – equity investments traded in an active market
private sector entity, audited financial statements, credit bureau
determined by reference to the relevant stock exchange quoted
reports, debt rating agency (e.g. Moody’s, Standard & Poor’s)
bid price; other equity investments determined by reference to the
reports, payment performance history (from trade references,
current market value of similar instruments or by reference to the
industry credit groups) and bank references.
discounted cash flows of the underlying net assets
Trade receivables consist of a large number of customers, spread
–– Short-term loans, overdrafts and commercial paper –
across diverse industries and geographical areas. Ongoing credit
approximates to the carrying amount because of the short maturity
evaluation is performed on the financial condition of accounts
of these instruments
receivable and, where appropriate, credit insurance is purchased
or factoring arrangements put in place. –– Long-term loans – based on quoted market prices (a level 1 fair
value measurement) in the case of European and US Medium
The amount of information obtained is proportional to the level of
Term Notes; approximates to the carrying amount in the case
exposure being considered. The information is evaluated quantitatively
of other fixed rate borrowings and floating rate bank loans
(i.e., credit score) and qualitatively (i.e. judgement) in conjunction with
the customer’s credit requirements to determine a credit limit. –– Contingent consideration for business acquisitions – based on
present values of expected future cash flows
Trade receivables are grouped into customer segments that have
similar loss patterns to assess credit risk while other receivables –– Interest rate swaps, foreign exchange forward contracts, swaps
other financial assets are assessed individually. Historical and and options – based on the present value of contractual cash
forward-looking information is considered to determine the flows or option valuation models using market sourced data
appropriate expected credit loss allowance. The Group believes (exchange rates or interest rates) at the balance sheet date
there is no further credit risk provision required in excess of the –– Receivables and payables, including put options – approximates
allowance for expected credit losses (see Note 24, ‘Trade and to the carrying amount
other receivables’).
–– Company-owned life insurance policies – based on cash
surrender value, and
–– Lease obligations – approximates to the carrying amount.
 201

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

42. Financial instruments and related disclosures continued

2018
Carrying Fair
value value
Notes £m £m
Financial assets measured at fair value through other comprehensive
income (FVTOCI):
Other investments designated at FVTOCI a 1,250 1,250
Trade and other receivables a,b 1,687 1,687

Financial assets measured at amortised cost:

Other non-current assets b 49 49
Trade and other receivables b 3,761 3,761
Liquid investments 84 84
Cash and cash equivalents 2,338 2,338
Other items in Assets held for sale b 47 47

Financial assets mandatorily measured at fair value through profit or loss (FVTPL):
Other investments a 72 72
Other non-current assets a,b 716 716
Trade and other receiveables a,b 120 120
Derivatives designated and effective as hedging instruments a,d,e 69 69
Held for trading derivatives that are not in a designated and
effective hedging relationship a,d,e 188 188
Cash and cash equivalents a 2,021 2,021
Total financial assets 12,402 12,402

Financial liabilities measured at amortised cost:

Borrowings excluding obligations under finance leases:
– bonds in a designated hedging relationship d (8,213) (8,279)
– other bonds (13,307) (15,475)
– bank loans and overdrafts (290) (290)
– commercial paper (630) (630)
– other borrowings (3,556) (3,556)
Total borrowings excluding obligations under finance leases f (25,996) (28,230)
Obligations under finance leases (68) (68)
Total borrowings (26,064) (28,298)
Trade and other payables c (13,338) (13,338)
Other provisions c (58) (58)
Other non-current liabilities c (149) (149)
Other items in Assets held for sale c (167) (167)

Financial liabilities mandatorily at fair value through profit or loss (FVTPL):

Contingent consideration liabilities a,c (6,286) (6,286)
Derivatives designated and effective as hedging instruments a,d,e (105) (105)
Held for trading derivatives that are not in a designated and
effective hedging relationship a,d,e (23) (23)
Total financial liabilities (46,190) (48,424)

Net financial assets and financial liabilities (33,788) (36,022)

The valuation methodology used to measure fair value in the above table and the table on page 202 is described and categorised on
page 200.
Trade and other receivables, Other non-current assets, Trade and other payables, Other provisions, Other non-current liabilities,
Contingent consideration liabilities and Other items in Assets held for sale are reconciled to the relevant Notes on pages 204 and 205.
Cash and cash equivalents in the table above include £485 million reported in Assets held for sale (see Note 26, ‘Assets held for sale’).
202

GSK Annual Report 2018

Notes to the financial statements continued

42. Financial instruments and related disclosures continued

2017
Carrying Fair
value value
Notes £m £m
Available-for-sale investments:
Liquid investments (Government bonds) a 78 78
Other investments a 918 918

Loans and receivables:

Cash and cash equivalents 3,833 3,833
Trade and other receivables and Other non-current
assets in scope of IAS 39 b 5,495 5,495

Financial assets at fair value through profit or loss:

Trade and other receivables and Other non-current
assets in scope of IAS 39 a,b 506 506
Derivatives designated as at fair value through profit or loss a,d,e 5 5
Derivatives classified as held for trading under IAS 39 a,d,e 71 71
Total financial assets 10,906 10,906

Financial liabilities measured at amortised cost:

Borrowings excluding obligations under finance leases:
– bonds in a designated hedging relationship d (4,315) (4,405)
– other bonds (11,894) (14,743)
– bank loans and overdrafts (236) (236)
– commercial paper (529) (529)
– other borrowings (49) (49)
Total borrowings excluding obligations under finance leases f (17,023) (19,962)
Obligations under finance leases (66) (66)
Total borrowings (17,089) (20,028)
Trade and other payables, Other provisions and certain
Other non-current liabilities in scope of IAS 39 c (20,325) (20,325)

Financial liabilities at fair value through profit or loss:

Contingent consideration liabilities a,c (6,172) (6,172)
Derivatives designated as at fair value through profit or loss a,d,e (26) (26)
Derivatives classified as held for trading under IAS 39 a,d,e (48) (48)
Total financial liabilities (43,660) (46,599)

Net financial assets and financial liabilities (32,754) (35,693)

Fair value of investments in GSK shares

At 31 December 2018, the Employee Share Ownership Plan (ESOP) Trusts held GSK shares with a carrying value of £161 million
(2017 – £400 million) and a market value of £619 million (2017 – £882 million) based on quoted market price. The shares are held by the
ESOP Trusts to satisfy future exercises of options and awards under employee incentive schemes. In 2018, the carrying value, which is the
lower of cost or expected proceeds, of these shares has been recognised as a deduction from other reserves. At 31 December 2018,
GSK held Treasury shares at a cost of £5,800 million (2017 – £5,800 million) which has been deducted from retained earnings.
 203

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

42. Financial instruments and related disclosures continued

(a) Financial instruments held at fair value
The following tables categorise the Group’s financial assets and liabilities held at fair value by the valuation methodology applied in
determining their fair value. Where possible, quoted prices in active markets are used (Level 1). Where such prices are not available, the asset
or liability is classified as Level 2, provided all significant inputs to the valuation model used are based on observable market data. If one or
more of the significant inputs to the valuation model is not based on observable market data, the instrument is classified as Level 3. Other
investments classified as Level 3 in the tables below comprise equity investments in unlisted entities with which the Group has entered into
research collaborations and also investments in emerging life science companies.

Level 1 Level 2 Level 3 Total

At 31 December 2018 £m £m £m £m
Financial assets at fair value
Financial assets at fair value through other comprehensive income (FVTOCI):
Other investments designated at FVTOCI 656 – 594 1,250
Trade and other receivables – 1,687 – 1,687
Financial assets mandatorily measured at fair value through profit or loss (FVTPL):
Other investments – – 72 72
Other non-current assets – 675 41 716
Trade and other receivables – 79 41 120
Derivatives designated and effective as hedging instruments – 69 – 69
Held for trading derivatives that are not in a designated and effective hedging relationship – 182 6 188
Cash and cash equivalents 2,021 – – 2,021
2,677 2,692 754 6,123
Financial liabilities at fair value
Financial liabilities mandatorily at fair value through profit or loss (FVTPL):
Contingent consideration liabilities – – (6,286) (6,286)
Derivatives designated and effective as hedging instruments – (105) – (105)
Held for trading derivatives that are not in a designated and effective hedging relationship – (23) – (23)
– (128) (6,286) (6,414)

Level 1 Level 2 Level 3 Total

At 31 December 2017 £m £m £m £m
Financial assets at fair value
Available-for-sale financial assets:
Liquid investments 77 1 – 78
Other investments 535 – 383 918
Other non-current assets – – 38 38
Financial assets at fair value through profit or loss:
Other non-current assets – 382 44 426
Trade and other receivables – – 42 42
Derivatives designated as at fair value through profit or loss – 5 – 5
Derivatives classified as held for trading under IAS 39 – 62 9 71
612 450 516 1,578

Financial liabilities at fair value

Financial liabilities at fair value through profit or loss:
Contingent consideration liabilities – – (6,172) (6,172)
Derivatives designated as at fair value through profit or loss – (26) – (26)
Derivatives classified as held for trading under IAS 39 – (47) (1) (48)
– (73) (6,173) (6,246)
204

GSK Annual Report 2018

Notes to the financial statements continued

42. Financial instruments and related disclosures continued

Movements in the year for financial instruments measured using Level 3 valuation methods are presented below:
2018 2017
£m £m
At 1 January (5,657) (5,486)
Net losses recognised in the income statement (1,233) (970)
Net gains recognised in other comprehensive income 123 22
Contingent consideration for businesses divested/acquired during the year – 80
Payment of contingent consideration liabilities 1,095 685
Additions 381 117
Disposals and settlements (27) (52)
Transfers from Level 3 (241) (24)
Exchange adjustments 27 (29)
At 31 December (5,532) (5,657)

The net losses of £1,233 million (2017 – £970 million) attributable to Level 3 financial instruments which were recognised in the income
statement were all attributable to financial instruments which were held at the end of the year. Losses of £1,233 million were reported in
Other operating income (2017 – £971 million losses in Other operating income and £1 million income in Finance income). £1,188 million
(2017 – £909 million) arose from remeasurement of the contingent consideration payable for the acquisition of the former Shionogi-ViiV
Healthcare joint venture and £56 million (2017 – £53 million) arose from remeasurement of the contingent consideration payable for the
acquisition of the Novartis Vaccines business. Net gains of £123 million (2017 – £22 million) attributable to Level 3 financial instruments
reported in Other comprehensive income as Fair value movements on equity investments included net gains of £117 million (2017 – net
losses of £6 million) in respect of financial instruments held at the end of the year, of which net gains of £98 million (2017 – net losses of
£6 million) arose prior to transfer from Level 3 on equity investments which transferred to a Level 1 valuation methodology as a result
of listing on a recognised stock exchange during the year.
Financial liabilities measured using Level 3 valuation methods at 31 December included £5,937 million (2017 – £5,542 million) in respect
of contingent consideration payable for the acquisition in 2012 of the former Shionogi-ViiV Healthcare joint venture. This consideration is
expected to be paid over a number of years and will vary in line with the future performance of specified products and movements in certain
foreign currencies. They also included £296 million (2017 – £584 million) in respect of contingent consideration for the acquisition in 2015
of the Novartis Vaccines business. This consideration is expected to be paid over a number of years and will vary in line with the future
performance of specified products, the achievement of certain milestone targets and movements in certain foreign currencies. Sensitivity
analysis on these balances is provided in Note 39, ‘Contingent consideration liabilities’.

(b) Trade and other receivables, Other non-current assets and other items in Assets held for sale in scope of
IFRS 9 (2017 – IAS 39)
The following table reconciles financial instruments within Trade and other receivables, Other non-current assets and other items in Assets
held for sale which fall within the scope of IFRS 9 (2017 - IAS 39) to the relevant balance sheet amounts. The financial assets are
predominantly non-interest earning. Financial instruments within the Other non-current assets balance include company-owned life insurance
policies. Non-financial instruments include tax receivables, pension surplus balances and prepayments, which are outside the scope of
IFRS 9 (2017 – IAS 39).
2018 2017
Non- Non-
Amortised Financial financial Loans and Financial financial
At FVTPL At FVTOCI cost instruments instruments Total At FVTPL receivables instruments instruments Total
£m £m £m £m £m £m £m £m £m £m £m
Trade and other receivables
(Note 24) 120 1,687 3,761 5,568 855 6,423 42 5,148 5,190 810 6,000
Other non-current assets
(Note 22) 716 – 49 765 811 1,576 464 347 811 602 1,413
Other items in Assets held
for sale (Note 26) – – 47 47 37 84 – – – – –
836 1,687 3,857 6,380 1,703 8,083 506 5,495 6,001 1,412 7,413

The Group applied IFRS 9 ‘Financial Instruments’ with effect from 1 January 2018 and therefore now accounts for expected credit losses on
initial recognition of financial assets. The following table shows the ageing of financial assets which were past due at 31 December 2017 and
for which no provision for bad or doubtful debts had been made at that date under IAS 39:
2017
£m
Past due by 1–30 days 142
Past due by 31–90 days 70
Past due by 91–180 days 64
Past due by 181–365 days 27
Past due by more than 365 days 108
411
 205

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

42. Financial instruments and related disclosures continued

(c) Trade and other payables, Other provisions, Other non-current liabilities, Contingent consideration liabilities
and other items in Assets held for sale in scope of IFRS 9 (2017 - IAS 39)
The following table reconciles financial instruments within Trade and other payables, Other provisions, Other non-current liabilities,
Contingent consideration liabilities and other items in Assets held for sale which fall within the scope of IFRS 9/IAS 39 to the relevant
balance sheet amounts. The financial liabilities are predominantly non-interest bearing. Accrued wages and salaries are included within
financial liabilities. Non-financial instruments includes payments on account, tax and social security payables and provisions which do not
arise from contractual obligations to deliver cash or another financial asset, which are outside the scope of IFRS 9/IAS 39.
2018 2017
Non- Non-
Amortised Financial financial Amortised Financial financial
At FVTPL cost instruments instruments Total At FVTPL cost instruments instruments Total
£m £m £m £m £m £m £m £m £m £m
Trade and other payables
(Note 27) – (13,338) (13,338) (699) (14,037) – (20,129) (20,129) (841) (20,970)
Other provisions
(Note 29) – (58) (58) (1,365) (1,423) – (117) (117) (1,148) (1,265)
Other non-current liabilities
(Note 30) – (149) (149) (789) (938) – (79) (79) (902) (981)
Contingent consideration
liabilities (Note 39) (6,286) – (6,286) – (6,286) (6,172) – (6,172) – (6,172)
Other items in Assets held
for sale (Note 26) – (167) (167) (53) (220) – – – – –
(6,286) (13,712) (19,998) (2,906) (22,904) (6,172) (20,325) (26,497) (2,891) (29,388)

(d) Derivative financial instruments and hedging programmes

Derivatives are only used for economic hedging purposes and not as speculative investments and are classified as ‘held for trading’, other
than designated and effective hedging instruments, and are presented as current assets or liabilities if they are expected to be settled within
12 months after the end of the reporting period, otherwise they are classified as non-current. The Group has the following derivative financial
instruments:
2018 2017
Fair value Fair value
Assets Liabilities Assets Liabilities
£m £m £m £m
Non-current
Cash flow hedges – Interest rate swap contracts
(principal amount – £1,266 million (2017 – £nil)) – (1) – –
Net investment hedges – Cross currency swaps
(principal amount – £1,575 million (2017 – £nil)) 64 – – –
Current
Cash flow hedges – Foreign exchange contracts
(principal amount – £1,809 million (2017 – £38 million)) 1 (56) – (1)
Net investment hedges – Foreign exchange contracts
(principal amount – £7,316 million (2017 – £6,333 million)) 4 (48) 5 (25)
Derivatives designated and effective as hedging instruments 69 (105) 5 (26)
Non-current
Embedded and other derivatives 4 – 8 –
Current
Foreign exchange contracts
(principal amount – £18,537 million (2017 – £14,449 million)) 82 (23) 62 (47)
Embedded and other derivatives 102 – 1 (1)
Derivatives classified as held for trading 188 (23) 71 (48)
Total derivative instruments 257 (128) 76 (74)

Fair value hedges

At 31 December 2018, the Group had no designated fair value hedges.
Net investment hedges
During the year, certain foreign exchange contracts were designated as net investment hedges in respect of the foreign currency translation
risk arising on consolidation of the Group’s net investment in its European (Euro) foreign operations as shown in the table above.
The carrying value of bonds on page 201 includes £8,213 million (2017 – £4,315 million) that are designated as hedging instruments in net
investment hedges.
206

GSK Annual Report 2018

Notes to the financial statements continued

42. Financial instruments and related disclosures continued

Cash flow hedges
During 2018, the Group entered into forward foreign exchange contracts which have been designated as cash flow hedges. These were
entered into to hedge the foreign exchange exposure arising on cash flows from Euro denominated coupon payments relating to notes issued
under the Group’s European Medium Term Note programme, on the buyout of Novartis’ non-controlling interest in the Consumer Healthcare
Joint Venture in 2018 and on the planned divestment of Horlicks and other nutrition brands in 2019.
The Group manages its cash flow interest rate risk by using floating-to-fixed interest rate swaps. In addition, the Group carries a balance
in reserves that arose from pre-hedging fluctuations in long-term interest rates when pricing bonds issued in prior years. The balance is
reclassified to finance costs over the life of these bonds.
Foreign exchange forward contracts and swaps
In the current year, the Group has designated certain foreign exchange forward contracts and swaps as cash flow and net investment
hedges. The following tables detail the foreign exchange forward contracts and swaps outstanding at the end of the reporting period,
as well as information on the related hedged items. Foreign exchange derivative financial assets and liabilities are presented in the line
‘Derivative financial instruments’ (either as assets or liabilities) on the Consolidated balance sheet. The notional value of foreign exchange
forward contracts and swaps is the absolute total of outstanding positions at the balance sheet date.
Hedge effectiveness is determined at the inception of the hedge relationship, and through periodic prospective effectiveness assessments
to ensure that an economic relationship exists between the hedged item and hedging instrument. The Group enters into hedge relationships
where the critical terms of the hedging instrument match exactly with the terms of the hedged item, and so a qualitative assessment of
effectiveness is performed. If changes in circumstances affect the terms of the hedged item such that the critical terms no longer match
exactly with the critical terms of the hedging instrument, the Group uses the hypothetical derivative method to assess effectiveness.
The main source of hedge ineffectiveness in these hedging relationships is the effect of the counterparty and the Group’s own credit risk
on the fair value of the foreign exchange forward contracts and swaps, which is not reflected in the fair value of the hedged item attributable
to changes in foreign exchange rates. No other sources of ineffectiveness emerged from these hedging relationships. Consequently, there
was no ineffectiveness to be recorded from cash flow hedges and net investments in foreign entity hedges.
2018
Average Foreign Notional Fair
exchange rate currency value value
Hedging instruments £m £m
Cash flow hedges
Foreign exchange contracts
Buy foreign currency:
Less than 3 months – – – –
3 to 6 months 1.13 Euro 26 1
Over 6 months – – – –
Sell foreign currency:
Less than 3 months – – – –
3 to 6 months – – – –
Over 6 months 96.40 Indian Rupee 1,783 (56)
1,809 (55)
Net investment hedges
Foreign exchange contracts
Sell foreign currency:
Less than 3 months 1.11 Euro 6,933 (40)
3 to 6 months – – – –
Over 6 months 1.11 Euro 383 (4)
7,316 (44)

2018

Balance in cash flow hedge

reserve/foreign currency
Change in value for calculating translation reserve for
hedge ineffectiveness continuing hedges
Hedged items £m £m
Cash flow hedges
Variability in cash flows from a highly probable forecast transaction 56 (49)
Variability in cash flows from foreign exchange exposure arising on
Euro denominated coupon payments relating to debt issued (1) 1
Net investment hedges
Investment in European foreign operations 50 286

There are no balances in the cash flow hedge reserve arising from hedging relationships for which hedge accounting is no longer applied.
 207

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

42. Financial instruments and related disclosures continued

The following table details the effectiveness of the hedging relationships and the amounts reclassified from the hedging reserve to
profit or loss:
2018
Amount reclassified to profit or loss
Line item Hedged
Amount in profit or future cash Line item
Hedging of hedge loss in flows in which
gains/(losses) ineffectiveness which hedge no longer As hedged reclassification
recognised in recognised in ineffectiveness expected to item affects adjustment
reserves profit or loss is included occur profit or loss is included
£m £m £m £m
Cash flow hedges
Variability in cash flows from a highly probable forecast transaction 127 – Other – (176) Other
operating operating
income/ income/
(expense) (expense)
Variability in cash flows from foreign exchange exposure arising on 1 – Finance – – Finance
Euro denominated coupon payments relating to debt issued income/ income/
(expense) (expense)
Net investment hedges
Net investment in European foreign operations 286 7 Finance – – Finance
income/ income/
(expense) (expense)

Interest rate swap contracts

The Group manages its cash flow interest rate risk by using floating-to-fixed interest rate swaps, where at quarterly intervals the difference
between fixed contract rates and floating rate interest amounts calculated by reference to the agreed notional principal amounts are exchanged.
The interest rate swap contracts, exchanging floating rate interest for fixed interest, have been designated as cash flow hedges to hedge the
variability of the interest cash flows associated with floating rate debt relating to notes issued under the Group’s European Medium Term Note
programme. The interest rate swaps and the interest payments on the loan occur simultaneously and the amount accumulated in equity is
reclassified to profit or loss over the period that the floating rate interest payments affect profit or loss.
The critical terms of the interest rate swap contracts and their corresponding hedged items are the same. A qualitative assessment of
effectiveness is performed and it is expected that the value of the interest rate swap contracts and the value of the corresponding hedged
items will systematically change in opposite directions in response to movements in the underlying interest rates. The main sources of
ineffectiveness in these hedge relationships are the effects of currency basis risk and the counterparty’s and the Group’s own credit risk on
the fair value of the interest rate swap contracts, which are not reflected in the fair value of the hedged item attributable to the change in
interest rates. No other sources of ineffectiveness emerged from these hedging relationships.
The following tables provide information regarding interest rate swap contracts outstanding and the related hedged items at 31 December
2018. Interest rate swap contract assets and liabilities are presented in the line ‘Derivative financial instruments’ (either as assets or liabilities)
on the Consolidated balance sheet.
2018
Change in
fair value for
Average Notional recognising Fair value
contracted fixed principal hedge assets/
rate value ineffectiveness (liabilities)
Hedging instruments % £m £m £m
Less than 1 year – – – –
1 to 2 years 0.11 676 – (1)
2 to 5 years 0.16 591 – 23
Over 5 years – – – –

2018
Change in value Balance in cash
used for flow hedge
calculating reserve for
hedge continuing
ineffectiveness hedges
Hedged items £m £m
Variable rate borrowings 3 (3)
208

GSK Annual Report 2018

Notes to the financial statements continued

42. Financial instruments and related disclosures continued

The following table details the effectiveness of the hedging relationships and the amounts reclassified from the hedging reserve to profit or loss:
2018
Amount reclassified to profit or loss
Line item Hedged
Amount in profit or future cash Line item
Hedging of hedge loss in flows in which
gains/(losses) ineffectiveness which hedge no longer As hedged reclassification
recognised in recognised in ineffectiveness expected to item affects adjustment is
reserves profit or loss is included occur profit or loss included
£m £m £m £m
Cash flow hedges
Variability in cash flows (3) – Finance – (2) Finance
income/ income/
(expense) (expense)

Pre-hedging of long-term interest rates 15 – Finance – 3 Finance

income/ income/
(expense) (expense)

(e) Offsetting of financial assets and liabilities

Financial assets and liabilities are offset and the net amount reported in the balance sheet where there is a legally enforceable right to offset
the recognised amounts, and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. There are
also arrangements that do not meet the criteria for offsetting but still allow for the related amounts to be offset in certain circumstances, such
as bankruptcy or the termination of a contract.
The following tables set out the financial assets and liabilities that are offset, or subject to enforceable master netting arrangements and other
similar agreements but not offset, as at 31 December 2018 and 31 December 2017. The column ‘Net amount’ shows the impact on the
Group’s balance sheet if all offset rights were exercised.
Gross Financial
financial (liabilities)/ Net financial Related
assets/ assets assets/ amounts not Net
(liabilities) offset (liabilities) offset amount
At 31 December 2018 £m £m £m £m £m
Financial assets
Trade and other receivables 5,568 – 5,568 (37) 5,531
Derivative financial instruments 257 – 257 (62) 195

Financial liabilities
Trade and other payables (13,338) – (13,338) 37 (13,301)
Derivative financial instruments (128) – (128) 62 (66)

Gross Financial
financial (liabilities)/ Net financial Related
assets/ assets assets/ amounts not Net
(liabilities) offset (liabilities) offset balance
At 31 December 2017 £m £m £m £m £m
Financial assets
Trade and other receivables 5,191 (1) 5,190 (31) 5,159
Derivative financial instruments 76 – 76 (64) 12

Financial liabilities
Trade and other payables (20,130) 1 (20,129) 31 (20,098)
Derivative financial instruments (74) – (74) 64 (10)

Amounts which do not meet the criteria for offsetting on the balance sheet but could be settled net in certain circumstances principally relate
to derivative transactions under ISDA (International Swaps and Derivatives Association) agreements where each party has the option to settle
amounts on a net basis in the event of default of the other party. As there is presently not a legally enforceable right of offset, these amounts
have not been offset in the balance sheet, but have been presented separately in the table above.
 209

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

42. Financial instruments and related disclosures continued

(f) Debt interest rate repricing table
The following table sets out the exposure of the Group to interest rates on debt, including commercial paper. The maturity analysis of fixed rate
debt is stated by contractual maturity and of floating rate debt by interest rate repricing dates. For the purpose of this table, debt is defined as
all classes of borrowings other than obligations under finance leases.
2018 2017
Total
debt Total
£m £m
Floating and fixed rate debt less than one year (5,769) (2,802)
Between one and two years (1,757) (1,340)
Between two and three years (1,570) (1,076)
Between three and four years (1,568) (16)
Between four and five years (2,010) (1,475)
Between five and ten years (5,833) (3,664)
Greater than ten years (7,489) (6,650)
Total (25,996) (17,023)
Original issuance profile:
Fixed rate interest (20,322) (16,209)
Floating rate interest (5,635) (765)
Total interest bearing (25,957) (16,974)
Non-interest bearing (39) (49)
(25,996) (17,023)

(g) Sensitivity analysis

The tables below illustrate the estimated impact on the income statement and equity as a result of hypothetical market movements in foreign
exchange and interest rates in relation to the Group’s financial instruments. The range of variables chosen for the sensitivity analysis reflects
management’s view of changes which are reasonably possible over a one-year period.
Foreign exchange sensitivity
The Group operates internationally and is primarily exposed to foreign exchange risk in relation to Sterling against movements in US Dollar,
Euro and Japanese Yen. Foreign exchange risk arises from the translation of financial assets and liabilities which are not in the functional
currency of the entity that holds them. Based on the Group’s net financial assets and liabilities as at 31 December, a weakening and
strengthening of Sterling against these currencies, with all other variables held constant, is illustrated in the tables below. The tables exclude
financial instruments that expose the Group to foreign exchange risk where this risk is fully hedged with another financial instrument.
2018 2017
Increase/(decrease) in Increase/(decrease) in
income income
Income statement impact of non-functional currency foreign exchange exposures £m £m
10 cent appreciation of the US Dollar 36 76
10 cent appreciation of the Euro (7) (5)
10 yen appreciation of the Yen 15 9

2018 2017
Increase/(decrease) in Increase/(decrease) in
income income
Income statement impact of non-functional currency foreign exchange exposures £m £m
10 cent depreciation of the US Dollar (30) (66)
10 cent depreciation of the Euro 6 4
10 yen depreciation of the Yen (13) (8)
210

GSK Annual Report 2018

Notes to the financial statements continued

42. Financial instruments and related disclosures continued

The equity impact, shown below, for foreign exchange sensitivity relates to derivative and non-derivative financial instruments hedging
the Group’s net investments in its European (Euro) foreign operations and cash flow hedges of its foreign exchange exposure arising on
Euro denominated coupon payments relating to notes issued under the Group’s European Medium Term Note programme.
2018 2017
Increase/(decrease) Increase/(decrease)
in equity in equity
Equity impact of non-functional currency foreign exchange exposures £m £m
10 cent appreciation of the US Dollar – 1
10 cent appreciation of the Euro (1,307) (1,028)

2018 2017
Increase/(decrease) Increase/(decrease)
in equity in equity
Equity impact of non-functional currency foreign exchange exposures £m £m
10 cent depreciation of the US Dollar – (1)
10 cent depreciation of the Euro 1,091 861

The tables below present the Group’s sensitivity to a weakening and strengthening of Sterling against the relevant currency based on the
composition of net debt as shown in Note 31 adjusted for the effects of foreign exchange derivatives that are not part of net debt but affect
future foreign currency cash flows.
2018 2017
(Increase)/decrease (Increase)/decrease
in net debt in net debt
Impact of foreign exchange movements on net debt £m £m
10 cent appreciation of the US Dollar (714) (637)
10 cent appreciation of the Euro (60) 197
10 yen appreciation of the Yen 15 (4)

2018 2017
(Increase)/decrease (Increase)/decrease
in net debt in net debt
Impact of foreign exchange movements on net debt £m £m
10 cent depreciation of the US Dollar 610 549
10 cent depreciation of the Euro 50 (165)
10 yen depreciation of the Yen (13) 4

Interest rate sensitivity

The Group is exposed to interest rate risk on its outstanding borrowings and investments where any changes in interest rates will affect future
cash flows or the fair values of financial instruments.
The majority of debt is issued at fixed interest rates and changes in the floating rates of interest do not significantly affect the Group’s net
interest charge, although the majority of cash and liquid investments earn floating rates of interest.
The table below hypothetically shows the Group’s sensitivity to changes in interest rates in relation to Sterling, US Dollar and Euro floating
rate financial assets and liabilities. If the interest rates applicable to floating rate financial assets and liabilities were to have increased by 1%
(100 basis points), and assuming other variables had remained constant, it is estimated that the Group’s finance income for 2018 would have
decreased by approximately £13 million (2017 – £5 million increase). A 1% (100 basis points) movement in interest rates is not deemed to
have a material effect on equity.
2018 2017
Increase/(decrease) Increase/(decrease)
in income in income
Income statement impact of interest rate movements £m £m
1% (100 basis points) increase in Sterling interest rates (2) 24
1% (100 basis points) increase in US Dollar interest rates 1 (24)
1% (100 basis points) increase in Euro interest rates (12) 5
 211

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

42. Financial instruments and related disclosures continued

(h) Contractual cash flows for non-derivative financial liabilities and derivative instruments
The following tables provide an analysis of the anticipated contractual cash flows including interest payable for the Group’s non-derivative
financial liabilities on an undiscounted basis. For the purpose of this table, debt is defined as all classes of borrowings except for obligations
under finance leases. Interest is calculated based on debt held at 31 December without taking account of future issuance. Floating rate
interest is estimated using the prevailing interest rate at the balance sheet date. Cash flows in foreign currencies are translated using spot
rates at 31 December. Contractual cash flows in respect of operating lease vacant space provisions are excluded from the table below as
they are included in the Commitments under non-cancellable operating leases table in Note 41, ‘Commitments’.
Finance charge Trade payables
Obligations on obligations and other
Interest under finance under finance liabilities not
Debt on debt leases leases in net debt Total
At 31 December 2018 £m £m £m £m £m £m
Due in less than one year (5,771) (714) (24) (5) (14,278) (20,792)
Between one and two years (1,775) (708) (18) (2) (1,107) (3,610)
Between two and three years (1,592) (675) (11) (2) (902) (3,182)
Between three and four years (1,592) (620) (6) (1) (851) (3,070)
Between four and five years (1,970) (567) (3) (1) (826) (3,367)
Between five and ten years (5,875) (2,370) (6) (5) (3,748) (12,004)
Greater than ten years (7,579) (3,764) – – (1,468) (12,811)
Gross contractual cash flows (26,154) (9,418) (68) (16) (23,180) (58,836)

Finance charge Trade payables

Obligations on obligations and other
Interest under finance under finance liabilities not
Debt on debt leases leases in net debt Total
At 31 December 2017 £m £m £m £m £m £m
Due in less than one year (2,802) (555) (23) (2) (21,521) (24,903)
Between one and two years (1,344) (497) (27) (2) (853) (2,723)
Between two and three years (1,078) (488) (8) (1) (813) (2,388)
Between three and four years (16) (488) (2) (1) (784) (1,291)
Between four and five years (1,483) (468) (1) (1) (752) (2,705)
Between five and ten years (3,694) (2,018) (5) (5) (3,609) (9,331)
Greater than ten years (6,720) (3,996) – – (1,471) (12,187)
Gross contractual cash flows (17,137) (8,510) (66) (12) (29,803) (55,528)

Anticipated contractual cash flows for the repayment of debt and debt interest have increased by £9.9 billion over the year due to funding
of the buyout of Novartis’ 36.5% stake in the Consumer Healthcare Joint Venture, an increase in the issuance of commercial paper and
unfavourable exchange impacts from the translation of non-Sterling denominated debt.
The table below provides an analysis of the anticipated contractual cash flows for the Group’s derivative instruments excluding equity options
which do not give rise to cash flows, and other embedded derivatives, which are not material, using undiscounted cash flows. Cash flows in
foreign currencies are translated using spot rates at 31 December. The gross cash flows of foreign exchange contracts are presented for the
purpose of this table although, in practice, the Group uses standard settlement arrangements to reduce its liquidity requirements on these
instruments.
2018 2017
Receivables Payables Receivables Payables
Foreign Foreign Foreign Foreign
exchange exchange exchange exchange
forward forward forward forward
Interest contracts Interest contracts Interest contracts Interest contracts
rate swaps and swaps rate swaps and swaps rate swaps and swaps rate swaps and swaps
£m £m £m £m £m £m £m £m
Due in less than one year 49 26,680 (3) (26,802) – 20,319 – (20,326)
Between one and two years 48 1,575 (3) (1,513) – – – –
Between two and three years 24 – (2) – – – – –
Gross contractual cash flows 121 28,255 (8) (28,315) – 20,319 – (20,326)

The amounts receivable and payable in less than one year have increased compared with 31 December 2017 predominantly from hedging of the
buyout of Novartis’ 36.5% stake in the Consumer Healthcare Joint Venture and the divestment of Horlicks and other nutrition brands to Unilever.
212

GSK Annual Report 2018

Notes to the financial statements continued

43. Employee share schemes

GSK operates several employee share schemes, including the Share Value Plan, whereby awards are granted to employees to acquire shares
or ADS in GlaxoSmithKline plc at no cost after a three year vesting period and the Performance Share Plan, whereby awards are granted to
employees to acquire shares or ADS in GlaxoSmithKline plc at no cost, subject to the achievement by the Group of specified performance
targets. The granting of these restricted share awards has replaced the granting of options to employees as the cost of the schemes more
readily equates to the potential gain to be made by the employee. The Group also operates savings related share option schemes, whereby
options are granted to employees to acquire shares in GlaxoSmithKline plc at a discounted price.
Grants of restricted share awards are normally exercisable at the end of the three-year vesting or performance period. Awards are normally
granted to employees to acquire shares or ADS in GlaxoSmithKline plc but in some circumstances may be settled in cash. Grants under
savings-related share option schemes are normally exercisable after three years’ saving. In accordance with UK practice, the majority of
options under the savings-related share option schemes are granted at a price 20% below the market price ruling at the date of grant.
Options under historical share option schemes were granted at the market price ruling at the date of grant.
The total charge for share-based incentive plans in 2018 was £393 million (2017 – £347 million; 2016 – £338 million). Of this amount,
£304 million (2017 – £276 million; 2016 – £271 million) arose from the Share Value Plan. See Note 9, ‘Employee Costs’ for further details.
GlaxoSmithKline share award schemes
Share Value Plan
Under the Share Value Plan, share awards are granted to certain employees at no cost. The awards vest after two and a half to three years
and there are no performance criteria attached. The fair value of these awards is determined based on the closing share price on the day of
grant, after deducting the expected future dividend yield of 4.8% (2017 – 4.8%; 2016 – 4.5%) over the duration of the award.

Shares Weighted ADS Weighted

Number of shares and ADS issuable Number (000) fair value Number (000) fair value
At 1 January 2016 32,577 17,520
Awards granted 12,983 £14.97 6,589 $39.18
Awards exercised (11,198) (6,214)
Awards cancelled (1,507) (812)
At 31 December 2016 32,855 17,083
Awards granted 13,018 £13.68 6,610 $35.63
Awards exercised (10,596) (5,674)
Awards cancelled (1,352) (627)
At 31 December 2017 33,925 17,392
Awards granted 12,751 £13.74 6,503 $35.28
Awards exercised (11,089) (5,583)
Awards cancelled (1,519) (925)
At 31 December 2018 34,068 17,387

Performance Share Plan

Under the Performance Share Plan, share awards are granted to Directors and senior executives at no cost. The percentage of each award
that vests is based upon the performance of the Group over a defined measurement period with dividends reinvested during the same period.
For awards granted from 2015, the performance conditions are based on three equally weighted measures over a three-year performance
period. These are adjusted free cash flow, TSR and R&D new product performance.
The fair value of the awards is determined based on the closing share price on the day of grant. For TSR performance elements, this is
adjusted by the likelihood of that condition being met, as assessed at the time of grant.
During 2018, awards were made of 4.7 million shares at a weighted fair value of £10.46 and 1.3 million ADS at a weighted fair value of
$29.43. At 31 December 2018, there were outstanding awards over 13.1 million shares and 3.4 million ADS.
 213

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

43. Employee share schemes continued

Share options and savings-related options
For the purposes of valuing savings-related options to arrive at the share-based payment charge, a Black-Scholes option pricing model has
been used. The assumptions used in the model are as follows:

2018 Grant 2017 Grant 2016 Grant

Risk-free interest rate 0.76% 0.54% 0.32%
Dividend yield 5.3% 5.9% 4.9%
Volatility 21% 23% 23%
Expected life 3 years 3 years 3 years
Savings-related options grant price (including 20% discount) £12.09 £10.86 £12.95

Share option Share option Savings-related

Options outstanding schemes – shares schemes – ADS share option schemes
Weighted Weighted Weighted
Number exercise Number exercise Number exercise
000 price 000 price 000 price
At 31 December 2018 1,796 £11.96 1,216 $36.19 5,929 £11.70
Range of exercise prices on options outstanding at year end £11.60 – £12.21 $33.42 – $38.14 £10.13 – £12.95
Weighted average market price on exercise during year £14.43 $39.77 £15.13
Weighted average remaining contractual life 0.9 years 0.9 years 2.6 years

Options over 2.9 million shares were granted during the year under the savings-related share option scheme at a weighted average fair value
of £2.40. At 31 December 2018, 5.5 million of the savings-related share options were not exercisable. All of the other share options and ADS
options are currently exercisable and all will expire if not exercised on or before 22 July 2020.
There has been no change in the effective exercise price of any outstanding options during the year.
Employee Share Ownership Plan Trusts
The Group sponsors Employee Share Ownership Plan (ESOP) Trusts to acquire and hold shares in GlaxoSmithKline plc to satisfy awards
made under employee incentive plans and options granted under employee share option schemes. The trustees of the ESOP Trusts purchase
shares with finance provided by the Group by way of loans or contributions. The costs of running the ESOP Trusts are charged to the income
statement. Shares held by the ESOP Trusts are deducted from other reserves and amortised down to the value of proceeds, if any, receivable
from employees on exercise by a transfer to retained earnings. The trustees have waived their rights to dividends on the shares held by the
ESOP Trusts.

Shares held for share award schemes 2018 2017

Number of shares (000) 41,391 66,558

£m £m
Nominal value 10 17
Carrying value 160 399
Market value 617 880

Shares held for share option schemes 2018 2017

Number of shares (000) 139 139

£m £m
Nominal value – –
Carrying value 1 1
Market value 2 2
­
214

GSK Annual Report 2018

Notes to the financial statements continued

44. Principal Group companies

The following represent the principal subsidiaries and their countries of incorporation of the Group at 31 December 2018. The equity share
capital of these entities is wholly owned by the Group except where its percentage interest is shown otherwise. All companies are
incorporated in their principal country of operation except where stated.

England US
Glaxo Group Limited Block Drug Company, Inc.
Glaxo Operations UK Limited Corixa Corporation
GlaxoSmithKline Capital plc GlaxoSmithKline Capital Inc.
GlaxoSmithKline Consumer Healthcare Holdings Limited GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
GlaxoSmithKline Consumer Healthcare (UK) Trading Limited GlaxoSmithKline Consumer Healthcare, L.P. (88%)
GlaxoSmithKline Consumer Trading Services Limited GlaxoSmithKline Holdings (Americas) Inc.
GlaxoSmithKline Export Limited GlaxoSmithKline LLC
GlaxoSmithKline Finance plc Human Genome Sciences, Inc.
GlaxoSmithKline Holdings Limited * GSK Consumer Health, Inc. (formerly Novartis Consumer Health, Inc.)
GlaxoSmithKline Research & Development Limited S.R. One, Limited
GlaxoSmithKline Services Unlimited * Stiefel Laboratories, Inc.
GlaxoSmithKline UK Limited ViiV Healthcare Company (78.3%)
Setfirst Limited
SmithKline Beecham Limited
ViiV Healthcare Limited (78.3%)
ViiV Healthcare UK Limited (78.3%)

Europe Others
GlaxoSmithKline Biologicals SA (Belgium) GlaxoSmithKline Argentina S.A. (Argentina)
GlaxoSmithKline Pharmaceuticals SA (Belgium) GlaxoSmithKline Australia Pty Ltd (Australia)
GlaxoSmithKline Biologicals S.A.S. (France) GlaxoSmithKline Consumer Healthcare Australia Pty Ltd (Australia)
GlaxoSmithKline Sante Grand Public SAS (France) GlaxoSmithKline Brasil Limitada (Brazil)
Laboratoire GlaxoSmithKline (France) GlaxoSmithKline Consumer Healthcare Inc. (Canada)
ViiV Healthcare SAS (France) (78.3%) GlaxoSmithKline Inc. (Canada)
GlaxoSmithKline Consumer Healthcare GmbH & Co. KG (Germany) ID Biomedical Corporation of Quebec (Canada)
GlaxoSmithKline GmbH & Co. KG (Germany) GlaxoSmithKline Limited (China (Hong Kong))
GSK Vaccines GmbH (Germany) GlaxoSmithKline (Tianjin) Co. Ltd (China) (90%)
GlaxoSmithKline Consumer Healthcare S.p.A. (Italy) Sino-American Tianjin Smith Kline & French Laboratories Ltd (China) (55%)
GlaxoSmithKline S.p.A. (Italy) GlaxoSmithKline Consumer Healthcare Limited (India) (72.5%)
GSK Vaccines S.r.l. (Italy) GlaxoSmithKline Pharmaceuticals Limited (India) (75%)
GlaxoSmithKline B.V. (Netherlands) GlaxoSmithKline Consumer Healthcare Japan K.K. (Japan)
GlaxoSmithKline Consumer Healthcare Sp.z.o.o. (Poland) GlaxoSmithKline K.K. (Japan)
GSK Services Sp z o.o. (Poland) ViiV Healthcare Kabushiki Kaisha (Japan) (78.3%)
GlaxoSmithKline Trading Services Limited (Republic of Ireland) (i) GlaxoSmithKline Pakistan Limited (Pakistan) (82.6%)
GlaxoSmithKline Healthcare AO (Russia) Glaxo Wellcome Manufacturing Pte Ltd. (Singapore)
GlaxoSmithKline S.A. (Spain) GlaxoSmithKline Korea Limited (Republic of Korea)
Laboratorios ViiV Healthcare, S.L. (Spain) (78.3%) GlaxoSmithKline llaclari Sanayi ve Ticaret A.S. (Turkey)
GSK Consumer Healthcare S.A. (Switzerland)

(i) Exempt from the provisions of section 347 and 348 of the Companies Act 2014 (Ireland), in accordance with the exemptions noted
in Section 357 of that Act. Further subsidiaries, as disclosed on pages 260 to 270, are exempt from these provisions as they are also
consolidated in the group financial statements.
* Directly held wholly owned subsidiary of GlaxoSmithKline plc.

The subsidiaries and associates listed above principally affect the figures in the Group’s financial statements. Each of GlaxoSmithKline
Capital Inc., GlaxoSmithKline Capital plc and GlaxoSmithKline LLC, is a wholly-owned finance subsidiary of the company, and the company
has fully and unconditionally guaranteed the securities issued by each of GlaxoSmithKline Capital Inc., GlaxoSmithKline Capital plc and
GlaxoSmithKline LLC.
See pages 260 to 270 for a complete list of subsidiary undertakings, associates and joint ventures, which form part of these financial
statements.
 215

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

45. Legal proceedings

The Group is involved in significant legal and administrative Dolutegravir/Tivicay/Triumeq
proceedings, principally product liability, intellectual property, In September and October 2017, ViiV Healthcare received
tax, anti-trust and governmental investigations, as well as related patent challenge letters under the Hatch-Waxman Act from Cipla,
private litigation. The most significant of these matters, other than Dr. Reddy’s Labs and Apotex for Triumeq and Tivicay, and from
tax matters, are described below. The Group makes provision for Lupin and Mylan for Triumeq and from Sandoz for Tivicay. ViiV
these proceedings on a regular basis as summarised in Note 2, Healthcare lists two patents for dolutegravir, the active ingredient
‘Accounting principles and policies’ and Note 29, ‘Other provisions’. in Tivicay and one of the active ingredients in Triumeq, in the FDA
Orange Book. One patent, covering the molecule dolutegravir,
The Group may become involved in significant legal proceedings
expires on 5 October 2027. A second patent, claiming a certain
in respect of which it is not possible to make a reliable estimate of
crystal forms of dolutegravir, expires on 8 December 2029. All the
the expected financial effect, if any, that could result from ultimate
letters challenged only the patent for the crystal form. Some generic
resolution of the proceedings. In these cases, appropriate
companies alleged that the crystal form patent is not valid. Others
disclosures about such cases would be included in this note,
challenged validity and asserted that their proposed product would
but no provision would be made for the cases.
not infringe the crystal form patent.
With respect to each of the legal proceedings described below,
On 7 February 2017, ViiV Healthcare filed patent infringement suits
other than those for which a provision has been made, the Group
against all the generic companies in the US District Court for the
is unable to make a reliable estimate of the expected financial effect
District of Delaware. Additionally, ViiV Healthcare also filed suit
at this stage. The Group does not believe that information about the
against certain of the generic companies in the US District Court for
amount sought by the plaintiffs, if that is known, would be meaningful
the District of New Jersey, and the US District Court for the District
with respect to those legal proceedings. This is due to a number of
of West Virginia. The case against Mylan is now proceeding in the
factors, including, but not limited to, the stage of proceedings, the
Northern District of West Virginia. The court has set the case against
entitlement of parties to appeal a decision and clarity as to theories
Mylan for trial in June 2020. The cases against the other defendants
of liability, damages and governing law.
are proceeding in the District of Delaware. The District of Delaware
Legal expenses incurred and provisions related to legal claims are has not yet set a trial date for the cases.
charged to selling, general and administration costs. Provisions
On 7 February 2018, ViiV Healthcare filed patent infringement
are made, after taking appropriate legal and other specialist advice,
litigation against Gilead Sciences Inc. (Gilead) over bictegravir in
where an outflow of resources is considered probable and a
the US District Court for the District of Delaware (U.S. Patent No.
reliable estimate can be made of the likely outcome of the dispute.
8,129,385) and the Canadian Federal Court (Canadian patent No.
For certain product liability claims, the Group will make a provision
2,606,282). ViiV Healthcare alleges that Gilead’s triple combination
where there is sufficient history of claims made and settlements
HIV drug containing the HIV integrase inhibitor bictegravir infringes
to enable management to make a reliable estimate of the provision
ViiV Healthcare’s patent covering dolutegravir and other compounds
required to cover unasserted claims. At 31 December 2018, the
that include dolutegravir’s unique chemical scaffold. In both the US
Group’s aggregate provision for legal and other disputes (not
and Canada, ViiV Healthcare seeks financial redress rather than
including tax matters described in Note 14, ‘Taxation’) was £219
injunctive relief. The District of Delaware case is set for trial in
million. However, this provision is offset by a related £37 million
September 2020. The Canadian court has not set a trial date for
receivable which means the net exposure to the Group is £182
the Canadian action.
million. The ultimate liability for legal claims may vary from the
amounts provided and is dependent upon the outcome of litigation Kivexa
proceedings, investigations and possible settlement negotiations. In 2018, ViiV Healthcare reached confidential agreements with
each of DOC Generici, Farmoz and Kyowa Pharmaceuticals to settle
The Group’s position could change over time, and, therefore, there
various challenges to the validity of the Supplementary Protection
can be no assurance that any losses that result from the outcome
Certificate (‘SPC’) for the patent covering the combination of
of any legal proceedings will not exceed by a material amount the
lamivudine and abacavir for Kivexa and certain counterclaims
amount of the provisions reported in the Group’s financial
brought by ViiV Healthcare for infringement of that SPC. These
statements. If this were to happen, it could have a material adverse
settlements brought an end to litigation and arbitration proceedings
impact on the results of operations of the Group in the reporting
between ViiV Healthcare and DOC Generici in Italy, between ViiV
period in which the judgements are incurred or the settlements
Healthcare and Farmoz in Portugal, and between ViiV Healthcare
entered into.
and Kyowa Pharmaceuticals in Japan.
Intellectual property
In June 2017, Biogaran commenced proceedings in France seeking
Intellectual property claims include challenges to the validity and
revocation of the French SPC covering Kivexa. No trial date has
enforceability of the Group’s patents on various products or
been set for this action.
processes as well as assertions of non-infringement of those
patents. A loss in any of these cases could result in loss of patent In Q2 2018, ViiV Healthcare commenced proceedings against
protection for the product at issue. The consequences of any such Sandoz in Switzerland. Sandoz countered challenging the validity
loss could be a significant decrease in sales of that product and of the patent relating to Kivexa. No trial date has been set for
could materially affect future results of operations for the Group. this action.
216

GSK Annual Report 2018

Notes to the financial statements continued

45. Legal proceedings continued

Product liability – Acts of violence
Pre-clinical and clinical trials are conducted during the development As of February 2019, there were six pending claims or cases
of potential products to determine the safety and efficacy of concerning allegations that patients who took paroxetine or Paxil
products for use by humans following approval by regulatory bodies. committed or attempted to commit suicide or acts of violence: five
claims or cases are in the US and one case is in Canada. One of the
Notwithstanding these efforts, when drugs and vaccines are
US cases, Dolin, involving the suicide of a man who allegedly took
introduced into the marketplace, unanticipated safety issues may
generic paroxetine manufactured by Mylan, resulted in a $3 million
become, or be claimed by some to be, evident. The Group is
verdict for the plaintiff; however, on 22 August 2018 the US Court
currently a defendant in a number of product liability lawsuits related
of Appeals for the Seventh Circuit reversed the jury verdict and
to the Group’s Pharmaceutical, Vaccine and Consumer Healthcare
found in favour of the Group. Plaintiff has filed a petition for writ of
products. The Group has been able to make a reliable estimate of
certiorari asking the US Supreme Court to review the case. The
the expected financial effect of the matters discussed in this
remaining US cases are largely dormant.
category and has included a provision, as appropriate, for the
matters below in the provision for legal and other disputes. Matters In the one pending Canadian action, Carmichael, the Group has filed
for which the Group has made a provision are also noted in Note 29, a motion for summary judgement based on the statute of limitations.
‘Other provisions.’
– Discontinuation
Avandia In the UK, a long-pending group action alleges that Seroxat caused
The Group has been named in product liability lawsuits on behalf severe discontinuation symptoms. In 2010, the Legal Services
of individuals asserting personal injury claims arising out of the use Commission (“LSC”) withdrew public funding from hundreds of
of Avandia. Economic loss actions have also been filed seeking claimants, causing termination of most claims. In 2015, the Legal Aid
restitution and penalties under consumer protection and other laws. Agency (formerly the LSC) discharged the public funding certificate
following a 2013 recommendation of its Special Cases Review
As of February 2019, there are seven remaining US cases. Four are
Panel that these cases have poor prospects of success.
personal injury actions subject to a settlement agreement and will
be dismissed once the settlement has been finalised. Two are class However, more recently, Fortitude Law was engaged with the
actions, brought by third-party payers asserting claims under the purpose of resurrecting the Seroxat group action, and obtained
Racketeer Influenced and Corrupt Organizations Act (RICO) and third-party funding for the experts and the 103 remaining claimants.
state consumer protection laws, and are on appeal from summary The Group asked the court to require the third-party funder to
judgements granted in favour of the Group. In the last of the seven, provide security for the litigation costs in the event plaintiffs lose.
the Santa Clara County (California) Action, summary judgement
On 8 December 2017, the High Court ruled in favour of the Group
was granted in favour of the Group on all issues except for the
on its application for an order that the claimants’ litigation funder
civil penalty claims under California’s False Advertising Act.
give security for costs for a sum in excess of the total funding it had
Additionally, there are 13 class actions pending in Canada, but the committed to the case. The trial of the action is scheduled to
Group has reached an agreement, subject to court approval, to commence in April 2019.
settle all of them.
Zofran
Seroxat/Paxil and Paxil CR Plaintiffs allege that their children suffered birth defects as a result
The Group has received numerous lawsuits and claims alleging that of the mothers’ ingestion of Zofran and/or generic ondansetron for
use of Paxil (paroxetine) has caused a variety of injuries. Most of pregnancy-related nausea and vomiting. Plaintiffs assert that the
these lawsuits contain one or more of the following allegations: (i) Group sold Zofran knowing it was unsafe for pregnant women, failed
that use of Paxil during pregnancy caused congenital malformations, to warn of the risks, and illegally marketed Zofran “off-label” for use
persistent pulmonary hypertension or autism; (ii) that Paxil treatment by pregnant women.
caused patients to commit suicidal or violent acts; and (iii) that the
As of February 2019, the Group is a defendant in 430 personal injury
Group failed to warn that patients could experience certain
lawsuits. All but two of the lawsuits are part of a multi-district
symptoms on discontinuing Paxil treatment.
litigation proceeding (“MDL”) in the US District Court for the District
– Pregnancy of Massachusetts.
The Group has reached agreements to settle the majority of the
In the MDL, the parties are in the process of completing case-
US claims relating to the use of Paxil during pregnancy as of
specific discovery and selecting cases for potential trials. While the
February 2019, but 11 lawsuits related to use during pregnancy
court recently denied the Group’s motion for summary judgment
are still pending in various courts in the US.
based on a federal preemption argument, the Group continues to
The Singh action in Alberta, Canada, a proposed national class seek the dismissal of individual cases on other grounds as
action, seeks to certify a class relating to birth defects generally. appropriate.
The court, after hearing argument in January 2019, has plaintiffs’
GSK is also a defendant in four proposed class actions in Canada.
class certification motion under consideration.
There has been no significant activity in these four matters; however,
Another Canadian class action, Jensen, alleging claims of Paxil the parties have recently agreed to a schedule for class certification
(and other SSRI) use and autism was filed in Saskatchewan in proceedings in the matter pending in Ontario.
January 2017; however, there has been no activity in the case
since the filing.
 217

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

45. Legal proceedings continued

Sales and marketing and regulation Average wholesale price
The Group’s marketing and promotion of its Pharmaceutical The Attorney General in Illinois filed suit against the Group and a
and Vaccine products are the subject of certain governmental number of other pharmaceutical companies claiming damages and
investigations and private lawsuits brought by litigants under various restitution due to average wholesale price (AWP) and/or wholesale
theories of law. The Group has been able to make a reliable estimate acquisition cost (WAC) price reporting for pharmaceutical products
of the expected financial effect of the matters discussed in this covered by the state’s Medicaid programmes. The case alleges that
category and has included a provision for such matters in the the Group reported or caused to be reported false AWP and WAC
provision for legal and other disputes, except as noted below. prices, which, in turn, allegedly caused the state Medicaid agency
to reimburse providers more money for covered medicines than the
Matters for which the Group has made a provision are also noted
agency intended. The state has sought recovery on behalf of itself as
in Note 29, ‘Other provisions’.
payer and on behalf of in-state patients as consumers. The case is
SFO and SEC/DOJ Anti-corruption enquiries ongoing, and no trial date has yet been set as to the Group.
On 27 May 2014, the UK Serious Fraud Office (SFO) began a
Cidra third-party payer litigation
formal criminal investigation into the Group’s commercial operations
On 25 July 2013, a number of major US healthcare insurers filed suit
in a number of countries, including China. The SFO inquiry followed
against the Group in the Philadelphia, Pennsylvania County Court
investigations initiated by China’s Ministry of Public Security in June
of Common Pleas seeking compensation for reimbursements they
2013 (the ‘China Investigations’), which resulted in a ruling in 2014
made for medicines manufactured at the Group’s former Cidra plant
that, according to Chinese law, GSK China Investment Co. Ltd.
in Puerto Rico. These insurers claim that the Group knowingly and
(‘GSKCI’) had offered money or property to non-government
illegally marketed and sold adulterated drugs manufactured under
personnel in order to obtain improper commercial gains and
conditions non-compliant with cGMP (current good manufacturing
GSKCI being found guilty of bribing non-government personnel.
practices) and that they, as third-party insurers, were unlawfully
On 30 September 2016, the Group reached a global resolution with induced to pay for them. The suit alleges both US federal and various
the US Securities and Exchange Commission (SEC) regarding the state law causes of action. Discovery is complete, and the Group
SEC’s investigation under the US Foreign Corrupt Practices Act has filed a motion for summary judgement, which likely will be heard
(FCPA) into the Group’s commercial practices in countries outside in spring 2019. No trial date has yet been set.
of the US, including China. As part of the resolution, the Group
Anti-trust/competition
agreed to pay a civil penalty of $20 million to the US Government.
Certain governmental actions and private lawsuits have been
The US Department of Justice (DOJ) confirmed that it had
brought against the Group alleging violation of competition or
concluded its investigation into the Group’s commercial practices
anti-trust laws. The Group has been able to make a reliable estimate
and would take no action against the Group. As part of the resolution
of the expected financial effect of the matters discussed in this
with the SEC, the Group agreed to certain undertakings, including
category and has included a provision for such matters in the
a period of self-monitoring and reporting. The Group’s obligations
provision for legal and other disputes, except as noted below.
under that resolution continued through 30 September 2018 and
Matters for which the Group has made a provision are also noted
have now concluded.
in Note 29, ‘Other provisions’.
In the course of its inquiry, the SFO had requested additional
UK Competition and Markets Authority investigation
information from the Group regarding third-party advisers engaged
On 12 February 2016, the UK Competition and Markets
by the company in the course of the China Investigations. The SEC
Authority (CMA) issued a decision fining the Group and two other
and DOJ are also investigating these matters following the Group’s
pharmaceutical companies for infringement of the Competition Act.
reporting of the SFO’s inquiries. The Group is co-operating and
The CMA imposed a fine of £37.6 million on the Group, as well as
responding to these requests. On 22 February 2019, the SFO
fines totaling £7.4 million against the other companies. This relates
announced that it would be closing its investigation and confirmed
to agreements to settle patent disputes between the Group and
that it would be taking no further action against the Group.
potential suppliers of generic paroxetine formulations, entered into
The SEC and DOJ investigations into these issues continue.
between 2001 and 2003. The Group terminated the agreements
The Group is unable to make a reliable estimate of the expected at issue in 2004. The Group believes it has strong grounds for its
financial effect of these investigations, and no provisions have appeal of the CMA’s finding to the Competition Appeal Tribunal
been made for them. (CAT) in order to overturn the fine or substantially reduce it.
US Vaccines subpoena The appeal concluded in April 2017. The CAT delivered its initial
On 25 February 2016, the Group received a subpoena from the US judgement on the appeal on 8 March 2018, referring all the principle
Attorney’s Office for the Southern District of New York requesting points at issue to the Court of Justice of the EU for a preliminary
documents relating to the Group’s Vaccines business. The Group ruling. The matter will then return to the CAT for final judgement.
responded to the subpoena and was informed by the government No provision has been made for this matter.
in 2018 that the government would be closing the matter without
further action.
218

GSK Annual Report 2018

Notes to the financial statements continued

45. Legal proceedings continued

Lamictal In addition to the SEC case, one private matter (the “Martinolich”
Purported classes of direct and indirect purchasers filed suit in case) remains. It is also pending in federal district court in Florida but
the US District Court for the District of New Jersey alleging that has been stayed pending the trial of the SEC matter. The allegations
the Group and Teva Pharmaceuticals unlawfully conspired to delay in the Martinolich case largely track those in the SEC matter: the
generic competition for Lamictal, resulting in overcharges to the plaintiff, a former Stiefel employee, alleges that Stiefel and its officers
purchasers, by entering into an allegedly anti-competitive reverse and directors violated the US Employee Retirement Income Security
payment settlement to resolve patent infringement litigation. A Act (ERISA) and federal and state securities laws by inducing Stiefel
separate count accuses the Group of monopolising the market. employees to sell their shares in the employee stock plan back to
Stiefel at a greatly undervalued price and without disclosing to
On 26 June 2015, the Court of Appeals reversed the trial court’s
employees that Stiefel was about to be sold to the Group.
decision to dismiss the case and remanded the action back to
the trial court. On 18 May 2016, the trial court denied the indirect Environmental matters
purchaser class plaintiffs’ motion for reconsideration of the Court’s The Group has been notified of its potential responsibility relating
dismissal of their claims. As a result, the indirect purchaser class to past operations and its past waste disposal practices at certain
representatives agreed to a settlement to exit the case and resolve sites, primarily in the US. Some of these matters are the subject of
their remaining claims. On 13 December 2018, the trial judge litigation, including proceedings initiated by the US federal or state
granted plaintiffs’ class certification motion, certifying a class of governments for waste disposal, site remediation costs and tort
direct purchasers in this action. The Group is pursuing an appeal actions brought by private parties.
with the Court of Appeals regarding the class certification.
The Group has been advised that it may be a responsible party at
Commercial and corporate approximately 16 sites, of which nine appear on the National Priority
The Group is a defendant in certain cases which allege violation List created by the Comprehensive Environmental Response
of US federal securities and ERISA laws. The Group has been able Compensation and Liability Act (Superfund). These proceedings
to make a reliable estimate of the expected financial effect of the seek to require the operators of hazardous waste facilities,
matters discussed in this category and has included a provision for transporters of waste to the sites and generators of hazardous
such matters in the provision for legal and other disputes. Matters waste disposed of at the sites to clean up the sites or to reimburse
for which the Group has made a provision are also noted in Note 29, the US Government for cleanup costs. In most instances, the
‘Other provisions”. Group is involved as an alleged generator of hazardous waste.
Securities/ERISA class actions – Stiefel Although Superfund provides that the defendants are jointly and
On 12 December 2011, the US Securities and Exchange severally liable for cleanup costs, these proceedings are frequently
Commission (SEC) filed a formal complaint against Stiefel resolved on the basis of the nature and quantity of waste disposed
Laboratories, Inc., and Charles Stiefel in the US District Court for of by the generator at the site. The Group’s proportionate liability for
the District of Florida alleging that Stiefel and its principals violated cleanup costs has been substantially determined for 18 of the sites
federal securities laws by inducing Stiefel employees to sell their referred to above.
shares in the employee stock plan back to the company at a greatly
The Group’s potential liability varies greatly from site to site. The cost
undervalued price and without disclosing to employees that the
of investigation, study and remediation at such sites could, over time,
company was about to be sold to the Group. The case was stayed
be significant. The Group has made a provision for these matters, as
while several private actions brought by former Stiefel employees
noted in Note 29, ‘Other provisions’.
proceeded through the courts but was returned to active status in
early summer 2015. It is unclear when the case ultimately will be
scheduled for trial.

46. Post balance sheet events

The agreement to acquire Tesaro, Inc. for $5.1 billion in cash, which On 31 January 2019, Mylan N.V. announced that the US Food and
was signed in December 2018, completed on 22 January 2019. Drug Administration had approved their therapeutically equivalent
generic of Advair Diskus for certain patients with asthma or chronic
obstructive pulmonary disease.
 219

GSK Annual Report 2018 Strategic report

Governance and remuneration

Company balance sheet – Financial statements

Investor information

UK GAAP
(including FRS 101 ‘Reduced Disclosure Framework’) as at 31 December 2018

2018 2018 2017 2017

Notes £m £m £m £m
Fixed assets – investments F 19,987 20,275

Current assets:
Trade and other receivables G 8,394 8,715
Cash at bank 12 15
Total current assets 8,406 8,730
Bank overdrafts (12) (15)
Short term borrowings H (3,500) –
Trade and other payables I (610) (837)
Total current liabilities (4,122) (852)
Net current assets 4,284 7,878

Total assets less current liabilities 24,271 28,153

Provisions for liabilities J (16) (27)
Other non-current liabilities K (282) (238)
Net assets 23,973 27,888

Capital and reserves

Share capital L 1,345 1,343
Share premium account L 3,091 3,019
Other reserves 1,420 1,420
Retained earnings:
At 1 January 22,106 15,538
(Loss)/profit for the year (62) 9,893
Other changes in retained earnings (3,927) (3,325)
M 18,117 22,106
Equity shareholders’ funds 23,973 27,888

The financial statements on pages 219 to 222 were approved by the Board on 11 March 2019 and signed on its behalf by

Philip Hampton
Chairman
GlaxoSmithKline plc
Registered number: 3888792

Company statement of changes in equity

for the year ended 31 December 2018

Share Share premium Other Retained Total

capital account reserves earnings equity
£m £m £m £m £m
At 1 January 2017 1,342 2,954 1,420 15,538 21,254
Profit and Total comprehensive income attributable to shareholders – – – 9,893 9,893
Dividends to shareholders – – – (3,906) (3,906)
Shares issued under employee share schemes 1 55 – – 56
Treasury shares transferred to the ESOP Trust – 10 – 581 591
At 31 December 2017 1,343 3,019 1,420 22,106 27,888
Loss and Total comprehensive expense attributable to shareholders – – – (62) (62)
Dividends to shareholders – – – (3,927) (3,927)
Shares issued under employee share schemes 2 72 – – 74
At 31 December 2018 1,345 3,091 1,420 18,117 23,973
220

GSK Annual Report 2018

Notes to the company balance sheet – UK GAAP

(including FRS 101 ‘Reduced Disclosure Framework’)

A) Presentation of the financial statements B) Accounting policies

Description of business Foreign currency transactions
GlaxoSmithKline plc is the parent company of GSK, a major global  oreign currency transactions are recorded at the exchange rate
F
healthcare group which is engaged in the creation and discovery, ruling on the date of transaction. Foreign currency assets and
development, manufacture and marketing of pharmaceutical liabilities are translated at rates of exchange ruling at the balance
products, including vaccines, over‑the-counter (OTC) medicines sheet date.
and health-related consumer products.
Dividends paid and received
Preparation of financial statements Dividends paid and received are included in the financial statements
The financial statements, which are prepared using the historical in the period in which the related dividends are actually paid or
cost convention (as modified to include the revaluation of certain received.
financial instruments) and on a going concern basis, are prepared
in accordance with Financial Reporting Standard 101 ‘Reduced Expenditure
Disclosure Framework’ and with UK accounting presentation and the Expenditure is recognised in respect of goods and services received
Companies Act 2006 as at 31 December 2018, with comparative when supplied in accordance with contractual terms. Provision is
figures as at 31 December 2017. made when an obligation exists for a future liability in respect of a
past event and where the amount of the obligation can be reliably
As permitted by section 408 of the Companies Act 2006, the estimated.
income statement of the company is not presented in this Annual
Report. Investments in subsidiary companies
Investments in subsidiary companies are held at cost less any
The company is included in the Group financial statements of
provision for impairment and also adjusted for movements in
GlaxoSmithKline plc, which are publicly available.
contingent consideration.
The following exemptions from the requirements of IFRS have
been applied in the preparation of these financial statements, Impairment of investments
in accordance with FRS 101: The carrying value of investments are reviewed for impairment
when there is an indication that the investment might be impaired.
–– Paragraphs 45(b) and 46 to 52 of IFRS 2, ‘Share-based payment’
Any provision resulting from an impairment review is charged to
–– IFRS 7, ‘Financial Instruments - Disclosures’ the income statement in the year concerned.
–– Paragraphs 91-99 of IFRS 13, ‘Fair value measurement’ Share-based payments
–– Paragraph 38 of IAS 1, ‘Presentation of financial statements’ The issuance by the company to its subsidiaries of a grant over
comparative information requirements in respect of the company’s shares, represents additional capital contributions
paragraph 79(a) (iv) of IAS 1 by the company in its subsidiaries. An additional investment in
subsidiaries results in a corresponding increase in shareholders’
–– Paragraphs 10(d), 10(f), 16, 38(A), 38 (B to D), 40 (A to D),
equity. The additional capital contribution is based on the fair value of
111 and 134 to 136 of IAS 1, ‘Presentation of financial statements’
the grant issued, allocated over the underlying grant’s vesting period.
–– IAS 7, ‘Statement of cash flows’
Taxation
–– Paragraph 30 and 31 of IAS 8, ‘Accounting policies, changes Current tax is provided at the amounts expected to be paid applying
in accounting estimates and errors’ tax rates that have been enacted or substantively enacted by the
–– Paragraph 17 of IAS 24, ‘Related party disclosures’ and the balance sheet date.
further requirement in IAS 24 to disclose related party transactions Deferred tax is provided in full, using the liability method, on
entered into between two or more members of temporary differences arising between the tax bases of assets
a Group. and liabilities and their carrying amounts in the financial statements.
Accounting convention and standards Deferred tax assets are only recognised to the extent that they are
The balance sheet has been prepared using the historical considered recoverable against future taxable profits.
cost convention and complies with applicable UK accounting Deferred tax is measured at the average tax rates that are expected
standards. to apply in the periods in which the temporary differences are
expected to be realised or settled. Deferred tax liabilities and assets
Accounting principles and policies are not discounted.
The preparation of the balance sheet in conformity with generally
accepted accounting principles requires management to make Financial guarantees
estimates and assumptions that affect the reported amounts of Liabilities relating to guarantees issued by the company on behalf
assets and liabilities and disclosure of contingent assets and of its subsidiaries are initially recognised at fair value and amortised
liabilities at the date of the balance sheet. Actual amounts could over the life of the guarantee.
differ from those estimates.
The balance sheet has been prepared in accordance with the
company’s accounting policies approved by the Board and
described in Note B. These policies have been consistently
applied, unless otherwise stated.
 221

GSK Annual Report 2018 Strategic report

Governance and remuneration

Financial statements

Investor information

C) Key accounting judgements and estimates The ultimate liability for legal claims may vary from the amounts
provided and is dependent upon the outcome of litigation
Legal and other disputes proceedings, investigations and possible settlement negotiations.
The company provides for anticipated settlement costs where The position could change over time and, therefore, there can be no
management makes a judgement that an outflow of resources is assurance that any losses that result from the outcome of any legal
probable and a reliable estimate can be made of the likely outcome proceedings will not exceed the amount of the provisions reported
of the dispute and legal and other expenses arising from claims in the company’s financial statements by a material amount.
against the company. The estimated provisions take into account the
specific circumstances of each dispute and relevant external advice, D) Operating profit
are inherently judgemental and could change substantially over time
as each dispute progresses and new facts emerge. A fee of £12,000 (2017 – £12,053) relating to the audit of the
company has been charged in operating profit.­
The company’s Directors, having taken legal advice, have
established provisions after taking into account the relevant facts
and circumstances of each matter and in accordance with
E) Dividends
accounting requirements. At 31 December 2018, provisions for legal The directors declared four interim dividends resulting in a dividend
and other disputes amounted to £16 million (2017 – £27 million). for the year of 80 pence, in line with the dividend for 2017. For further
details, see Note 16 to the Group financial statements, ‘Dividends’.­

F) Fixed assets – investments

2018 2017
£m £m
Shares in GlaxoSmithKline Services Unlimited 613 613
Shares in GlaxoSmithKline Holdings (One) Limited 18 18
Shares in GlaxoSmithKline Holdings Limited 17,888 17,888
Shares in GlaxoSmithKline Mercury Limited 33 33
18,552 18,552
Capital contribution relating to share-based payments 1,139 1,139
Contribution relating to contingent consideration 296 584
19,987 20,275

G) Trade and other receivables

2018 2017
£m £m
Amounts due within one year:
UK Corporation tax recoverable 10 31
Other receivables – 1
Amounts owed by Group undertakings 7,889 8,299
7,899 8,331
Amounts due after more than one year:
Amounts owed by Group undertakings 495 384
8,394 8,715

H) Short-term borrowings
The £3.5 billion borrowing relates to a facility taken out in June 2018 as part of the financing of the buyout of the non-controlling interest in the
Consumer Healthcare Joint Venture held by Novartis. The facility has a maturity date of 1 December 2019.

I) Trade and other payables

2018 2017
£m £m
Amounts due within one year:
Other creditors 567 438
Contingent consideration payable 14 346
Amounts owed to Group undertakings 29 53
610 837

The company has guaranteed debt issued by its subsidiary companies from two of which it receives fees. In aggregate, the company has
outstanding guarantees over £22.2 billion of debt instruments (2017 – £16.7 billion). The amounts due from the subsidiary company in relation
to these guarantee fees will be recovered over the life of the bonds and are disclosed within ‘Trade and other receivables’ (see Note G).
222

GSK Annual Report 2018

Notes to the company balance sheet – UK GAAP

(including FRS 101 ‘Reduced Disclosure Framework’) continued
J) Provisions for liabilities
2018 2017
£m £m
At 1 January 27 23
Exchange adjustments 2 (3)
Charge for the year 16 52
Utilised (29) (45)
At 31 December 16 27

The provisions relate to a number of legal and other disputes in which the company is currently involved.

K) Other non-current liabilities

2018 2017
£m £m
Contingent consideration payable 282 238
282 238

The contingent consideration relates to the amount payable for the acquisition in 2015 of the Novartis Vaccines portfolio. The current year
liability is included within ‘Trade and other payables’.

L) Share capital and share premium account

Share
premium
Ordinary Shares of 25p each account
Number £m £m
Share capital authorised
At 31 December 2017 10,000,000,000 2,500
At 31 December 2018 10,000,000,000 2,500
Share capital issued and fully paid
At 1 January 2017 5,368,316,062 1,342 2,954
Issued under employee share schemes 4,237,758 1 55
Treasury shares transferred to the ESOP Trust – – 10
At 31 December 2017 5,372,553,820 1,343 3,019
Issued under employee share schemes 6,513,804 2 72
At 31 December 2018 5,379,067,624 1,345 3,091

31 December 31 December
2018 2017
000 000
Number of shares issuable under employee share schemes 56,723 38,647
Number of unissued shares not under option 4,564,209 4,588,799

At 31 December 2018, of the issued share capital, 41,530,909 shares were held in the ESOP Trusts, 414,605,950 shares were held as
Treasury shares and 4,922,930,765 shares were in free issue. All issued shares are fully paid. The nominal, carrying and market values of the
shares held in the ESOP Trusts are disclosed in Note 43, ‘Employee share schemes’.

M) Retained earnings
The loss of GlaxoSmithKline plc for the year was £62 million (2017 – £9,893 million profit), which after dividends of £3,927 million
(2017 – £3,906 million), gave a retained loss of £3,989 million (2017 – profit of £5,987 milion). After the effect of £nil Treasury shares
transferred to a subsidiary company (2017 – £581 million), retained earnings at 31 December 2018 stood at £18,117 million
(2017 – £22,106 million), of which £4,096 million was unrealised (2017 – £4,096 million).

N) Group companies
See pages 260 to 270 for a complete list of subsidiaries, associates and joint ventures, which forms part of these financial statements.